Literature screening report

COVID-19 vaccines in the WHO's Emergency Use Listing (EUL) Report (9)

Report submission date:	30.11.2021

Responsible authors: *Authors contributed equally	Sabina Rodriguez Velásquez* [A,B] Gabriela Guizzo Dri* [A,B] Camille Beatrice Gaza Valera* [A,B]
Co-authors/ collaborators:	Muaamar Al Gobari [B,C] Sara Botero-Mesa [A,B] Olivia Keiser [A]
Affiliation:	[A] Institute of Global Health, University of Geneva, Switzerland [B] Association Actions en Santé Publique (ASP) & The GRAPH Network, [C] Department of Occupational and Environmental Health, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Epalinges-Lausanne, Switzerland.

Coordination contact:	Jorgen Bauwens (SSPH+)

Abstract

This report focuses on the World Health Organization's (WHO) Emergency Use Listing (EUL) of authorized vaccines as of 26 November 2021. Bharat Biotech's new vaccine **COVAXIN/ BBV152** received WHO EUL authorisation on 3 November 2021 leading to **seven** vaccines being now authorised for emergency use: BNT162b2/COMIRNATY (Pfizer-BioNTech, USA), Spikevax/Moderna COVID-19 Vaccine/ mRNA-1273 (Moderna, USA), Vaxzevria/ChAdOx1 nCoV-19/AZD1222/Covishield (AstraZeneca/Oxford, UK, India), Janssen Covid-19 vaccine/Johnson & Johnson (Janssen, USA), Sinopharm/BBIBP-CorV (China), Sinovac/CoronaVac (China), and COVAXIN/BBV152 (Bharat Biotech, India)]. This report provides a condensed summary concerning vaccine efficacy, safety, protection against variants, and further important information for each vaccine, in the form of a synoptic table. The information and data in this synoptic table was extracted from phase III clinical trials and observational studies. This report focuses on the latest data on vaccine effectiveness, vaccine induced immunity, breakthrough infections, and booster doses.

Content

Abstract	1
Content	2
Preamble	3
Background	3
Methodology	4
Results	4
Latest Data on Vaccine Effectiveness	4
Vaccine Induced Immune Responses	6
Breakthrough Infections and SARS-CoV-2 Transmission	7
Booster Dose	8
Synoptic Table	10
General Vaccine Information	10
Effectiveness against any Sars-Cov-2 Infection	12
Effectiveness against Variants	17
Effectiveness against Hospitalization	21
Safety and Adverse Events	37
Children Vaccination	44
Heterologous Vaccination	48
Booster Doses	52
Heterologous Booster Doses	60
Annexes	64
Further Information	64
Efficacy	66
Efficacy Against Variants	69
Phase III Trials Results	71
Phase III Trial Other	73
Vaccine Production Sites	74
References	77

Preamble

A large number of scientific publications become available on a daily basis, reflecting the rapid development of knowledge and progress of science on COVID-19 related issues. Leading authorities should base decisions or policies on this knowledge; hence they need to master the actual state of this knowledge. Due to the large number of publications shared daily, decision makers heavily depend on accurate summaries of these publications, in the different public health domains. Therefore, the authors of this report were mandated by the Swiss School of Public Health plus (SSPH+), upon request of the Federal Office of Public Health (FOPH), to inform the FOPH on recent findings from the literature.

Background

According to the current global data on vaccinations, 53.8% of the world populations, of which only 5.5% of people in low-income countries, have received at least one dose of a marketed COVID-19 vaccine as of 26 November 2021[1]. Currently, seven vaccines [namely, Comirnaty/BNT162b2 (Pfizer-BioNTech, USA), Spikevax/Moderna COVID-19 Vaccine/mRNA-1273 (Moderna, USA), Vaxzevria/ChAdOx1_nCoV-19/AZD1222/Covishield (AstraZeneca/Oxford, UK, India), Janssen Covid-19 vaccine/Johnson & Johnson (Janssen, USA), Sinopharm/BBIBP-CorV (China), Sinovac/CoronaVac (China), and COVAXIN/BBV152 (Bharat Biotech, India)] were assessed and granted an authorization by WHO as of 26 November 2021. **Articles regarding the latest data on vaccine effectiveness, vaccine induced immune response, breakthrough infections and transmission, and booster doses were prioritized during the literature search and are the latest additions to the table. Data from clinical trials and observational studies for the seven EUL-accepted vaccines and the vaccine candidate Novavax regarding these highlighted topics were summarized and can be found in the synoptic table below.**

[1] https://ourworldindata.org/covid-vaccinations (accessed on 26.11.2021).

Methodology

We screened the data for the EUL-accepted vaccines and the vaccine candidate Novavax as of 26 November 2021 from PubMed, Embase, medRxiv, bioRxiv, Cochrane, and clinical trials databases such as ClinicalTrials and WHO Trial Registry. The methods used were reported previously and can be found in prior reports[2].

Results

As phase III COVID-19 vaccine trials confirmed vaccine efficacy and safety for all seven WHO EUL authorized vaccines, and as the share of fully vaccinated people begin to increase across countries, it is important to assess vaccine effectiveness in real-world conditions, especially in relation to evolving variants of concern (VOC).

Latest Data on Vaccine Effectiveness

No significant updates regarding vaccine effectiveness were identified since the previous synoptic table this month. In a recent study, final analyses of the blinded phase of Moderna's mRNA1273 vaccine efficacy and safety further support existing evidence of its effectiveness against COVID-19 infection and severe disease. From the clinical trial's 30,315 subjects, there were 55 confirmed COVID-19 cases among individuals who received mRNA-1273 compared with 744 COVID-19 cases among individuals in the placebo group; resulting in vaccine efficacy preventing COVID-19 infection **at 93.2% (95% CI, 91.0 to 94.8)**.[3] In terms of prevention against severe disease, vaccine efficacy was **98.2% (95% CI, 92.8 to 99.6)** while vaccine efficacy against asymptomatic infection 14-days after dose completion was 63.0% **(95% CI,**

[2] COVID-19 vaccines: efficacy and safety (Literature Review 1). *Swiss School of Public Health*. https://www.bag.admin.ch/dam/bag/de/dokumente/mt/k-und-i/aktuelle-ausbrueche-pandemien/2019-nCoV/Literaturrecherchen/literaturrecherchen_covid-19-impfstoffe_20210209.pdf.download.pdf/20210209_Literaturrecherchen_Covid-19-Impfstoffe_EN.pdf

[3] Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinding Phase. *New England Medical Journal of Medicine.* https://www.nejm.org/doi/10.1056/NEJMoa2113017

56.6 to 68.5).[4] Results were consistent across age, ethnicity, and individuals with coexisting conditions.

Alternatively, a national cohort study conducted in Norway from January to September 2021 investigated vaccine effectiveness by age and product-specific vaccine (homologous and heterologous regimens) effectiveness against various COVID-19 disease outcomes. Overall, full vaccine dosages were found to provide better protection when compared with partial doses. Resulting effectiveness against any COVID-19 infection for those fully vaccinated was at **72.1% (95% CI, 71.2-73.0)**, **95.5% (95% CI 92.6-97.2)** against ICU hospitalization, and **88.0% (95% CI 82.5-91.8)** against death.[5] Furthermore, when comparing specific vaccine regimens among fully vaccinated, heterologous mRNA vaccines demonstrated the highest protection with effectiveness against infection at **84.7% (95% CI 83.1-86.1)** followed by homologous regimens; mRNA-1273 and BNT162b2 at **78.3% (95% CI 76.8-79.7)** and **69.7% (95% CI 68.6-70.8)** respectively, and **60.7% (95% CI 57.5-63.6)** for ChADox nCOV-19.[6]

With regard to the newly WHO EUL approved vaccine BBV152/Covaxin, data in a recent preprint from *The Lancet* show that during dominance of the Delta variant, Covaxin demonstrated, statistically, relatively good effectiveness against severe COVID-19 in India. In this multi-centric, hospital-based case-control study conducted on Covaxin and Covishield effectiveness, results of the investigation illustrated that full dose Covaxin effectiveness was at **69% (95% CI, 54.0-79.0)** for the Delta variant plus its sub-lineages, while Covishield had an effectiveness **of 80% (95% CI, 73.0-86.0)**.[7]

[4] Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinding Phase. *New England Medical Journal of Medicine.* https://www.nejm.org/doi/10.1056/NEJMoa2113017

[5] Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalization among adults in Norway: a national cohort study, January – September 2021. *medRxiv.* https://www.medrxiv.org/content/10.1101/2021.11.24.21266401v1

[6] Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalization among adults in Norway: a national cohort study, January – September 2021. *medRxiv.* https://www.medrxiv.org/content/10.1101/2021.11.24.21266401v1

[7] Effectiveness of BBV152/Covaxin and AZD1222/Covishield Vaccines Against Severe COVID-19 and B.1.617.2/Delta Variant in India, 2021: A Multi-Centric Hospital-Based Case-Control Study. *Preprint with The Lancet.* https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3955739

Vaccine Induced Immune Responses

A recent study compared the kinetic of humoral and cellular immune responses elicited by Pfizer-BioNTech's BNT162b2 vaccine (2-dose schedule), Moderna's mRNA-1273 vaccine (2-dose schedule), and Janssen's Ad26.COV2.S vaccine (1-dose schedule). The study followed participants from peak immunity (2-4 weeks post full immunization) until to 8 months post-vaccination[8]. Similar to vaccine effectiveness data outcomes, Moderna's mRNA-1273 vaccine demonstrated higher median neutralizing antibody (NAb) titres (**5,848**), pseudovirus neutralizing antibody tires (**1,569**), and receptor-binding domain (RBD) specific binding antibody titre (**25,677**) than recipients of the BNT162b2 vaccine (NAb titre: **1,789**; pseudovirus NAb titre: **700**; RBD titre: **21,564**) at peak immunity. Janssen's Ad26.COV2 induced significantly lower median titres compared to both mRNA vaccines (NAb titre: 146; pseudovirus NAb titre: 391; RBD titre: 1,361). While both mRNA vaccines' titres decreased over time, Ad26.COV2's titres did not. mRNA-1273 titres declined by a factor of **44** (NAb titre), **6** (pseudovirus NAb titre), and **17** (RBD titre), while BNT162b2 titres decreased by a factor of **34, 4, and 29**, respectively[9]. All three vaccines demonstrated "broad cross-reactivity against SARS-CoV-2 variants" and had CD8+ T cell responses of **0.017%**, **0.016%**, and **0.12%** 8 months after full immunization for the mRNA-1273, BNT162b2, and Ad26.COV2 vaccines, respectively[10].

A Colombian surveillance study evaluated the sensitivity of Pfizer-BioNTech's BNT162b2 vaccine to neutralize three SARS-CoV-2 strains in Colombia: Mu (B.1.621; Variant of Interest), Gamma (P1; Variant of Concern) and the B.1.111 lineage ("lacks genetic markers associated with greater virulence")[11]. While the BNT162b2 vaccine demonstrated robust neutralization against both the B.1.111 lineage and P.1 strain, albeit the Gamma variant titre (**GMT 65.2 $TCID_{50}$**) was **3.4-fold lower** than the geometric mean titre of the B.1.111 lineage (**GMT 224.2 $TCID_{50}$**), the Mu variant escaped BNT162b2-elicited neutralization (**11/14 (78.5%) of serum**

[8] Differential kinetics of immune responses elicited by COVID-19 vaccines. *New England Journal of Medicine.* https://www.nejm.org/doi/full/10.1056/NEJMc2115596

[9] Differential kinetics of immune responses elicited by COVID-19 vaccines. *New England Journal of Medicine.* https://www.nejm.org/doi/full/10.1056/NEJMc2115596

[10] Differential kinetics of immune responses elicited by COVID-19 vaccines. *New England Journal of Medicine.* https://www.nejm.org/doi/full/10.1056/NEJMc2115596

[11] Low neutralizing antibody titers against the Mu variant of SARS-CoV-2 in BNT162b2 vaccinated individuals. *medRxiv.* https://www.medrxiv.org/content/10.1101/2021.11.19.21266552v1.full

samples was not able to neutralize SARS-CoV-2). The mean geometric mean titre against B.1.621 was **41**- and **20-fold lower** (***P*<0.0001**) compared to B.1.111 and P.1 lineages[12].

Breakthrough Infections and SARS-CoV-2 Transmission

While all WHO EUL authorised vaccines have demonstrated to be effective against severe SARS-CoV-2 infections and hospitalization, the combined effects of low vaccination rates[13], waning vaccine immunity, and the emergence of the Delta variant has led to increased cases of SARS-CoV-2 breakthrough infections, raising concerns among the general population. Breakthrough infections typically have higher viral loads, prolonged PCR positivity, and demonstrate lower levels of vaccine induced NAbs[14,15]. For example, symptomatic hospital staff in Ho Chi Minh City (all vaccinated with the ChAdOx1 nCoV-19) demonstrated higher viral loads (median IQR: **16.5**) relative to asymptomatic cases (median viral load IQR: **30.8**)[16]. Additionally, breakthrough infections were characterised by having lower levels of neutralizing antibodies after vaccination (median % of NAb inhibition: 69.4) and when positive for SARS-CoV-2 (median % of NAb inhibition: 59.4) relative to control participants (median % of NAb inhibition after vaccination: 91.3; median % of NAb inhibition at 7-8 weeks uninfected control: 91.1). The authors highlighted that "the absence of correlation between neutralizing antibody levels and peak viral loads suggested that vaccine might not lower the transmission potential of breakthrough infection cases"[17]. The authors' claim is corroborated by a recently published serological study that confirmed SARS-CoV-2 transmission is correlated to high viral loads, which is uncorrelated to vaccination status and/or the presence of COVID-19 symptoms[18].

[12] Low neutralizing antibody titers against the Mu variant of SARS-CoV-2 in BNT162b2 vaccinated individuals. *medRxiv.* https://www.medrxiv.org/content/10.1101/2021.11.19.21266552v1.full

[13] Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals. *Nature Medicine*. https://www.nature.com/articles/s41591-021-01407-5

[14] An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. *The Lancet.* https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00423-5/fulltext

[15] Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type. *medRxiv.* https://www.medrxiv.org/content/10.1101/2021.11.22.21266676v1.full.pdf

[16] An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. *The Lancet.* https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00423-5/fulltext

[17] An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. *The Lancet.* https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00423-5/fulltext

[18] Isolation of 4000 SARS-CoV-2 shows that contagiousness is associated with viral load, not vaccine or symptomatic status. *Emerging Microbes & Infections.* https://www.tandfonline.com/doi/full/10.1080/22221751.2021.2008776

Despite the concerns surrounding breakthrough cases, infections are clinically milder[19], are more likely to recover swiftly from illness than unvaccinated persons[20,21], and are still less likely to infect others[22,23]. Studies are recommending continuing the implementation of social distancing and non-pharmaceutical measures in order to mitigate pandemic effects.

Booster Dose

As evidence on the efficacy, safety, effectiveness, and immunogenicity of third (booster) doses becomes available, many countries are continuing to expand their recommendations for booster shots and are slowly beginning to administer third doses to all adults, and sometimes adolescents, who have received their full COVID-19 vaccine jabs at least six months ago. Recently, on 23 November 2021, Switzerland joined other countries in approving the booster to its general population by approving the extension of the Pfizer-BioNTech booster dose to everyone aged 16 years and older[24]. This decision was supported by the published data, made available by Pfizer-BioNTech, on the efficacy and safety of the BNT162b2 booster doses on 10,000 participants 16 years of age and older who completed a two-dose series of the BNT162b2 vaccine[25]. Based on those results, the vaccine efficacy of the booster dose against symptomatic COVID-19 in participants without evidence of prior infection was **95.3%** (95% CI, 89.5-97.9) and **96.5%** (95% CI, 89.3-99.3) for participants aged 16-55 years of age and **93.1%** (95% CI, 78.4-98.6) for participants aged over 55 years[25]. Additionally, the booster dose demonstrated to be safe and well tolerated. On top being efficacious in clinical trials, booster doses have also shown to have a high effectiveness and significantly increase the immune response of recipients. During a test-negative case-control study, the vaccines effectiveness

[19] Vaccination after prior COVID-19 infection: Implications for dose sparing and booster shots. *EBioMedicine.* https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00379-0/fulltext

[20] Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study. *The Lancet.* https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02183-8/fulltext

[21] Understanding breakthrough infections following mRNA SARS-CoV-2 vaccination. *JAMA.* https://jamanetwork.com/journals/jama/fullarticle/2786040

[22] Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. *bioRXiv.* https://www.medrxiv.org/content/10.1101/2021.07.28.21261295v1.full?origin=app

[23] Understanding breakthrough infections following mRNA SARS-CoV-2 vaccination. *JAMA Network.* https://jamanetwork.com/journals/jama/fullarticle/2786040

[24] COVID-19 vaccine from Pfizer-BioNTech: Swissmedic approves he extension of the booster dose to everyone aged 16 years and over. *Swissmedic.* https://www.swissmedic.ch/swissmedic/en/home/news/coronavirus-covid-19/covid-19-impfstoff-pfizer-biontech-boosterdosis.html

[25] Efficacy & Safety of BNT162b2 booster – C4591031 2 month interim analysis [press release]. *Pfizer and BioNTech, CDC.* https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-11-19/02-COVID-Perez-508.pdf.

against symptomatic COVID-19 of the booster dose BNT162b2 in individuals aged 50 years and over who received the ChAdOx1-S or BNT162b2 in the UK was estimated. Based on the results, an effectiveness of **87.4%** (95% CI, 84.9-89.4) for individuals who received the ChAdOx1-S as their full jab and an effectiveness of **84.4%** (95% CI, 82.8-85.8) for individuals who received the BNT162b2 as their full jab was calculated[26]. Additionally, when estimating the vaccine effectiveness against symptomatic COVID-19 of unvaccinated individuals and individuals who received the booster dose from 14 days after vaccination, an absolute effectiveness of **93.1%** (95% CI, 91.7-94.3) after receiving ChAdOx1-S as the primary course and **94.0%** (95% CI 93.4-94.6) after receiving BNT162b2 as the primary course were estimated[26].

Further (biweekly) updated data on the seven WHO EUL vaccines and the vaccine candidate Novavax are synthesized in the synoptic table and new data has been highlighted in yellow

[26] Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study. *medRxiv.* https://www.medrxiv.org/content/10.1101/2021.11.15.21266341v1

Synoptic Table

Synoptic table about SARS-CoV-2 vaccines accepted in the WHO's Emergency Use Listing and Novavax Vaccine (as of 26 November 2021)

								AWAITING APPROVAL FROM WHO EUL
	BNT162b2/ COMIRNATY (Pfizer-BioNTech, USA)	**Spikevax/ Moderna COVID-19 Vaccine/ mRNA-1273 (Moderna, USA)**	**Vaxzevria/ ChAdOx1 nCoV-19/ AZD1222/ Covishield (AstraZeneca/Oxford, UK, India)**	**Janssen COVID-19 vaccine/Johnson & Johnson (Janssen, USA)**	**BBIBP-CorV, (Sinopharm, China)**	**CoronaVac (Sinovac, China)**	**COVAXIN / BBV152 (Bharat Biotech, India)**	**Novavax/ NVX-CoV2373**
GENERAL VACCINE INFORMATION								
Platform	mRNA-based vaccine	mRNA-based vaccine	Non-replicating vector-based vaccine	Non-replicating vector-based vaccine	Inactivated virus (Vero cell)	Inactivated virus (Vero cell)	Whole-virion inactivated Vero cell	Recombinant protein (nanoparticle) vaccine with Matrix-M adjuvant
Dose and frequency	2 doses, 21 days apart	2 doses, 28 days apart	2 doses, 4-12 weeks apart	1 dose, once [Phase III trials currently testing 2-dose regime, 56 days apart][i]	2 doses, 21 days apart	2 doses, 14 days apart	2 doses, 28 days apart	2 doses, 21 days apart

[i] Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S. *Johnson & Johnson*. https://www.jnj.com/johnson-johnson-announces-real-world-evidence-and-phase-3-data-confirming-strong-and-long-lasting-protection-of-single-shot-covid-19-vaccine-in-the-u-s

Target population	12 years old and over	12 years old and over	18 years old and over	18 years old and over	18 years old and over	18 years old and over	18 years old and over	18 years old and over
Storage conditions	2°C to 8 °C (for 1 month)	2°C to 8 °C (for 1 month)	2°C until 8 °C	2°C to 8 °C (for 3 months)	2°C until 8 °C	2°C until 8 °C	2°C until 8 °C	2°C to 8 °C
Approving authorities	FDA (11.12.20)[ii]; EMA (21.12.20); WHO EUL (31.12.20); and list of 103 countries (including Switzerland – approved on 20.12.20)	FDA (18.12.20); EMA (06.01.21); WHO EUL (30.04.21); and list of 76 countries (including Switzerland – approved 12.01.21)	FDA (awaiting on approval); EMA (29.01.21); WHO EUL (15.02.21); and list of 124 countries (Switzerland awaiting on approval)	FDA (27.02.21); EMA (11.03.21), WHO EUL (12.03.21), and list of 75 countries (including Switzerland – approved 22.03.21)	WHO EUL (07.05.21); and list of 68 countries (e.g., Argentina, Bahrain, Brazil, China, Indonesia, United Arab Emirates, Zimbabwe)	WHO EUL (01.06.21), and list of 42 countries (e.g., Albania, Chile, Egypt, Hong Kong, Malaysia, Tunisia, Turkey, Ukraine)	WHO EUL (03.11.21) and list of 9 countries (Guyana, Inidia, Iran, Mauritius, Mexico, Nepal, Paraguay, Philippines & Zimbabwe)	Waiting on approval (Not-yet-approved by countries or WHO for emergency use)
Booster shot approving authorities	EMA approved booster for those aged 18 and above, 6 months after the 2nd dose[1] FDA approved booster for those ages 16 and above, 6 months after the 2nd dose[iii]	EMA authorised booster dose for immunocompromised individuals[iv] FDA approved third booster dose for individuals >65 and high-risk individuals, 6 months after the 2nd dose[v]	-	-	-	-	-	-

[ii] Pfizer-BioNTech's Comirnaty Vaccine received full FDA approval on 23 August 2021 for people age 16 and above, moving it beyond emergency use status. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine

[iii] FDA authorizes booster dose of Pfizer-BioNTech COVID-19 vaccine for certain populations. *FDA News Release*. https://www.fda.gov/news-events/press-announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations

[iv] Comirnaty and Spikevax: EMA recommendations on extra doses and boosters. *European Medicines Agency*. https://www.ema.europa.eu/en/news/comirnaty-spikevax-ema-recommendations-extra-doses-boosters

[v] F.D.A. Panel recommends booster for many Moderna vaccine recipients. *The New York Times*. https://www.nytimes.com/2021/10/14/us/politics/fda-moderna-vaccine-boosters.html

EFFECTIVENESS AGAINST ANY SARS-COV-2 INFECTION								
Effectiveness single dose	*Against any SARS-CoV-2 infection:* **70%**[2]. **77.6%** (95% CI, 70.9-82.7)[3] **36.8%** (95% CI, 33.2-40.2) [3 weeks after first dose][4] **57%** (95% CI, 52-61; Spain) [Apr-Aug][5] **72%** (pooled meta-analysis)[6] **64%** (95% CI, 59%-68%; United States) [May to July 2021][7vi] **19.6%** (95% CI, 17.3-21.9; Norway) [Jan-Sep][8] *Against symptomatic disease*:	*Against SARS-CoV-2 infection:* **60%** (95% CI, 57-64; >2 weeks after dose)[11].[viii] **88.9%** (95% CI, 78.7-94.2)[3] **66%** (95% CI, 56-73; Spain) [Apr-Aug][5] **69%** (pooled meta-analysis)[6] **64%** (95% CI, 59%-68%; United States) [May to July 2021][7ix] **39.6%** (95% CI, 36.3-42.8; Norway) [Jan-Sep][8] *Against symptomatic disease*: **71%** (95% CI, 61-79; Spain) [Apr-Aug][5]	*Against SARS-CoV-2 infection:* **31.4%** (95% CI, 25.7-36.7; Norway) [Jan-Sep][8] *Symptomatic disease:* **67%**[12] **49%** (95% CI, 32.0-62.0; India) [Apr-Jun][13] **41%** (95% CI, 34-48; Spain) [Apr-Aug][5] **51%** (pooled meta-analysis)[6] **46%** (95% CI, 37-54; Spain) [Apr-Aug][5] *Individuals ≥70:* Symptomatic disease: **58%**[9].	*Against SARS-CoV-2 infection:* **50.6%** (95% CI, 14.0-74.0) [<2 weeks after dose]; **76.7%** (95% CI, 30.3-95.3) [>2 weeks after dose][14]; **79%** (95% CI, 77-80) (when corrected for under-recording, VE was estimated to be **69%** (95% CI, 67-71)[15]. **71%** (95% CI, 56-81) [11 March – 15 August][16]. **61%** (95% CI, 29-84) [January-June][17] **50.9%** (95% CI, 35.1-63.0) [June-September; Brazil][18]	Partial protection[22].[xii]	**15.5%** for preventing COVID-19; **37.4%** for preventing hospitalization; **44.7%** for preventing admission to the ICU; and **45.7%** for preventing of COVID-19 related death[23]. **18.6%** (95% CI, 17.6-19.6) against SARS-CoV-2 infection, **28.1%** (95% CI, 26.3-29.9) against hospitalization, **28.5%** (95% CI, 25.4-31.4) against ICU admission, and **29.4%** (95% CI, 26.7.3-31.9) against death [January-April][24]	*Against symptomatic disease*: **45%** (95% CI,6.0-68.0; India) [Apr-Jun][13] **40%** (95% CI, -21-71; India) less than 7 days after first dose [April-May][25] **1%** (95% CI, -30-25); India) at least 7 days after first dose [April-May][25] **-1%** (95% CI, -51-33; India) at least 21 days after first dose [April-May][25]	Ongoing studies in South Africa[26] and the United Kingdom[27]

[vi] Results do not disaggregate between mRNA vaccines, BNT162b2 and mRNA-1273.
[viii] mRNA-aggregated data (results do not disaggregate between BNT162b2 and mRNA-1273).
[ix] Results do not disaggregate between mRNA vaccines, BNT162b2 and mRNA-1273.
[xii] Study did not report numerical data on vaccine effectiveness. Further studies are required to validate results.

	66% (95% CI, 60-71; Spain) [Apr-Aug][5] *Individuals ≥70:* Symptomatic disease: **58%**[9]. Hospitalization risk reduced by 35-**45%**[9]. Risk of death reduced by **54%**[9]. *Individuals ≥50:* ≥14 days after first dose: **54%** (95% CI, 47-61) effectiveness against hospitalization [1 January-22 June[10]. [vii]	*Individuals ≥70:* Symptomatic disease: **64%** (95% CI, 46-78; >2 weeks after dose)[11].[x] *Individuals ≥50:* ≥14 days after first dose: **54%** (95% CI, 47-61) effectiveness against hospitalization [1 January-22 June[10].[xi]	Hospitalization risk reduced by **35-45%**[9].	**50.0%** (95% CI, 42.0-57.0; Spain) [Apr-Aug][5] **73.6%** (95% CI, 65.9-79.9; US) [Feb-Jul][19] *Symptomatic disease*: **54%** (95% CI, 45-62; Spain) [Apr-Aug][5] **81%** (95% CI, 79-84) for preventing hospitalization when corrected for under-recording, VE was estimated to be **73%** (95% CI, 69-76)[15]. **75%** (95% CI, 65-82) against severe critical COVID-19[20] **66.1%** against moderate to severe-critical				

[vii] mRNA-aggregated data (results do not disaggregate between BNT162b2 and mRNA-1273).
[x] mRNA-aggregated data (results do not disaggregate between BNT162b2 and mRNA-1273).
[xi] mRNA-aggregated data (results do not disaggregate between BNT162b2 and mRNA-1273).

				COVID-19 cases after 28 days [ENSEMBLE study; Sep 2020-Nov 2021)[21] **85.4%** against severe COVID-19 cases after 28 days [ENSEMBLE study; Sep 2020-Nov 2021)[21] *Individuals ≥50:* 68% (95% CI, 50-79)[10].				
Effectiveness of two doses	*SARS-Cov-2 infection:* **85%**[2]. **94.6%**[28]. **94.5%**[29]. **76%** (95% CI, 69-81) [Jan-Jul][30]. **88.8%** (95% CI, 84.6-91.8) [Dec 2020-May][3] **74%** (95% CI, 72-76) [Jan-Jun][17]	*SARS-Cov-2 infection:* **100%**[28]. **86%** (95% CI, 81-90.6) [January-July][30]. **96.3%** (95% CI, 91.3-98.4) [December-May][3]	*Asymptomatic efficacy:* 61.9%[37] *SARS-CoV-2 infection*: **53%** (95% CI, 12-84) [January-June][17] **27%** (95% CI, 17-37) [4 months	Not Applicable (one dose schedule)	Partial protection[22].[xx]	**65.9%** for preventing COVID-19; **87.5%** for preventing hospitalization; **90.3%** for preventing ICU admission; and **86.3%** for preventing COVID-19 related death[23].	*Against symptomatic disease*: **71%** (95% CI, 41-85; India) [Apr-Jun][13] *Effectiveness of full vaccination:* **69%** (95% CI; 54-79; India) [May - July 2021][38]	Ongoing studies in South Africa[26] and the United Kingdom[27] **89.7%** protection against SARS-CoV-2 infection (95% CI, 80.2-94.6; United Kingdom)[40]

[xx] Study did not report numerical data on vaccine effectiveness. Further studies are required to validate results. Death reports on fully vaccinated doctors (10 cases during June 2021 in Indonesia). It may be related to new variants [media report]. Indonesian Covid deaths add to questions over Sinovac vaccine. *The Guardian* [press release]. https://www.theguardian.com/world/2021/jun/28/indonesian-covid-deaths-add-to-questions-over-sinovac-vaccine

	77.5% (95% CI, 76.4-78.6) [first month after second dose][4] **47%** (95% CI, 43-51) [5 months after second dose][31] **56%** (95% CI, 53-59) [4 months after second dose][32] **69%** (95% CI, 66-72; Spain) [Apr-Aug][5] **88%** (pooled meta-analysis)[6] **84%** (95% CI, 40-96; Italy) [27 Dec 2020 – 24 Mar 2021] 14-21 days from the first dose and **95%** (95% CI, 62-99; Italy) [27 Dec 2020 – 24 Mar 2021] at least 7 days from the second dose[33] **95%** (95% CI, 93%-96%; United States) [May to July 2021][7xiii]	**85%** (95% CI, 80-90) [January-June][17] **71%** (95% CI, 68-74) [4 months after second dose][32] **63%** (95% CI, 44-76) [June-August][36] **82%** (95% CI, 78-86; Spain) [Apr-Aug][5] **80%** (pooled meta-analysis)[6] **95%** (95% CI, 93%-96%; United States) [May to July 2021][7xvi] **78.2%** (95% CI, 76.7-79.6; Norway) [Jan-Sep][8] *Symptomatic disease*: **91%** after second dose][32] **88%** (95% CI, 79.0-94.0; India) [Apr-Jun][13] **54.0%** (95% CI, 48-60; Spain) [Apr-Aug][5] **43.4%** (95% CI, 4.4-66.5; Norway) [Jan-Sep][8] *Effectiveness of full vaccination:* **80%** (95% CI; 73-86; India) [May - July 2021][38] *Symptomatic disease*: **90%**[12]. **56%** (95% CI, 48-63; Spain) [Apr-Aug][5]				**52.7%** (95% CI, 52.1-53.4) against SARS-CoV-2 infection, **72.8%** (95% CI, 71.8-73.7) against hospitalization, **73.8%** (95% CI, 72.2-75.2) against ICU admission, and **73.7%** (95% CI, 72.3-75.0) against death [January-April][24] *In pregnant women*: **41%** (95% CI, 27.1-52.2%; Brazil) against symptomatic COVID-19, **85%** (95% CI, 59.5-94.8; Brazil) against severe COVID-19, and **75%** (95% CI 27.9-91.2; Brazil)[39]	**50%** (95% CI, 33-62; India) 14 days after second dose [April-May][25] **47%** (95% CI, 29-61; India) 14 days after second dose – excluding participants with previous SARS-CoV-2 infections [April-May][25] **46%** (95% CI, 22-62; India) 28 days after second dose [April-May][25] **57%** (95% CI, 21-76; India) 42 days after second dose [April-May][25]	

[xiii] Results do not disaggregate between mRNA vaccines, BNT162b2 and mRNA-1273.

[xvi] Results do not disaggregate between mRNA vaccines, BNT162b2 and mRNA-1273.

	69.7% (95% CI, 68.6-70.8; Norway) [Jan-Sep][8] *Symptomatic disease*: **72%** (95% CI, 69-75; Spain) [Apr-Aug][5] *Asymptomatic SARS-CoV-2 infection:* **90.6%**[34].[xiv] **73.1** (95% CI, 70.3-75.5)[4] *Hospitalization:* **85%** (95% CI, 73-93) [January-July][30]. **88%** (95% CI, 85-91) [11 March – 15 August][16]. **89%** (95% CI, 87-91) for individuals ≥50 years [1	(95% CI, 89-93; >2 weeks after dose)[11].[xvii] **85%** (95% CI, 80-89; Spain) [Apr-Aug][5] *Asymptomatic SARS-CoV-2 infection:* **90.6%**[34].[xviii] **71%** (95% CI, 61-78) [January-August][36] *Hospitalization:* **91.6%** (95% CI, 81-97) [January-July][30]. **93%** (95% CI, 91-95) [11 March – 15 August)[16]. **89%** (95% CI, 87-91) for individuals ≥50 years [1						

[xiv] Results do not disaggregate between BNT162b2 and mRNA-1273
[xvii] Results do not disaggregate between BNT162b2 and mRNA-1273.
[xviii] Results do not disaggregate between BNT162b2 and mRNA-1273

	January-22 June[10]. [xv] **90%** (95% CI, 89-92) [Dec 2020 – Aug 2021][31] *Individuals ≥65:* **61%** (95% CI, 57-65) against SARS-CoV-2 infection and **86%** (95% CI, 82-88) against hospitalizations[31] *Individuals ≥ 80:* VE of **68.3%** (95% CI, 65.5-70.9) for infections, **73.2%** (95% CI, 65.3-79.3) for hospitalization, **85.1%** (95% CI, 80.0-89.0) for mortality [Germany, 09 Jan – 11 Apr 2021][35]	January-22 June[10]. [xix]							
EFFECTIVENESS AGAINST VARIANTS[xxi]									

[xv] mRNA-aggregated data (results do not disaggregate between BNT162b2 and mRNA-1273).
[xix] mRNA-aggregated data (results do not disaggregate between BNT162b2 and mRNA-1273).
[xxi] Effectiveness data against the latest variant of interest (Mu) will be included in upcoming reports based on data availability.

Alpha (B.1.1.7)	*Single dose:* **48.7%** (95% CI, 45.5 to 51.7)[41] **66%** (95% CI,64-68)[42]. **54.5%** (95 CI, 50.4-58.3)[43] *Two doses:* **93.7%** (95% CI, 91.6 to 95.3)[41] **92%** (95% CI, 90-93)[44]. **89%** (95% CI, 86-91)[42]. **78%** (95% CI, 68-84)[45] **84.4%** (95 CI, 81.8-86.5)[43]	*Single dose:* **88.1%** (95% CI, 83.7 to 91.5)[46] **83%** (95% CI, 80-86)[42]. *Two doses:* **100%** (95% CI, 91.8 to 100)[46] **92%** (95% CI, 86-96)[42]. **98.4%** (95% CI, 96.9-99.1)[47]	*Single dose:* **48.7%** (95% CI 45.5 to 51.7)[41] 6**4%** (95% CI, 60-68)[42]. *Two doses:* **74.5%** (95% CI, 68.4 to 79.4)[41] **73%** (95% CI, 66-78)[44]. 79% (95% CI, 56-90)[45].	-	No published data	*Two doses:* Equally effective **(~76%**) in neutralizing D614G, B.1.1.7 and B.1.429 as the wild-type strain.	No available data	Ongoing studies in South Africa[26] and the United Kingdom[27] Post hoc analysis showed efficacy of **86.3%** (95% CI, 71.3-93.5; United Kingdom) **against B.1.1.7 variants** and **96.4%** (95% CI, 73.8-99.5; United Kingdom) **against non-B.1.1.7 variants.**[40]
Beta (1.351)	*Single dose:* **60%** (95% CI, 52-67)[42]. *Two doses:* **84%** (95% CI, 69-92)[42].	*Single dose:* **61.3%** (95% CI, 56.5 to 65.5)[46] **77%** (95% CI, 69-92)[42]. *Two doses:* **96.4%** (95% CI, 91.9 to 98.7)[46]	*Single dose:* **48%** (95% CI, 28-63)[42].	-	No published data	Neutralization capacity was decreased by factor **5.27**[48].	No available data	No available data

Gamma (P.1)	Neutralization activity reduced by **3.3-fold**[49].	No available data	No available data	No available data	No published data	Demonstrated **42%** vaccine effectiveness in a setting with high P.1 transmission, in individuals aged 70 and above[50]. **50.2%** against P.1 (>14 days after 2nd dose)[51]. Neutralization was decreased by factor **3.92**[48].	No available data	No available data
Delta (1.617.2)	*Single dose:* **30.7%** (95% CI, 25.2 to 35.7)[41]; **57%** (95% CI, 50-63)[45] **22.5%** (95 CI, 17.0-27.4)[43] *Two doses:* **88.0%** (95% CI, 85.3 to 90.1)[41]; **80%** (95% CI, 77-83)[45] **79%** (95% CI,75-82)[44]. **80%** (95% CI, 77-83)[45] **40.5%** (95% CI, 8.7-61.2)[52].	*Single dose:* **72%** effective against symptomatic SARS-Cov-2 infection[56]. *≥14 days after second dose:* **76%** (95% CI, 58-87)[30]. **94.5%** (95% CI, 94.1-95) [2-9 weeks after second dose][53]. **50.6%** (95% CI, 45.0-55.7) [among nursing home residents][54].	*Single dose:* **30.7%** (95% CI 25.2 to 35.7)[41] **73%** (95% CI, 64-80; India) [May – July 2021][38] *Two doses:* **67.0%** (95% CI, 61.3 to 71.8)[41] **67%** (95% CI, 62-71)[45]. **60%** (95% CI, 53-66)[44]. **66.7%** (95% CI, 45-49.6) [2-9 weeks after second dose][53].	**78%** (95% CI, 73-82) against SARS-CoV-2 infection[15]. **3%** (95% CI, -7-12) [August][55] *Individuals ≥50:* **83% (**95% CI, 81-85)[15]	No available data	*Single dose:* **13.8%** (95% CI, -60.2-54.8)[59]. *Two doses:* **59%** (95% CI, 16-81.6) against SARS-CoV-2 infection and **70.2%** (95% CI, 29.6-89.3) against moderate COVID-19 infection[59].	*Single dose*: **44%** (95% CI, 0-71; India) [May – July 2021][38] *Two doses:* **64%** (95% CI, 40-79; India) [May – July 2021][38]	No available data

	42% (95% CI, 13-62)[30]. **89.8%** (95% CI, 89.6-90.0) [2-9 weeks after second dose][53]. **69.7%** (95% CI, 68.7-70.5) [≥20 weeks after second dose][53]. **64.6%** (95 CI, 60.6-68.2)[43] **52.4%** (95% CI, 48.0-56.4) [among nursing home residents][54]. **53%** (95% CI, 39-65) [4 months after second dose][31] **50%** (95% CI, 47-52) [August; elderly Veteran population][55] *Against severe COVID-19:* **91.4%** (95% CI, 82.5-95.7)[52].	**86.7%** (95% CI, 84.3-88.7)[47] **56.6%** (95% CI, 42.0-67.5) *against infection*[57] **84.2%** (95% CI, 56.4-94.3) *against symptomatic infection*[57] **64%** (95% CI, 62-66) [August; elderly Veteran population][55] *10-14 weeks after second dose:* **90.3%** (95% CI, 67.2-97.1)[53].	**47.3%** (95% CI, 66.3-67.0) [≥20 weeks after second dose][53]. **81%** (95% CI, 71-88; India) [May – July 2021][38] Odds ratio of **5.45** (95% CI, 1.39-21.4) to become infected with B.1.167.2 compared to non-B.1.167.2 [58].					
Mu (B.1.621)	Mu variant is 9.1 times more resistant than the	*Two doses:* **90.4%** (95% CI, 73.9-96.5)[47]	No available data	No available data	No available data	No available data		No available data

	wild type strain when vaccinated with BNT162b2[60]	(demonstrated similar protective measures as against the Alpha variant)					No available data	
EFFECTIVENESS AGAINST HOSPITALIZATION								
Any SARS-CoV-2 infection	*Single dose:* **85%** (pooled meta-analysis)[6] *Two doses:* **91%** (pooled meta-analysis)[6] **91%** (95% CI, 93%-96%; United States) [May to July 2021][7xxii]	*Single dose:* **73%** (pooled meta-analysis)[6] *Two doses:* **88%** (pooled meta-analysis)[6] **91%** (95% CI, 93%-96%; United States) [May to July 2021][7xxiii]	*Single dose:* **56%** (pooled meta-analysis)[6] *Two doses:* **91%** (pooled meta-analysis)[6]	No available data	No available data	No available data	No available data	No available data
Alpha	Single dose: **83%** (95% CI, 62-93) **53%** (95% CI, 7-83; England) [Feb-Sep 2021][61] Two doses: **95%** (95% CI, 78-99)[62]. **71%** (95% CI, 12-95; England) [Feb-Sep 2021][61] *Against death:*	No available data	Single dose: **76%** (95% CI, 61-85) **3%** (95% CI, -38 – 39; England) [Feb-Sep 2021][61] Two doses: **86%** (95% CI, 53-96)[62]. **26%** (95% CI, -39 – 73; England) [Feb-Sep 2021][61] *Against death:*	***Beta*** **67%** effective at preventing hospitalizations[63]. *Against death:* 96% effective at preventing death[63].	No available data	No available data	No available data	No available data

[xxii] Results do not disaggregate between mRNA vaccines, BNT162b2 and mRNA-1273.
[xxiii] Results do not disaggregate between mRNA vaccines, BNT162b2 and mRNA-1273.

	98.2% (95% CI, 95.9-99.2) [2-9 weeks][53]. **90.4%** (95% CI, 85.1-93.8) [≥20 weeks][53].		**94.1%** (95% CI, 91.8-95.8) [2-9 weeks][53]. **78.7%** (95% CI, 52.1-90.4) [≥20 weeks][53].					
Gamma	No available data	No available data	No available data	**72.9%** (95% CI, 35.1-91.1)[18] *Against ICU admission:* **92.5%** (95% CI, 54.9-99.6)[18] *Against death:* **90.5%** (95% CI, 31.5-99.6)[18]	No available data	No available data	No available data	No available data
Delta	*Single dose:* **94%** (95% CI, 46-99)[62]. **91%** (95% CI, 90-93)[64] **4%** (95% CI, -21 – 44; England) [Feb-Sep 2021][61] *Two doses:* **96%** (95% CI, 86-99)[62].	*Single dose:* **81%** (95% CI, 81-90.6)[30]. *Two doses:* **84%** (95% CI, 80-87)[64] **95%** (95% CI, 92-97) [June-August][66] **96.7%** (95% CI, 93.9-98.2)[8]	*Single dose:* **71%** (95% CI, 51-83)[62] **88%** (95% CI, 83-91)[64] **2%** (95% CI, -19 – 31; England) [Feb-Sep 2021][61] *Two doses:* **92%** (95% CI, 75-97)[62].	**71%** [63] **85%** (95% CI, 73-91)[15]. **91%** (95% CI, 88-94)[64] **85%** effective at preventing severe disease and hospitalization[69].	*Single dose:* Does not offer clinically meaningful protection against severe illness [70,xxiv] *Two doses:* **88%** (95% CI, 55-98) adjusted risk reduction in	*Single dose:* Does not offer clinically meaningful protection against severe illness [70,xxvi] *Two doses:* **88%** (95% CI, 55-98) adjusted risk reduction in	No available data	No available data

[xxiv] Study does not differentiate between the two inactivated vaccines, BBIBP-CorV and CoronaVac.
[xxvi] Study does not differentiate between the two inactivated vaccines, BBIBP-CorV and CoronaVac.

	88% (95% CI, 78.9-93.2)[52]. **75%** (95% CI, 24-93.9)[30]. **84%** (95% CI, 79-89)[65]. **98.4%** (95% CI, 97.9-98.8) [2-9 weeks][53]. **92.7%** (95% CI, 90.3-94.6) [≥20 weeks][53]. **96%** (95% CI, 95-96)[64] **80%** (95% CI, 73-85) [June-August][66] **93%** (95% CI, 84-96)[67] **96.8%** (95% CI, 93.9-98.3)[2 months after the second dose][4] **93%** (95% CI, 84-96)[31] **91.5%** (95% CI, 89.5-93.2)[8] **24%** (95% CI, -2 – 64; England) [Feb-Sep 2021][61] *Against death:*	*Against ICU admission:* **86%** (95% CI, 79-90)[64] **96%** against severe COVID-19 infection[56].	**95.2%** (95% CI, 94.6-95.6) [2-9 weeks][53]. **77.0%** (95% CI, 70.3-82.3) [≥20 weeks][53]. **94%** (95% CI, 92-95)[64] **14%** (95% CI, -5 – 46; England) [Feb-Sep 2021][61] *Against ICU admission:* *Single dose:* **92%** (95% CI, 84-96)[64] *Two doses*: **96%** (95% CI, 94-98)[64] *Against death:* **91%** (95% CI, 86-94) [≥2 weeks after second dose][68]	*Individuals ≥50:* **84% (**95% CI, 81-85)[15] *Against ICU admission:* **94%** (95% CI, 88-98)[64]	developing severe illness.[70,xxv]	developing severe illness.[70,xxvii]		

[xxv] Study does not differentiate between the two inactivated vaccines, BBIBP-CorV and CoronaVac.
[xxvii] Study does not differentiate between the two inactivated vaccines, BBIBP-CorV and CoronaVac.

	90% (95% CI, 83-94) [≥2 weeks after second dose][68]							
DURATION OF PROTECTION, TRANSMISSION & BREAKTHROUGH INFECTIONS								
Duration of protection (antibodies)	Median time between second dose and infection: **146 days (IQR, 121-167)**[71] *Anti-SARS-CoV-2 Antibodies:* 1 month after 2nd dose: **1762 KU/L (IQR: 933-3761)** 3 months after 2nd dose: **1086 KU/L (IQR: 629-2155)** 6 months after 2nd dose: **802 KU/L (IQR, 447-1487)**[72] No health worker had antibodies BELOW method-dependent cut-off (0.8 KU/L) *Neutralizing antibodies:*	*Preliminary phase I results:* Antibody activity remained high in all age groups at **day 209** (approximately 6 months) GMT were lower in ≥56 years old[76] *Neutralizing antibodies:* At peak immunity, NAb titre was **5,848**, after 8 months titre was **133**[73] *Pseudovirus neutralizing antibodies:* At peak immunity, pseudovirus NAb titre was **1,569**, after 8 months titre was **273**[73]	*Antibody Response:* After single dose, antibody response declined within one year, but remained above baseline levels. Antibody levels after **day 180**: 0.54 GMR (CI, 0.47-0.61). Antibody levels after **day 320**: 0.30 GMR (CI, 0.24-0.39)[77] *Cellular Immune Response:* **Day 182** after first dose: median of **237 SFUx10^6 PBMC (IQR, 109-520)**[77] **6 months** after second dose: **(median 1240,**	*Neutralizing antibodies:* Remained largely stable for **8-9 months**[78] Remained **stable for 8 months**; At 4 weeks after immunization NAb titre was **146**, after 8 months titre was **629**[73] *Pseudovirus neutralizing antibodies:* Remained **stable for 8 months**; At 4 weeks after immunization pseudovirus NAb titre was **391**, after 8 months titre was **185**[73] *Binding antibodies:*	*Antibody Response:* **Unexposed subjects:** After 1st dose: **43.6 IU/mL** (95% CI, 30.3-62.8) After 2nd dose: **377.0 IU/mL** (95% CI: 324.3-438.3) 3 months after 2nd dose: **125.4 IU/mL** (95% CI: 88.2-178.4)[80] **Exposed subjects:** Before 1st dose: **203.2 UI/mL** (95% CI: 42.9-962.4) After 1st dose: **761.7 UI/mL** (95% CI: 381.1-1522) After 2nd dose: **719.9 UI/mL** (95% CI : 264.6-1959) 3 months after 2nd dose: **484.4 IU/mL**	A phase I/II clinical trial found that NAbs titres dropped below the seropositive cut-off of 8, **6 months** after the administration of the first dose[82]. **80-90%** of anti-S IgG and Nab titers against wild type waned **6 months** after second vaccination[83] *Anti-spike Protein RBD IgG Antibodies:* **Younger age groups (<60):** 1 month after 2nd dose: 97% seropositivity, **11.3** (IQR, 6.2-20.7) 3 months after 2nd dose: 76%	No available data	No available data

	At peak immunity, NAb titre was **1,789**, after 8 months titre was **53**[73] *Pseudovirus neutralizing antibodies:* At peak immunity, pseudovirus NAb titre was **700**, after 8 months titre was **160**[73] *Anti-spike Protein RBD IgG Antibodies:* At peak immunity, RBD titre was **21,564**, after 8 months titre was **755**[73] **Younger age groups (<60):** 1 month after 2nd dose: 100% seropositivity, **35.3** (IQR, 27.6-40.0) 3 months after 2nd dose: 100% seropositivity, **19.2** (IQR, 8.2-23.1)[74]	*Anti-spike Protein RBD IgG Antibodies:* At peak immunity, RBD titre was **25,677**, after 8 months titre was **1,546**[73] *Humoral & Cellular Immune Response:* CD8+ T cell response was **0.017%** 8 months after full vaccination[73]	**IQR 432-2002**) in groups with 15-25 week interval between doses[77] *Anti-spike Protein RBD IgG Antibodies:* **Younger age groups (<60):** 1 month after 2nd dose: 100% seropositivity, **17.1** (IQR, 9.9-23.6) 3 months after 2nd dose: 97% seropositivity, **6.5** (IQR, 3.5-9.3)[74] **Older age groups (≥60)**: 1 month after 2nd dose: 96% seropositivity, **13.3** (IQR, 6.9-27.7) 3 months after 2nd dose: 90% seropositivity, **3.9** (IQR, 1.9-8.4)[74]	Remained stable **6 months** irrespective of age group[78] *Humoral & Cellular Immune Response:* Antibody responses were detected in all vaccine recipients on **day 239** (stable response for at least 8 months)[79] CD8+ T cell response was **0.12%** 8 months after vaccination[73] *Anti-spike Protein RBD IgG Antibodies:* Remained **stable for 8 months**; At 4 weeks after immunization titre was **1,361**, after 8 months titre was **843**[73]	(95% CI: 147.3-1593)[80] *Anti-RBD IgG*: Decreased up to **41.8%** 2 months after second dose and dropped to **42.9%** decrease after 7 months[81] *Binding Antibodies:* Decreased **82.1%** 7 months after second dose[81]	seropositivity, **2.4** (IQR, 1.0-5.0)[74] **Older age groups (≥60)**: 1 month after 2nd dose: 88% seropositivity, **6.4** (IQR, 2.5-13.6) 3 months after 2nd dose: 60% seropositivity, **1.3** (IQR, 0.5-3.3)[74]		

	Older age groups (≥60): 1 month after 2nd dose: 100% seropositivity, **29.4** (IQR, 22.5-33.3) 3 months after 2nd dose: 100% seropositivity, **14.8** (IQR, 7.4-18.7)[74] <u>*Sub-populations:*</u> **Older age (≥65): 38%** to **42%** decrease of humoral antibodies compared to 18- to 45-year-old[75] **Older age (≥65) AND men: 37%** to **46%** decrease compared to 18- to 45-year-old women[75] **Immunosuppression: 65% to 70%** decrease compared to non-immunosuppressed[75]									

	Obesity (BMI ≥30): **31%** increase in neutralizing antibody compared with nonobese[75] *Humoral & Cellular Immune Response:* CD8+ T cell response was **0.016%** 8 months after full vaccination[73]							
Duration of protection (vaccine effectiveness)	*Effectiveness against any SARS-CoV-2 Infection:* After reaching peak VE (77.5%) 1 month after 2nd dose, VE dropped to **20%** in **months 5-7** after 2nd dose[84] VE reduced from **87%** (95% CI, 85-89) to **56%** (95%	**36.4** (95% CI, 17.1-51.5) reduction of observed incidence rate (SARS-CoV-2 infection) if vaccinated from Dec 2020 – Apr 2021 than Jul 2021 – Dec 2020.[90] **46.0** (95% CI, -52.4-83.2) reduction of	VE reduced by 7% (95% CI, -18 - 2) for every 30 days from the second dose for those aged 18 to 64 years[45]. VE reduced from **58%** (95% CI, 51-65) to **27%** (95% CI, 17-37) after 4 months.[32] VE reduced from **88%** (95% CI, 87-	A study observed sustained and stable vaccine effectiveness starting 14 days post vaccination to a maximum of **152** days after vaccination[15]. VE decreased from **89.4%** in May to **51.7%** in July[36]	No available data	No available data	No available data	No available data

	CI, 53-59) after 4 months.[32] VE reduced from **91%** (95% CI, 91-92) in March to **50%** (95% CI, 47-52) in August[55] VE reduced from **89.0%** (95% CI, 84.6-92.1; United States) [May to August] to **62.7%** (95% CI, 62.4-63.1; United States) [May to August][85xxviii] VE decreased by **18.5% points** (95% CI 8.4-33.4) among all ages and **19.9% points** among older individuals (95% CI; 9.2-36.7) [Overall average from Systematic	observed incidence rate (**severe** SARS-CoV-2 infection) if vaccinated from Dec 2020 – Apr 2021 than Jul 2021 – Dec 2020.[90] VE against the Delta variant declined from **94.1%** (95% CI, 90.5-96.3) 14-60 days after vaccination to **80.0%** (95% CI, 70.2-86.6) 151-180 days after vaccination.[47] **91%** [January-March] **71%** (95% CI, 53-83) [April-May] **63%** (95% CI, 44-76)[36]	89) in March to **3%** (95% CI, -7-12) in August[55] VE decreased by **18.5% points** (95% CI 8.4-33.4) among all ages and **19.9% points** among older individuals (95% CI; 9.2-36.7) [Overall average from Systematic Review and Meta-Regression][86xlii] *Effectiveness for symptomatic COVID-19 disease:* VE decreased by **25.4%** (95% CI, 13.7-42.5) among all ages and **32.0%** (95% CI, 11.0-69.0) among older individuals [Overall average	VE decreased from **86.4%** (95% CI, 85.2-87.6) in March 2021 to **13.1%** (95% CI, 9.2-16.8) in September 2021[88] *Fully vaccinated HCWs*: Adjusted **VE was 82.3%** (95% CI, 75.1-87.4%; United States) [16 Dec 2020 to 30 Sept 2021][89xlv] *Fully vaccinated HCWs during the period of Delta variant predominance*: Adjusted **VE was 76.5%** (95% CI, 40.9-90.6; United States) [01 July 2021 to 30 Sept 2021][89xlvi]				

[xxviii] Study does not differentiate between the two mRNA vaccines, Pfizer and Moderna.
[xlii] Study does not differentiate between Pfizer/BioNTech-Comirnaty, Moderna-mRNA-1273, Janssen-Ad26.COV2.S and AstraZeneca-Vaxrevria.
[xlv] Study does not differentiate between Pfizer, Moderna, and Janssen.
[xlvi] Study does not differentiate between Pfizer, Moderna, and Janssen.

	Review and Meta-Regression][86xxix] *Effectiveness for symptomatic COVID-19 disease:* VE decreased by **25.4%** (95% CI, 13.7-42.5) among all ages and **32.0%** (95% CI, 11.0-69.0) among older individuals [Overall average from Systematic Review and Meta-Regression[86xxx] *Effectiveness for severe COVID_19 disease:* VE decreased by **8.0%** (95% CI, 3.6-15.20) among all ages and **9.7%** (95% CI; 5.9-14.7) among older	VE reduced from **90%** (95% CI, 88-91) to **71%** (95% CI, 68-74) after 4 months[32] VE reduced from **91%** (95% CI, 72-98) in January-March to **71%** (95% CI, 53-83) in April-May to **63%** (95% CI, 44-76) in June-August[36] VE reduced from **92%** (95% CI, 92-93) in March to **64%** (95% CI, 62-66) in August[55] VE against infection was **82%** (95% CI, 79-85) 14-90 days after the second dose and appeared to	from Systematic Review and Meta-Regression][86xliii] *Effectiveness for severe COVID_19 disease:* VE decreased by **8.0%** (95% CI, 3.6-15.20) among all ages and **9.7%** (95% CI; 5.9-14.7) among older individuals [Overall average from Systematic Review and Meta-Regression][86xliv]	VE decreased by **18.5% points** (95% CI 8.4-33.4) among all ages and **19.9% points** among older individuals (95% CI; 9.2-36.7) [Overall average from Systematic Review and Meta-Regression][86xlvii] *Effectiveness for symptomatic COVID-19 disease:* VE decreased by **25.4%** (95% CI, 13.7-42.5) among all ages and **32.0%** (95% CI, 11.0-69.0) among older individuals [Overall average from Systematic				

[xxix] Study does not differentiate between Pfizer/BioNTech-Comirnaty, Moderna-mRNA-1273, Janssen-Ad26.COV2.S and AstraZeneca-Vaxrevria.
[xxx] Study does not differentiate between Pfizer/BioNTech-Comirnaty, Moderna-mRNA-1273, Janssen-Ad26.COV2.S and AstraZeneca-Vaxrevria.
[xliii] Study does not differentiate between Pfizer/BioNTech-Comirnaty, Moderna-mRNA-1273, Janssen-Ad26.COV2.S and AstraZeneca-Vaxrevria.
[xliv] Study does not differentiate between Pfizer/BioNTech-Comirnaty, Moderna-mRNA-1273, Janssen-Ad26.COV2.S and AstraZeneca-Vaxrevria.
[xlvii] Study does not differentiate between Pfizer/BioNTech-Comirnaty, Moderna-mRNA-1273, Janssen-Ad26.COV2.S and AstraZeneca-Vaxrevria.

	individuals [Overall average from Systematic Review and Meta-Regression][86xxxi] *Effectiveness against Hospitalization and Death:* After reaching peak VE (96.8%) 2 months after 2nd dose, **VE did not decline over time**, except for 7th months (VE 55.6%) with very few cases[84] VE reduced by 22% (95% CI, 6-41) for every 30 days from the second dose for those aged 18 to 64 years[45].	**wane over time** and was **63%** (95% CI, 55-68) 91-180 days after the second dose [27 Dec 2020 – 26 Oct 2021; Finland][87xxxv] VE decreased from **89.2%** (95% CI, 88.8-89.6) in March 2021 to **58.0%** (95% CI, 56.9-59.1) in September 2021[88] *Fully vaccinated HCWs*: Adjusted **VE was 82.3%** (95% CI, 75.1-87.4%; United States) [16 Dec 2020 to 30 Sept 2021][89xxxvi] *Fully vaccinated HCWs during the*		Review and Meta-Regression][86xlviii] *Effectiveness for severe COVID_19 disease:* VE decreased by **8.0%** (95% CI, 3.6-15.20) among all ages and **9.7%** (95% CI; 5.9-14.7) among older individuals [Overall average from Systematic Review and Meta-Regression][86xlix]				

[xxxi] Study does not differentiate between Pfizer/BioNTech-Comirnaty, Moderna-mRNA-1273, Janssen-Ad26.COV2.S and AstraZeneca-Vaxrevria.
[xxxv] Study does not differentiate between COMIRNATY/BNT162b2 and SPIKEVAX/ mRNA-1273.
[xxxvi] Study does not differentiate between Pfizer, Moderna, and Janssen.
[xlviii] Study does not differentiate between Pfizer/BioNTech-Comirnaty, Moderna-mRNA-1273, Janssen-Ad26.COV2.S and AstraZeneca-Vaxrevria.
[xlix] Study does not differentiate between Pfizer/BioNTech-Comirnaty, Moderna-mRNA-1273, Janssen-Ad26.COV2.S and AstraZeneca-Vaxrevria.

	VE against infection was **82%** (95% CI, 79-85) 14-90 days after the second dose and appeared to **wane over time** and was **63%** (95% CI, 55-68) 91-180 days after the second dose [27 Dec 2020 – 26 Oct 2021; Finland][87xxxii] VE decreased from **86.9%** (95% CI, 86.5-87.3) in March 2021 to **43.3%** (95% CI, 41.9-44.6) in September 2021[88] *Fully vaccinated HCWs*: Adjusted **VE was 82.3%** (95% CI, 75.1-87.4%; United States) [16	*period of Delta variant predominance*: Adjusted **VE was 76.5%** (95% CI, 40.9-90.6; United States) [01 July 2021 to 30 Sept 2021][89xxxvii] VE reduced from **89.0%** (95% CI, 84.6-92.1; United States) [May to August] to **62.7%** (95% CI, 62.4-63.1; United States) [May to August][85xxxviii] VE decreased by **18.5% points** (95% CI 8.4-33.4) among all ages and **19.9% points** among older individuals (95% CI; 9.2-36.7) [Overall average from Systematic							

[xxxii] Study does not differentiate between COMIRNATY/BNT162b2 and SPIKEVAX/ mRNA-1273.
[xxxvii] Study does not differentiate between Pfizer, Moderna, and Janssen.
[xxxviii] Study does not differentiate between the two mRNA vaccines, Pfizer and Moderna.

	Dec 2020 to 30 Sept 2021][89xxxiii] *Fully vaccinated HCWs during the period of Delta variant predominance*: Adjusted **VE was 76.5%** (95% CI, 40.9-90.6; United States) [01 July 2021 to 30 Sept 2021][89xxxiv]	Review and Meta-Regression][86xxxix] *Effectiveness for symptomatic COVID-19 disease:* VE decreased by **25.4%** (95% CI, 13.7-42.5) among all ages and **32.0%** (95% CI, 11.0-69.0) among older individuals [Overall average from Systematic Review and Meta-Regression)[86xl] *Effectiveness for severe COVID_19 disease:* VE decreased by **8.0%** (95% CI, 3.6-15.20) among all ages and **9.7%** (95% CI; 5.9-14.7) among older individuals							

[xxxiii] Study does not differentiate between Pfizer, Moderna, and Janssen.
[xxxiv] Study does not differentiate between Pfizer, Moderna, and Janssen.
[xxxix] Study does not differentiate between Pfizer/BioNTech-Comirnaty, Moderna-mRNA-1273, Janssen-Ad26.COV2.S and AstraZeneca-Vaxrevria.
[xl] Study does not differentiate between Pfizer/BioNTech-Comirnaty, Moderna-mRNA-1273, Janssen-Ad26.COV2.S and AstraZeneca-Vaxrevria.

		[Overall average from Systematic Review and Meta-Regression][86xli]						
Transmission prevention	*Prior Delta Variant:* Vaccine effectiveness against infectiousness given infections **41.3%**[91] VE against transmission **88.5%**[91] VE against onwards transmission of Alpha **57% (95% CI, 5-85)**[61] *During Delta Variant:* Similar Ct values (<25) were found in both vaccinated and unvaccinated groups[92]	VE against onwards transmission: **52%** (95% CI, 33-69)[17] VE against transmission from vaccinated index case to unvaccinated contact is **63%** (95% CI, 46-75) and **40%** (95% CI, 20-54) to a vaccinated contact. [95li]	**48%** (limited data) May not be able to block the transmission of the alpha variant as efficiently as the wild type[96]. VE against transmission from vaccinated index case to unvaccinated contact is **63%** (95% CI, 46-75) and **40%** (95% CI, 20-54) to a vaccinated contact. [95lii] Evidence of fully vaccinated individuals infecting other	Limited data	Unknown	Unknown	No available data	No available data

[xli] Study does not differentiate between Pfizer/BioNTech-Comirnaty, Moderna-mRNA-1273, Janssen-Ad26.COV2.S and AstraZeneca-Vaxrevria.

[li] Study does not differentiate between Comirnaty/BNT162b2, Spikevax/ mRNA-1273, and Vaxzevria/ ChAdOz1 nCOV-19.

[lii] Study does not differentiate between Comirnaty/BNT162b2, Spikevax/ mRNA-1273, and Vaxzevria/ ChAdOz1 nCOV-19.

	Studies from Scotland and England demonstrated reductions in secondary infections among families of vaccinated individuals compared to families of unvaccinated individuals[93,94]. VE against onwards transmission: **62%** (95% CI, 57-67)[17] VE against transmission from vaccinated index case to unvaccinated contact is **63%** (95% CI, 46-75) and **40%** (95% CI, 20-54) to a vaccinated contact. [95l]		fully vaccinated individuals[97] 81 breakthrough infections among 1100 HCWs; 32 breakthrough infections among 4000 HCWs[97] VE against onwards transmission of Alpha **35% (95% CI, -26 – 74)**[61] VE against onwards transmission of Delta **42% (95% CI, 14-69)**[61]						

[l] Study does not differentiate between Comirnaty/BNT162b2, Spikevax/ mRNA-1273, and Vaxzevria/ ChAdOz1 nCOV-19.

	VE against onwards transmission of Delta **31% (95% CI, -3 – 61**)[61]							
Breakthrough infections	From 6,161 patients with a positive nasopharyngeal SARS-CoV-2 PCR, 1,120 (18%) were breakthrough infections – 97% of these occurred after 2 May (emergence of Delta variant). Of the 1,120 cases, 126 (12%) were hospitalized. Of the 126 breakthrough admissions, 59 were vaccinated with BNT162b2[98]. Individuals vaccinated in January and February had a **51%** (95% CI, 40-68) increased risk for breakthrough infections	From 6,161 patients with a positive nasopharyngeal SARS-CoV-2 PCR, 1,120 (18%) were breakthrough infections – 97% of these occurred after 2 May (emergence of Delta variant). Of the 1,120 cases, 126 (12%) were hospitalized. Of the 126 breakthrough admissions, 36 were vaccinated with mRNA-1273. Breakthrough infections remained under 1% for fully vaccinated individuals (no difference	As of 10 June, 1.5 million individuals have been fully vaccinated with Covishield in Odisha Province, India. Between 1 March to 10 June, 239 breakthrough infections (SARS-CoV-2 positive after having received two doses of Covishield) were identified. Of these, 199 (83.3%) were symptomatic, 24 (10.0%) were hospitalized - 59 individuals had comorbidities[100] Median antibody titer: 647.5 AU/ml[100] Vietnamese study:	From 6,161 patients with a positive nasopharyngeal SARS-CoV-2 PCR, 1,120 (18%) were breakthrough infections – 97% of these occurred after 2 May (emergence of Delta variant). Of the 1,120 cases, 126 (12%) were hospitalized. Of the 126 breakthrough admissions, 10 were vaccinated with Ad26.COV2.S[98]. **4.2%** of fully vaccinated HCWs developed breakthrough infections – all cases were	No available data	No available data	As of 10 June, 380,000 individuals have been fully vaccinated with Covaxin in Odisha Province, India. Between 1 March to 10 June, 35 breakthrough infections (SARS-CoV-2 positive after having received two doses of Covishield) were identified. Of these, 29 (82.9%) were symptomatic, 3 (8.6%) were hospitalized. 5 individuals had comorbidities[100] Median antibody titer: 213.5 AU/ml[100]	No available data

	compared to individuals vaccinated in March and April[99] Breakthrough infections remained under 1% for fully vaccinated individuals (no difference between Pfizer or Moderna recipients between May and August 2021.[85]	between Pfizer or Moderna recipients between May and August 2021.[85]	High viral loads were observed 2-3 days before symptom onset among 49 symptomatic breakthrough cases (out of 62). Their peak viral loads measured at any point in time were higher than that of asymptomatic cases (IQR: 16.5 log10/mL vs 30.8 log10/mL, respectively). NAbs were measured for 10 breakthrough cases, all 10 cases had lower NAbs at day 14 and 90 post second vaccination compared to controls[101]	symptomatic but mild, only one case required hospitalization[liii] 102 Rate of breakthrough infections was comparable to Pfizer and Moderna recipients during the initial stages of the study, but increased to 1.96% (2 times the breakthrough rate of mRNA vaccines).[85]			**4.2%** of fully vaccinated HCWs developed breakthrough infections – all cases were symptomatic but mild, only one case required hospitalization [liv] 102	

[liii] Study does not differentiate between Covishield (*n*=62.4%) and Covaxin (*n*=37%).
[liv] Study does not differentiate between Covishield (*n*=62.4%) and Covaxin (*n*=37%).

SAFETY AND ADVERSE EVENTS								
Common side effects	Pain at the injection site, fatigue, headache, myalgia, chills and fever[103], arthralgia[104] Optimal safety for asthma patients[105]. The vaccine is considered safe for cancer patients undergoing treatments[106].	Pain at injection site, headache, fatigue, myalgia, arthralgia[107], Covid arm (cutaneous hypersensitivity)[108]. The vaccine is considered safe for cancer patients undergoing treatments[106].	Fatigue, myalgia, arthralgia, headache[109], lethargy, fever, & nausea[110].	Headache, fever, chills, fatigue, myalgia, and nausea[111].	Pain at the injection site, dizziness, fever, headache, fatigue, nausea, vomiting, & allergic dermatitis[110,112].	Pain at injection site, headache, fatigue, tremors, & flushing[113], inflammatory reaction, urticaria[114], myalgia[115]	Pain at injection site, headache, pyrexia, fatigue, myalgia[116]	Pain at injection-site, headache, muscle pain, fatigue[40]
Rare adverse events	Myocarditis & myopericarditis[117-119], anaphylaxis and swelling of the lips, face, and tongue related to anaphylaxis[120] (11 anaphylaxis cases per million doses administered)[121], axillary lymphadenopathy, paroxysmal ventricular arrhythmia, leg paresthesia[122],	Myocarditis & myopericarditis [117-119], orofacial swelling & anaphylaxis[120]. Potential risk factor for Bell's palsy[140] (most improve upon follow-up)[163], herpes zoster reactivation[127], varicella zoster reactivation[127], herpes zoster ophtalmicus[164],	Transverse myelitis, high fever[109,174], cutaneous hypersensitivity[174], vasculitis[175], thromboembolism[176], vaccine induced immune thrombotic thrombocytopenia[177, 178-180], intracerebral haemorrhage[181], small vessel vasculitis[178-180],	Thrombosis, thrombocytopenia, increased risk of developing Guillain-Barré syndrome post vaccination[200], herpes zoster ophtalmicus[164], pseudothrombocytopenia[201], vaccine induced thrombocytopic thrombosis[202], cutaneous reactions[159]	Cutaneous reactions[159] Rare adverse events were similar among the vaccine groups and control group within 7 days[203]. Pityriasis rosea[204], uveitis[205]	Myalgia, fever[113], pityriasis rosea (lesions improved completely after ~8 weeks)[124], reactivation of herpes zoster and herpes simplex[114]. Most reactions improved without treatment within a few weeks[114], Guillain-Barré syndrome[206], subacute thyroiditis[207],	No available data	Cutaneous reactions[159] Myocarditis was reported in one vaccine recipient, occurring 3 days after second dose[40]

	pityriasis rosea[123] (lesions improved completely after ~8 weeks)[124], lymphocytic vasculitis[125], varicella-zoster reactivation [126-128], Kikuchi-Fujimoto disease[129], thrombotic thrombocytopenic purpura[130,131], IgA nephropathy flare-up[132], Guillain-Barré syndrome [133,134], pustural psoriasis[135], immunoglobulin A vasculitis[136], immune complex vasculitis[137], Rhabdomyolysis[138], subacute thyroiditis[139], Bell's Palsy[140], erythema multiforme[141], vaccine induced interstitial lung disease[142], macular neuroretinopathy[143], brachial	eczema & urticaria[165], transverse myelitis[166], Guillain-Barré syndrome[167,168], acute generalized exanthematous pustulosis[169], rhabdomyolysis[170, 171], herpes zoster ophtalmicus[164], eczema & urticaria[165], transverse myelitis[166], Guillain-Barré syndrome[167,168], acute generalized exanthematous pustulosis[169], rhabdomyolysis[170, 171], cervical lymphadenopathy[172], glomerulonephritis[151], Behçet's disease[173], neurological autoimmune disease[154], axillary adenopathy[155], multiple	psoriasis[182], rosacea, raynaud's phenomenon[165], Ischaemic stroke[183], anaphylaxis[184], recurrent herpes zoster[185,lv], generalized bullous fixed drug eruption[186], Guillain-Barré syndrome[134,187], pityriasis rosea[188,189]. Vaccination in individuals with adrenal insufficiency can lead to adrenal crises[134,187], Dariers disease[188,189], vaccine induced acute localized exanthematous pustulosis[190], Henoch-Schönlein Purpura[191], rhabdomyolysis[192], Grave's disease[193], acute	97% of reported reactions after vaccine administration were non-serious[111].		erythema multiforme[208], uveitis[205], vaccine induced thrombotic thrombocytopenia[209], serum sickness-like reaction[210], cutaneous reactions[159]		

[lv] All cases occurred in patients with chronic urticaria and were being treated with cyclosporine.

	neuritis[144], thyroid eye disease[145], exacerbation of subclinical hyperthyroidism[146], rhabdomyolysis[147], internal jugular vein thrombosis[148], herpes simplex virus keratitis[149], cervical lymphadenopathy[150],glomerulonephritis[151], Ramsay-Hunt syndrome[152], Sweet's syndrome[153], neurological autoimmune disease[154], axillary adenopathy[155], multiple sclerosis[156], meningoencephalitis[157], intracerebral haemorrhage due to vasculitis[158], cutaneous reactions[159], pigmented purpuric dermatosis[160]	sclerosis[156], cutaneous reactions[159]	demyelinating polyradiculoneuropathy[194], erythema nodosum [195], polyarthralgia[196], recurrence of cutaneous T-cell lymphoma[197], neurological autoimmune disease[154], multiple sclerosis[156], sudden sensorineural hearing loss[198], acute-onset polyradiculoneuropathy[199], cutaneous reactions[159]						

	Systemic allergic symptoms were more common in BNT162b2 than mRNA-1273, however, anaphylaxis rates were similar for both mRNA vaccines[161] Having adverse reactions is associated with enhanced SARS-CoV-2 IgG antibody response[162]							
Potential associated adverse events (causal links not yet proven)	Cerebral venous sinus thrombosis and intracranial haemorrhage[211], aseptic meningitis[212], autoimmune hepatitis[213,214], multiple sclerosis relapse[215], myeloperoxidase anti-neutrophil cytoplasmic antibody-positive optic perineuritis[216],	Cerebral venous sinus[231], Autoimmune hepatitis[213], myocardial infarction[232], autoimmune haemolytic anaemia[233], hypophysitis & panhypopituitarism[234], erythema nodosum-like rash[234], pulmonary embolism[235], minimal change disease[236],	Autoimmune hepatitis[213,240,241], Acute hyperglycaemic crisis[242], Facial nerve palsy, cervical myelitis[183], alopecia areata[243], takotsubo (stress) cardiomyopathy[244], acute disseminated encephalomyelitis[245], cerebral venous sinus thrombosis[246,231]	Facial Diplegia[248], acute macular neurotinopathy[249], cerebral venous sinus thrombosis[231,250], oral lichen planus[251]	No available data	Likely vaccine associated disease enhancement (VADE)[252]	No available data	No available data

	central retinal vein occlusion[217], paracentral acute middle maculopathy & acute macular neurotinopathy[218], Stevens-Johnson syndrome/ toxic epidermal necrolysis[219,220], lichenoid cutaneous skin eruption[221], acute mania and psychotic features[222], acute psychosis due to anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis[223], alopecia areata[224], rhombencephalitis[225], multisystem inflammation and organ dysfunction[226], aplastic anaemia[227], bullous pemphigoid[228], minimal change disease[229], miller fisher syndrome[230]	encephalomyelitis[237], lupus nephritis[238] One case developed IgA Nephropathy after receiving the second dose of mRNA-1273[239].	(higher risk for women)[177], ophthalmic vein thrombosis[247]						

Myocarditis data	Mainly reported in young adults and adolescents [253] Israeli study: Estimated incidence within 42 days after receipt of first dose per 100,000 vaccinated persons was **2.13** cases (95% CI, 1.56-2.7)[254] Male patients Incidence of **4.12** (95% CI, 2.99-5.26) per 100,000 vaccinated[254] **3.19** cases (95% CI, 2.37-4.02) per 100,000 vaccinated[255] Female patients	Mainly reported in young adults and adolescents [253] 5.8 cases per 1 million second dose administrations[256]	No available data	No available data	No available data	No available data	No available data	Myocarditis was reported as viral myocarditis. Participant fully recovered after 2 days of hospitalisation. No episode of anaphylaxis or vaccine-associated enhanced COVID-19 was reported[40]

	Incidence of **0.23** (95% CI, 0-0.49) per 100,000 vaccinated[254] **0.39** cases (95% CI, 0.10-0.68) per 100,000 vaccinated[255] <u>≥30 years</u> Incidence of **1.13** (95% CI, 0.66-1.60) per 100,00 vaccinated[254] 5.8 cases per 1 million second dose administrations[256] 5.07 cases per 100,000[257] <u>Disease severity</u> Mild: **1.62** (95% CI, 1.12-2.11) Intermediate: **0.47** (95% CI, 0.21-0.74) Fulminant: **0.04** (95% CI, 0-0.12)[254]								

	Risk per 100,000 persons 1st dose (male): **0.64** 2nd dose (male); **3.83** 1st dose (female): **0.07** 2nd dose (female): **0.46** 1st dose (male 16-19): **1.34** 2nd dose (male 16-19): **15.07**[255]							
	CHILDREN VACCINATION							
Efficacy	*Adolescents (12-15):* After one dose had efficacy of **75% (CI, 7.6-95.5)** After second dose efficacy of **100% (CI, 78.1-100)**[258]. *Children (5-11):* After second dose efficacy of **90.7% (CI, 67.7-98.3)**[259]	*Adolescents (12-17):* After one dose had efficacy of **92.7% (CI, 67.8-99.2)** After second dose efficacy of **93.3% (CI, 47.9-99.9)**[261]. *Children (6month-11):* Ongoing trials[262]	No available data Paused ongoing trials in children aged 6-17 due to concerns over rare blood clots reported in adult population[263].	No available data Announced at begging of April ongoing study in adolescents but paused to investigate blood clots in adult population[263].	*Children (3-17):* Unknown. Ongoing clinical trial only looked at safety, tolerability, and immunogenicity[lvi] * * The study design administered **three doses** of 2 µg, 4 µg, or 8 µg of vaccine	*Children (3-17):* Unknown. Clinical trial only looked at safety, tolerability and immunogenicity[264].	No available data	*Adolescents (16-17):* PREVENT-19 clinical trial[lvii] expanded to assess efficacy, safety, and immunogenicity in 12–17-year-old adolescents[265]

[lvi] Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. *The Lancet Infectious Diseases.* https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00462-X/fulltext

[lvii] A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥18 Years With a Pediatric Expansion in Adolescents (12 to <18 Years) at Risk for SARS-CoV-2. *ClinicalTrials.gov*. ClinicalTrials.gov Identifier: NCT04611802. https://clinicaltrials.gov/ct2/show/NCT04611802?term=Novavax&cond=Covid19&draw=2

	Children (Under 5 years): Ongoing trials[260]							
Immunogenicity	*Adolescents (12-15) serum-neutralizing titer:* 1 month after 2nd dose had **1283.0 GMN_{50} (CI, 1095.5-1402.5)**[258]. *Adolescents/young adult (16-25) serum-neutralizing titer:* 1 month after 2nd dose had **705.1 GMN_{50} (CI, 621.4-800.2)**[258]. *Children (5-11):* 1 month after 2nd dose had **1,197.6 GMT (95% CI, 1106.1-1296.6)** SARS-CoV-2-neutralizing antibody[259] *Children (Under 5):* Ongoing trials[260]	*Adolescents (12-17):* Neutralizing antibody titer after 2nd dose was **1401.7 GMN_{50} (CI, 1276.3-1539.4)** Serological response was **98.8% (CI, 97.0-99.7)** *Children (6-11):* Seroreponse of **99.3%**[266] *Children (6month-11):* Ongoing trials[262]	No available data	No available data	*Children (3-17):* Neutralizing antibodies after 28 days after 2nd dose ranged from **105.3-180.2 GMT** in 3-5 years cohort, **84.1-168.6 GMT** in 6-12 years cohort, and **88.0-155.7 GMT** in 13-17 years cohort Neutralizing antibodies after 28 days after 3rd dose ranged from **143.5-224.5 GMT** in 3-5 years cohort, **127-184.8 GMT** in 6-12 years cohort, and **150.7-199 GMT** in 13-17 years cohort[267]	*Children (3-17):* Neutralizing antibody response after 2nd dose **(100%)** with GMT ranging from **45.9-212.6**[264]	Ongoing clinical trial[268]	Ongoing clinical trial[269]

Effectiveness	*Against SARS-CoV-2 infection:* **91.5%** (95% CI, 88.2-93.9)[270] **91%** (95% CI, 88-93)[271] *Against hospitalization:* **81%** (95% CI, -55-98)[271] **93%** (95% CI,83-97)[272]	No available data	No available data	No available data	No available data	No available data	No available data	No available data
Safety and Adverse events	*Adolescents (12-15):* Local and systemic events were generally mild to moderate Severe injection-site pain **(1.5%)** Fever **(20%)** High Fever **(0.1%)** Adverse events **(6%)** Severe adverse events **(0.6%)**[258]. *Adolescent/young adults (16-25):* Local and systemic events were generally mild to moderate	*Adolescents (12-17):* Solicited local reactions after 2nd dose **(93.4%)** Most common solicited adverse reactions were Injection-site pain **(92.7%)** Headache **(70.2%)** Fatigue **(67.8%)** Grade 3 adverse events **(6.8%)** Few reported cases of acute myocarditis and pericarditis	No available data	No available data	*Children (3-17):* Most common adverse reaction was pain at injection site in 3–5-year group **(4%)**, 6-12-year group **(1.2%)**, and 13-17-year group **(7.9%)** Most common systemic reactions in all three age cohorts were mild to moderate **fever** and **cough** Adverse events were mostly mild	*Children (3-17):* Adverse reactions in 12–17 year group **(35%)**, 3-5 year group **(26%)**, and 6-11 year group **(18%)** Reported at least one adverse event **(27%)** Most reported events were mild and moderate and only **(<1%)** grade 3 events Injection-site pain **(13%)** Fever **(25%)**[264]	Ongoing clinical trial[268]	Ongoing clinical trial[269]

	Severe injection-site pain **(3.4%)** Fever **(17%)** Adverse events **(6%)** Severe adverse events **(1.7%)**[258]. *Children (5-11):* Pain at injection site, fatigue, headache, chills were reported. Overall, the vaccine is safe and tolerable[259] *Children (Under 5):* Ongoing trials[260] Multisystem inflammatory syndrome (causal link not yet proven)[273] *Adverse events cases:* 15-year old boy developed nephrotic syndrome[274]	(mainly in males)[275] *Children (6-11):* Vaccine was generally well tolerated[266] *Children (6month-11):* Ongoing trials[262]			to moderate in severity[267]				

Myocarditis Data	Few reported cases of acute myocarditis and pericarditis in 16-25 year olds (mainly in males)[275] <u>16-29 years</u> Incidence of **5.49** (95% CI, 3.59-7.39) per 100,00 vaccinated[254] <u>Male patients (16-29 years)</u> Incidence of **10.69** (95% CI, 6.93-14.46) per 100,000 vaccinated[254] Incidence of **13.6 cases** (95% CI, 9.30-19.20) per 100,000 vaccinated[255]	Few reported cases of acute myocarditis in adolescents and young adults	No available data	No available data	No available data	No available data	No available data	No available data
HETEROLOGOUS VACCINATION								

Vaccine Schedule	**BNT162b2/ChAdOx1** Administration of ChAdOx1 as second/booster dose	**ChAdOx1/mRNA-1273** Administration of mRNA-1273 as second/booster dose	**ChAdOx1/BNT162b2** Administration of BNT162b2 as second/booster dose	Not Applicable (one dose schedule) For more information refer to booster section	**BBIBP/BNT162b2**	**CoronaVac/ChAdOx1** Press releases have confirmed that Thailand will use the AstraZeneca vaccine as the second dose for individuals whose first dose was Sinovac[lviii] **CoronaVac/Convidecia**	**ChAdOx1/BBV152** Administration of Covaxin as second/booster dose	Ongoing trial[276] (Com-Cov2)[lix]
Immunogenicity	*GMCs of SARS-CoV-2 anti-spike IgG at 28 days post booster:* Heterologous **(7133 ELU/mL, CI 6415-7932)** vs. Homologous **(14080 ELU/mL, CI 12491-15871)**[277]. *SFC frequency (T0cell ELISpot):*	**Spike-specific IgG antibodies:* Heterologous **(3602 BAU/mL)** vs. Homologous **(4189 BAU/mL)**[48] **Neutralizing antibodies:* Heterologous **(100%)** vs. Homologous **(100%)**[278].	*RBD antibody titres:* Heterologous **(7756.68 BAU/mL, CI 7371.53-8161.96)** vs. Homologous **(99.84 BAU/mL, CI 76.93-129.59)** at day 14[279]. *IgG antibody titres:*	Not Applicable (one dose schedule) For more information refer to booster section	Unknown (on-going clinical trial)[49]	**CoronaVac/ChAdOx1 :** *Anti-S Antibodies:* Heterologous **(797 U/mL; 95% CI, 598.7-1062)** vs. Homologous CoronaVac **(94.4 U/mL; 95% CI : 76.1-122.1)** vs. Homolougous ChAdOx1 **(818**	*RBD antibody titres:* Heterologous **(1866 GMT; 95% CI, 1003-3472)** vs. Homologous Covishield **(2260 GMT; 95% CI, 1881-2716)** vs. Homologous Covaxin **(710**	No available data Ongoing trial[276]

[lviii] Malaysia to stop using Sinovac vaccine after supply ends - minister. *Reuters* [press release]. https://www.reuters.com/world/asia-pacific/malaysia-stop-using-sinovac-vaccine-after-supply-ends-minister-2021-07-15/

[lix] Comparing COVID-19 Vaccine Schedule Combinations. *University of Oxford.* https://comcovstudy.org.uk/about-com-cov2

	Heterologous **(99 SFC/10^6 PBMCs)** vs. Homologous **(80 SFC/10^6 PBMCs)**[277]**.** ***Heterologous mRNA:*** **84.7%** effectiveness (95% CI, 83.1-86.1)[8]	***Heterologous mRNA:*** **84.7%** effectiveness (95% CI, 83.1-86.1)[8] *Results based on immunosuppressed population	Heterologous **(3684 BAU/mL)** vs. Homologous **(101.2 BAU/mL)** at day 14[279]. *Neutralizing antibodies:* Heterologous **(100%)** at day 14 vs. Homologous **(30%)** at day 14[279]. Heterologous (**median 99%)** vs. Homologous (BNT162b2/BNT162b2) **(median 62%)**[280]			**U/mL; 95% CI: 662.5-1010)**[281] **CoronaVac/Convidecia** *Neutralizing antibodies :* Heterologous **54.4 GMT** (95% CI, 37.9-78) vs. Homologous CoronaVac **12.8 GMT** (95% CI, 9.3-17.5)[282]	**GMT, 95% CI, 461-1092)**[283] *N-protein IgG:* Heterologous **(1145 GMT; 95% CI, 520.7-2520)** vs. Homologous Covishield **(353.7 GMT; 95% CI, 219.9-568.9)** vs. Homologous Covaxin **(742.4 GMT; 95% CI, 485.8-1134)**[283] *Neutralizing antibody titres :* Heterologous **(171.4 GMT; 95% CI, 121.3-242.3)** vs. Homologous Covishield **(111 GMT; 95% CI, 98.59-124.9)** vs. Homologous Covaxin **(86 GMT; 95% CI, 138.2-252.0)**[283]	

Immunogenicity against variants	No available data	No available data	*Neutralizing Antibodies for Alpha, Beta, Gamma, and Delta:* Heterologous **2.3-fold to 3.6-fold** higher neutralizing antibodies than homologous[280]	No available data	No available data	No available data	*Neutralizing antibody titres **B.1**:* **539.4 GMT (95% CI, 263.9-1103)[283]** *Neutralizing antibody titres **Alpha**:* **396.1 GMT (95% CI, 199.1-788)[283]** *Neutralizing antibody titres **Beta**:* **151 GMT (95% CI, 80.21-284.3)[283]** *Neutralizing antibody titres **Delta**:* **241.2 GMT (95% CI, 74.99-775.9)[283]**	No available data
Reactogenicity	Observed increase in systemic reactogenicity after boost in heterologous schedules in comparison with homologous schedules[277]	*Adverse events in heterologous and homologous vaccination groups were very similar[278]. *Majority of adverse events self-reported were Pain at injection	*Adverse events in heterologous:* Headache **(44%)**, Myalgia **(43%)**, Malaise **(42%)**, Fever **(2%)**, Injection site pain **(88%)**, Induration **(35%)**, Erythema **(31%)**[279].	Not Applicable (one dose schedule) For more information refer to booster section	Unknown (on-going clinical trial)[284]	**CoronaVac/ChAdOx1:** Unknown **CoronaVac/Convidecia:** Convidecia recipients reported more adverse reactions and reported higher	*Most common local adverse events:* Pain at injection site **(11.1%)[283]** *Most common systemic adverse events:*	No available data Ongoing trial[276]

	Adverse events in heterologous: Adverse events **(90)** Grade 1 **(54.4%)** Grade 2 **(37.8%)** Grade 3 **(7.8%)** Grade 4 **(0%)** Arthralgia, Migraine, Back Pain[277]. *Adverse events in homologous:* Adverse events **(81)** Grade 1 **(59.3%)** Grade 2 **(39.5%)** Grade 3 **(1.2%)** Grade 4 **(0%)**[277].	site, Swelling at injection site, Fever, Headaches, Fatigue, Chills, GI effects, Myalgia, Arthralgia[278]. *Results based on immunosuppressed population	*Severity of adverse events in heterologous:* Mild **(68%)**, Moderate **(30%)**, Severe **(2%)**[279].			occurrence of solicited injection-site pain)[282]	Pyrexia **(27.77%, 11.1%)** after 1st and 2nd dose Malaise **(33.3%, 5.5%)** after 1st and 2nd dose[283]	
BOOSTER DOSES								
Vaccine Schedule	**BNT162b2/BNT162b2**	**mRNA-1273/mRNA-1273**	**ChAdOx1/ChAdOX1**	**Ad26.CoV.2.S/ Ad26.CoV.2.S**	**SinoPharm/SinoPharm**	**CoronaVac/CoronaVac**	**Covaxin/Covaxin**	**NVX-CoV2373/NVX-CoV2373**
Approved Administration	*Israel:* 12-year-old and over can received homologous booster shot 5	Phase II booster trial of three booster doses are ongoing[285]	Preliminary results on tolerability and immunogenicity of third dose of ChAdOx1	Johnson & Johnson has said it will submit all of their new data to the FDA for	*UAE:* Offering booster doses of Pfizer and Sinopharm to people who	**Turkey** and the **United Arab Emirates** began	Ongoing clinical trials[lxv]	Ongoing phase II trials[287]

[lxv] Bharat Biotech to initiate trials of booster dose of Covid-19 vaccine. *Clinical Trials Arena.* https://www.clinicaltrialsarena.com/news/bharat-biotech-booster-dose/

	months after full jab[lx] *United States:* Starting September, adults who received mRNA vaccine 8 months ago are eligible for booster *Europe:* Starting in fall, most European countries are planning on rolling out booster shots to immunocompromised and elder populations with some countries administering to overall population[lxi]	Moderna sought FDA approval of its COVID-19 vaccine booster[lxii] *United States:* Starting September, adults who received mRNA vaccine 8 months ago are eligible for booster.	vaccines showed strong boost to the immune response[286]	potential consideration for adding a booster dose and consideration to authorize two-dose regimen[lxiii]	received full Sinopharm jab ≥6 months ago	homologous booster shots **Indonesia** and **Thailand** are considering giving homologous booster shot to HCW[lxiv]		Results below are based on ongoing phase II trial

[lx] Israel offers COVID-19 booster to all vaccinated people. *Reuters* [press release]. https://www.reuters.com/world/middle-east/israel-offers-covid-19-booster-shots-all-vaccinated-people-2021-08-29/

[lxi] A country-by-country guide to coronavirus vaccine booster plans. *POLITICO* [press reléase]. https://www.politico.eu/article/vaccine-booster-coronavirus-covid-19-europe-delta-varian-who/

[lxii] Moderna seeks U.S. authorization for COVID-19 vaccine booster. *Reuters* [press release]. https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-submits-initial-data-covid-19-vaccine-booster-us-fda-2021-09-01/

[lxiii] Two dose version of Johnson & Johnson shot 94% effective against Covid-19, study finds. *CNN.* https://edition.cnn.com/2021/09/21/health/johnson-vaccine-two-doses-booster/index.html

[lxiv] Indonesia and Thailand consider booster shots amid doubts over Sinovac vaccine. *Reuters* [press release]. https://www.reuters.com/world/china/indonesia-thailand-consider-booster-shots-amid-doubts-over-sinovac-vaccine-2021-07-08/

Time-to-booster dose	**6 months to 8 months** after initial two-dose regimen Israel offers up to **5 months** after initial two-dose regimen	**6 months to 8 months** after initial two-dose regimen	**6-9 months** after initial two-dose regimen	**6 months** after one dose regimen[78]	**6 months** after initial two-dose regimen	**6 months to 12 months** After primary vaccination **8 months** after the primary vaccination to healthy adults ≥60 years	Ongoing clinical trials[xxxvii]	**6 months** after initial two-dose regimen (**189 days**)[287]
Efficacy	*Symptomatic COVID-19:* **95.6%** during Delta prevalent period[288] **95.3% (**95% CI, 89.5-98.3)[289] **96.5%** (95% CI, 89.3-99.3) in *16-55 year old*[289] **93.1%** (95% CI, 78.4-98.6) in *≥55 year old*[289]	No available data	No available data	No available data	No available data	No available data	Ongoing clinical trials[xxxvii]	No available data
Immunogenicity	*Neutralizing titers:* Elicits **>5-8 more** for wild type after 6 months after 2nd dose[290] *IgG Antibodies in ≥ 60 years:*	Booster doses (mRNA1273 or mRNA1273.351) increased neutralizing antibody titers against wild-type[292]	*Antibody Levels:* Higher levels after third dose (tIgG EU **3746**; IQR: 2047-6420) [286]	5X10[10] vp booster dose elicited **9-fold** increase at day 7 compared to first dose after 29 days in 18-55-year-olds[78]	Ongoing trial[284] *IgG Seroconversion:* **175/176** vaccinees were seropositive for IgG 14 days after	Neutralizing Antibodies: **60%** higher NAbs activity against wild-type compared to 2-doses[83]	Ongoing clinical trials[xxxvii]	*Anti-spike IgG:* Increase of **4.6-fold** compared to peak response after 2nd dose (**Day 217 GMEU = 200408**; 95% CI:

	97% seroconversion with increase in IgG antibody titers[291]		*Spike Cellular Immune Response:* Increased from **200 SFUx10^6 PBMC (IQR, 127-389)** after the second dose to **399 SFUx10^6 PBMC (IQR, 314-662)** after the third one[286]	1.25X10^{10} vp booster dose elicited **6-7.7-fold** increase at day 28 compared to first dose after 29 days in 18-55 and ≥65-year-old[78]	receiving third dose[81] Mean IgG value increased **8.00-fold** compared to before third vaccination[81] *Anti-RBD IgG:* Increased by **8.14-fold** higher than before third vaccine[81] *Memory B cells:* Third dose increased the percentage of RBD-specific memory B cells **(0.96%)[81]**	Anti-S IgG and NAbs: **20-fold** increase 4 weeks post booster vaccination NAbs were maintained **60** to **180 days** post booster[83]		159796-251342)[287] *Wild-type Neutralizing Response:* Increase of **4.3-fold** compared to peak response after 2nd dose **(IC50 = 6231; 95% CI: 4738-8195)** [287] *Older Participants (60-84):* **5.4-fold** increase in antibody response[287] *Younger Participants (18-59):* **3.7-fold** increase in antibody response[287]
Immunogenicity against variants	*Beta (B.1.351):* Elicits **15-21** more neutralizing titers for Beta variant after 6 months after 2nd dose[290]	Preliminary results of booster doses of mRNA-1273 vaccine show robust antibody	Third dose provided higher antibody titters against Alpha, Beta, and Delta variants[286]	No available data	Ongoing trial[284] **Beta (B.1.351):** **71.6%** plasma inhibitions against Beta variant[81]	**Beta (B.1.351):** **3.0-fold** decrease in neutralizing antibodies	Ongoing clinical trials[xxxvii]	High levels of functional antibodies against Alpha (B.1.1.7), Beta (B.1.351), and

	Delta (B.1.671.2): **>5-fold** increase in neutralizing titers against Delta compared to dose 2 titers in 18–55-year-olds **>11-fold** increase in neutralizing titers against Delta compared to dose 2 titers in 65–85-year-olds[290]	response against Delta variant[285]			**Delta (B.1.671.2):** **83.4%%** plasma inhibitions against Delta variant[81] **Lambda:** **89.0%** plasma inhibitions against Lambda variant[81]	compared to wild type[83] **Gamma (P.1):** **3.1-fold** decrease in neutralizing antibodies compared to wild type[83] **Delta (B.1.671.2):** **2.3-fold** decrease in neutralizing antibodies compared to wild type **2.5-fold** higher neutralizing potency than 2-dose vaccination[83]		Delta (B.1.671.2)[287] *Delta (B.1.671.2):* Increase of **6.6-fold** in antibody response compared to Delta response observed with primary vaccination[287]
Reactogenicity	Preliminary results show consistent tolerability[290] **25%** reported at least one adverse event[289] *Common solicited AE:* Injection site pain, injection site redness, injection site swelling,	Similar safety and tolerability compared to second dose[285] *Common solicited local adverse events:* Injection-site pain **(68.4% for mRNA-1273.351, 90% for mRNA-1273)** fatigue **(36.8% for mRNA-1273.351,**	Lower reactogenicity after third dose compared to first dose[77]	No available data	Ongoing trial[284]	The third shot is considered to be safe[82]. *Common side effects:* Pain at the injection site. *Adverse events:* Unrelated to the vaccination	Ongoing clinical trials[xxxvii]	Booster dose was **well tolerated** Local and systemic **reactogenicity increased** between Dose 1, Dose 2, and Dose 3 **90%** of symptoms were

	fatigure, muscle pain, fever[289] *≥Grade 3 AE:* **6.6%** reported grade 3 or higher reactogenicity with **0.7%** being local reactions and **5.9%** systemic events[289]	**70% for mRNA-1273)** headache **(36.8% for mRNA1273.351, 55.0% for mRNA-1273)** myalgia **(31.6% for mRNA-1273.351, 45.0% for mRNA-1273)** arthralgia **(21.1% for mRNA-1273, 50.0% for mRNA-1273)**[292]						rated as mild or moderate[287]
Protection against COVID-19	***Confirmed Infection:*** Youngest age group (16-29): **17.6 (95% CI, 15.6-19.9) lower rate** in booster group[293] 30-39 age group: **8.8 (95% CI, 8.2-9.5) lower rate** in booster group[293] 40-49 age group: **9.7 (95% CI, 9.2-10.4) lower rate** in booster group[293]	No available information	No available information	No available information	No available information	No available information	Ongoing clinical trials[xxxvii]	No available information

	50-59 age group: **12.2 (95% CI, 11.4-13.1) lower rate** in booster group[293] Oldest age group (≥60): **11.3 (95% CI, 10.4-12.3) lower rate** in booster group [294] **12.4 (95% CI, 11.9-12.9) lower rate** in booster group[293] ***Severe Illness:*** 40-59 age group: **22.0 (95% CI, 10.3-47.0) lower rate** in booster group[293] Older population (≥60): **19.5 (95% CI, 12.9-29.5) lower rate** in booster group[294] **18.7 (95% CI, 15.7-22.4) lower**								

	rate in booster group[293]								
Other	Detailed report from Pfizer regarding booster doses can be found here: https://www.fda.gov/media/152161/download 14-20 days after booster, marginal effectiveness increases to **70-84%**[295] *Effectiveness in ≥50:* **84.4%** (95% CI, 82.8-85.8) against symptomatic COVID-19[296] **94.0%** (93.4-94.6) against symptomatic COVID-19 compared with unvaccinated[296]					For more detailed information regarding immunogenicity of third dose refer to study[lxvi]			

[lxvi] A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2. *medRxiv.* *https://www.medrxiv.org/content/10.1101/2021.09.02.21261735v1*

	HETEROLOGOUS BOOSTER DOSES							
Vaccine Schedule	*Heterologous 1:* **mRNA1273/BNT162b2** *Heterologous 2:* **Ad26.CoV.2.S/BNT162b2** ***Received BNT162b2 as booster dose	*Heterologous 1:* **BNT162b2/mRNA1273** *Heterologous 2:* **Ad26.CoV.2.S/mRNA1272** ***Received mRNA1273 as booster dose	No available data	*Heterologous 1:* **BNT162b2/Ad26.CoV.2.S** *Heterologous 2:* **mRNA1273/Ad26.CoV.2.S** ***Received Ad26.CoV.2 as booster dose	*Heterologous:* **SinoPharm/BNT162b2**	*Heterologous 1:* **CoronaVac/ChAdOx1** *Heterologous 2 :* **CoronaVac/BNT162b2**	No available data	*Heterologous:* Ongoing trial of heterologous booster shot using NVX-CoV2373[lxvii]
Time-to-booster dose	At least **3 months** after receiving two dose regimen	At least **3 months** after receiving two dose regimen	No available data	**4 months** after initial two-dose BNT162b2 regimen[297] At least **3 months** after receiving two dose regimen	**6 months** after initial two-dose regimen	*Heterologous 1:* **21 to 26 days** after full jab of CoronaVac *Heterologous 2:* **6 months** after primary vaccination of CoronaVac	No available data	No available data
Immunogenicity	*Binding Antibody Responses:* **2-fold or greater rise** in bAb noted in **98-100%** of BNT162b2 recipients[298]	*Binding Antibody Responses:* **2-fold or greater rise** in bAb noted in **96-100%** of mRNA1273 recipients[298]	No available data	*Heterologous 1:* **14.8 to 32.4-fold** increase in neutralization titers against wild-type virus[297]	No available data	*Heterologous 1:* Heterologous vaccination had a **9-fold greater GMT** (7,947 U/mL) than fully patients fully vaccinated with	No available data	No available data

[lxvii] COV-Boost Evaluating COVID-19 Vaccine Boosters. *University of Southampton & NHS.* https://www.covboost.org.uk/home

	Neutralizing Antibody Responses: **341.3-677.9 IU50/mL** 15 days after booster with BNT162b2[298] Participants who received mRNA-based booster vaccination had four-fold increase compared to Ad26.COV2.S. [298]	*Neutralizing Antibody Responses:* **676.1-901.8 IU50/mL** 15 days after booster with mRNA1273[298] Participants who received mRNA-based booster vaccination had four-fold increase compared to Ad26.COV2.S. [298]		*Binding Antibody Responses (bAb):* **2-fold or greater rise** in bAb noted in **98-100%** of Ad26.COV2.S. recipients[298] *Neutralizing Antibody Responses:* **31.2-382.2 IU50/mL** 15 days after booster with Ad26.COV2.S. [298]		AZD1222 and the highest antibody response, IgA, and neutralizing antibodies than other groups[299] *Heterologous 2:* Median values of IgG-S titers were higher in group that received BNT162b2 as booster than CoronaVac BNT162b2 boosted IgG-S median titers by **factor of 46.6** but IgG-N titers decreased by **factor of 6.5**[300] Single booster dose of BNT162b2 induced higher anti-spike RBD IgG antibody levels, compared to single booster dose of CoronaVac[74]		

Immunogenicity against variants	*Binding Antibody Responses:* Baseline bAb levels for **Delta** were **34-45% lower** compared to Wa-1 strain[298] Following boost, bAB levels for **Delta** were **15-36% lowe**r compared to Wa-1 strain[298]	*Binding Antibody Responses:* Baseline bAb levels for **Delta were 34-45% lower** compared to Wa-1 strain[298] Following boost, bAB levels for **Delta** were **15-36% lower** compared to Wa-1 strain[298] *Neutralizing Antibody Responses:* **Delta and Beta** variants were only available in those boosted with mRNA-1273[298]	No available data	*Heterologous 1:* **10.9 to 21.2-fold** increase in pseudo virus neutralization assay (one volunteer did not have any against B.1.351) [297] *Binding Antibody Responses:* Baseline bAb levels for **Delta** were **34-45% lower** compared to Wa-1 strain[298] Following boost, bAB levels for **Delta** were **15-36% lower** compared to Wa-1 strain[298]	No available data	*Heterologous 1:* Neutralizing activity against the wild type and variant strains showed higher neutralizing activity in the following order: **wild type > B.1.617.2 > B.1.1.7 > B.1.351**[299]	No available data	No available data
Reactogenicity	*Adverse Events:* **72-92%** participants reported local pain or tenderness[298]	*Adverse Events:* **75-86%** participants reported local pain or tenderness[298]	No available data	*Adverse Events:* **71-84%** participants reported local pain or tenderness[298]	No available data	Similar results to homologous booster administration	No available data	No available data

	Malaise, myalgias, and headaches were commonly reported[298] **14.4%** of the participants reported unsolicited adverse events[298]	Malaise, myalgias, and headaches were commonly reported[298] **15.6%** of participants reported unsolicited adverse events[298]		Malaise, myalgias, and headaches were commonly reported[298] **12%** of participants reported unsolicited adverse events[298]				
Other	*Heterologous 2 – Effectiveness in ≥50:* **87.4%** (95% CI, 84.9-89.4) against symptomatic COVID-19[296] **93.1%** (95% CI, 91.7-94.3) against symptomatic COVID-19 compared to unvaccinated[296]					Ongoing clinical trial examining immunogenicity and safety of third dose vaccination with ChAdOx1 or BNT162b2 vaccine among adults who received full jab of CoronaVac[lxviii]		

[lxviii] Third Dose Vaccination with AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine. *ClinicalTrials.gov.* https://clinicaltrials.gov/ct2/show/NCT05049226

ANNEXES

	BNT162b2/ COMIRNATY (Pfizer-BioNTech, USA)	Spikevax/ Moderna COVID-19 Vaccine/ mRNA-1273 (Moderna, USA)	Vaxzevria/ ChAdOx1 nCoV-19/ AZD1222/ Covishield (AstraZeneca/Oxford, UK, India)	Janssen COVID-19 vaccine/Johnson & Johnson (Janssen, USA)	Sinopharm/BBIBP-CorV, China	Sinovac CoronaVac, China	COVAXIN/ BBV152 (Bharat Biotech, India)	Novavax/ NVX-CoV2373
	FURTHER INFORMATION							
Storage conditions	2°C to 8 °C (for 1 month)	2°C to 8 °C (for 1 month)	2°C until 8 °C	2°C to 8 °C (for 3 months)	2°C until 8 °C	2°C until 8 °C	2°C until 8 °C	2°C to 8 °C
Approving authorities	FDA (11.12.20)[lxix]; EMA (21.12.20); WHO EUL (31.12.20); and list of countries (including Switzerland – approved on 20.12.20)	FDA (18.12.20); EMA (06.01.21); WHO EUL (30.04.21); and list of 51 countries (including Switzerland – approved 12.01.21)	FDA (awaiting on approval); EMA (29.01.21); WHO EUL (15.02.21); and list of 121 countries (Switzerland awaiting on approval)	FDA (27.02.21); EMA (11.03.21), WHO EUL (12.03.21), and list of 59 countries (including Switzerland – approved 22.03.21)	WHO EUL (07.05.21); and list of 55 countries (e.g., Argentina, Bahrain, Brazil, China, Indonesia, United Arab Emirates, Zimbabwe)	WHO EUL (01.06.21), and list of 33 countries (e.g., Albania, Chile, Egypt, Hong Kong, Malaysia, Tunisia, Turkey, Ukraine)	WHO EUL (03.11.21) and list of 9 countries (Guyana, Inidia, Iran, Mauritius, Mexico, Nepal, Paraguay, Philippines & Zimbabwe)	Waiting on approval (Not-yet-approved by countries or WHO for emergency use)

[lxix] Pfizer-BioNTech's Comirnaty Vaccine received full FDA approval on 23 August 2021 for people age 16 and above, moving it beyond emergency use status. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine

IMMUNOGENICITY								
Immunogenicity	*7-14 days after second dose:* *18-55 years*: GMT ranged from **1.7 to 4.6** times the GMT of the convalescent serum[301]. *65-85 years*: GMT ranged from **1.1 to 2.2** times the GMT of the convalescent serum[301].	*14 days after second dose:* *18-55 years*: $PRNT_{80}$ GMT **654.3 (95% CI, 460.1-930.5**)[302]. *56-70 years:* $PRNT_{80}$ GMT **878 (95% CI, 516-1494**)[303]. *≥71 years*: $PRNT_{80}$ GMT **317 (95% CI, 181-557**)[303].	*28 days after second dose median antibody titres:* *18–55 years*: **20,713 AU/mL [IQR 13,898 - 33,550**][304] *56–69 years*: 1**6,170 AU/mL [IQR 10,233 - 40,353]**[304]. *≥70 years*: **17,561 AU/mL [IQR 9,705 - 37,796]**[304].	*29 days after vaccination:* *18-55 years:* GMC **586 (95% CI, 445-771**); GMT **224 (95% CI, 168-298**)[305]. *≥65 years*: GMC **312 (95% CI, 246-396); GMT 212 (95% CI, 163-266**)[305]. *57 days after vaccination:* *18-55 years*: **754 (95% CI, 592-961**); GMT **288 (95% CI, 221-376**)[305].	*14 days after second dose:* *18-55 years:* GMT ***211.2* (95% CI, 158.9-280.6**)[306]. *≥60 years: GMT **131.5** (95% CI, 108.2-159.7**)[306].	*Single dose (≥4 weeks)*: **37.7±57.08 IU/ml (min: 0, max: 317.25);** 57.02% of participants did not develop sufficient antibody titres (<25.6 IU ml) *Two doses (≥4 weeks)*: **194.61±174.88 IU/ml (min: 0, max: 677.82);** 11.48% of participants did not develop sufficient antibody titres (<25.6 IU ml)[307]. *2 weeks after second dose:* 164.4 BAU/ mL[308] *4 weeks after second dose:* 94.8 BAU/ mL[308] *8-12 weeks after second dose:*	*Single dose (≥4 weeks:* **43.8%** seropositive for anti-spike antibody > 15 AU/mL[309] GMT **16.8 (95% CI, 15.80-17.88)** for SARS-CoV-2 spike antibody titre[309] *Two doses (≥4 weeks)*: **80.0%** seropositive for anti-spike antibody > 15 AU/mL[309] GMT **48.3 (95% CI, 47.46-48.92)** for SARS-CoV-2 spike antibody titre[309]	

						34.7 BAU/ mL[308]		
Immunogenicity against the Mu variant	6.8-fold decrease in neutralizing titres when compared to convalescent sera[310]	Neutralizing titre similar to that of BNT162b2 sera[310]	Neutralizing titre similar to that of BNT162b2 sera[310]	No available data	No available data	No available data	No available data	No available data
				EFFICACY				
Single dose[lxx]	**52%** (95% CI, 29.5 to 68.4; starting at 12 days) or 82.2% (75.1 to 87.3; starting at ≥14 days)[311]. **91%** (95% CI, 85-94)[312]. ≥80 years : **71.4%** (95% CI, 46.5-90.6) vaccine efficacy for symptomatic disease 14 days after one dose	**95.2%** (95% CI, 91.2.8 to 97.4; starting at >14 days)[107].	**72.8%** (starting at 22 days up to 60 days)[314]. **88%** (95% CI, 75-94)[312].[lxxii] ≥80 years : **80.4%** (95% CI, 36.4-94.5) vaccine efficacy for symptomatic disease 14 days after one dose [United Kingdom, 18 Dec 2020 – 26 Feb 2021[313] ≥65 years :	Single dose vaccine	Unknown	**35.1%** (95% CI, -6.6 to -60.5) [conducted in a setting with high P.1 transmission][315].	No available data	**83.4%** (95% CI, 73.6-89.5) starting at ≥14 days[40]

[lxx] Against SARS-COV-2 infection

[lxxii] Conducted between 8 December 2020 and 8 February 2021. Study sample = ≤1 million participants.

	[United Kingdom, 18 Dec 2020 – 26 Feb 2021][313] ≥65 years : **56%** (95% CI 19-76) at 28-34 days and **62%** (95% CI 23-81) at 35-48 days post-vaccination [United Kingdom, 8 Dec 2020 – 15 Mar 2021][313] [lxxi]		**56%** (95% CI 19-76) at 28-34 days and **62%** (95% CI 23-81) at 35-48 days post-vaccination [United Kingdom, 8 Dec 2020 – 15 Mar 2021][313] [lxxiii]					
Two doses[lxxiv]	**95.0%** (95% CI, 90.3-97.6) starting at ≥7 days in population without prior SARS-CoV-2 infection[122] **94.6%** (95% CI, 89.9-97.3) starting at ≥7 days in population with or without prior infection[122]	**94.1%** (95% CI, 89.3-96.8) after median follow-up of less than 63 days[107] **93.2%** (95% CI, 91.0-94.8)[316] Against severe disease: **98.2%** (95% CI, 92.8-99.6)[316]	**63.1% (**95% CI, 51.8-71.7) starting at ≥14 days for two standard doses[314] **80.7%** (95% CI, 62.1-90.2) starting at ≥14 days for first low dose and standard second dose[314] **66.7%** (95% CI, 57.4-74.0) starting at ≥14 days for	**66.9%** (95% CI 59.0-73.4) after 14 days and **66.1%** (95% CI 55.0-89.1) after 28 days for VE against moderate-severe-critical COVID-19[318] **76.7%** (95% CI 54.6 to 89.1) after 14 days and **85.4%** (95% CI 54.2 to 96.9) after 28 days for VE	After 14 days, efficacy against symptomatic cases was **72.8%** (95% CI 58.1-82.4; in WIV04 vaccine) or **78.1%** (95% CI 64.8 to 86.3; in HBO2 vaccine).[203]	After 14 days, efficacy against symptomatic cases was **50.7%** (95% CI 35.9 to 0-62.0).[113] 99.17% of NAb titres were above or equal to the Nab positivity cut-off (20 units) against wild-type[319].	*Symptomatic SARS-CoV-2 infection:* **77.8%** (95% CI, 65.2-86.4)[320] *Severe symptomatic SARS-CoV-2 infection:* **93.4** (95% CI, 57.1-99.8)[320] *Symptomatic COVID-19 in ≥60 years old:*	**89.7%** (95% CI, 80.2-94.6) starting at ≥7 days[40] **90.4%** (95% CI, 82.9-94.6)[321] **100%** (95% CI, 87-100) against moderate-to-severe COVID-19[321] **100%** (95% CI, 34.6-100)

[lxxi] Does not differentiate between BNT162b2 and ChAdOx1 nCoV-19.
[lxxiii] Does not differentiate between BNT162b2 and ChAdOx1 nCoV-19.
[lxxiv] Against SARS-CoV-2 infection.

		Prevention against COVID-19 illness: **93.2%** (95% CI, 91.0-94.8; United States) [316] *Prevention against severe disease:* **98.2%** (95% CI, 92.8-99.6; United States) [316] *Prevention against asymptomatic infection starting 14 days after second infection:* **63.0%** (95% CI, 56.6-68.5; United States) [316]	pooled analysis efficacy[314] *Against mild-to-moderate symptomatic COVID-19 >14 days after second injection*: **21.9%** (95% CI, -49.9 to 59.8; South Africa) [24 June – 09 November 2020][317]	against severe-critical COVID-19[318]			**67.8%** (95% CI, 65.2-86.4) against symptomatic COVID-19[320] *Symptomatic COVID-19 in 18-59 years old:* **79.4%** (95% CI, 66.0-88.2) against symptomatic COVID-19[320]	against severe COVID-19[321] **90%** (95% CI, 80-95) (≥7 days after second dose)[322]
Against asymptomatic infection	**90%** (starting at 14 days) regardless of symptom status[323]	**63.0%** (95% CI, 56.6-68.5)[316]	Statistically non-significant **reduction of 22.2%** (95% CI -9.9 to 45.0) for asymptomatic cases **61.9%** efficacy[37]	At day 71, vaccine efficacy against asymptomatic infections was **65.5%** (95% CI 39.9 to 81.1)[318].	Efficacy against symptomatic and asymptomatic cases was **64%** (95% CI 48.8 to 74.7; in WIV04 vaccine) or 73.5% (95% CI 60.6 to 82.2; in HBO2 vaccine)[203].	Unknown	**63.6** (95% CI, 29.0-82.4) efficacy against asymptomatic cases[320]	Unknown

EFFICACY AGAINST VARIANTS								
Alpha (B.1.1.7)	Two doses of the vaccine **effectively neutralize** the B.1.1.7 variant and the D614G substitution[324].	**NAbs remained high** and consistent with titres of the wildtype for the B.1.1.7 variant[325].	**70.4%** (95% CI, 43.6-84.5) against symptomatic infection with alpha variant (B.1.1.7); **28.9%** (95% CI, -77.1 to 71.4) against asymptomatic infection with B.1.1.7[96].	**3.6-fold** reduction in neutralization capacity when compared to wild-type.	Demonstrated reduced neutralizing capacity. However, there were no differences in the NAbs titres against B.1.351 in vaccinated individuals vs. those naturally infected, suggesting the vaccine has a similar level of protection against infection as natural infections[326].	**10.4-fold** reduction in neutralization capacity when compared to natural infection sera[319]. **85.83%** of NAb titres were above or equal to the Nab positivity cut-off (20 units) against wild-type[319]. Neutralization decreased by **4.1-fold** when compared to wild-type[327].	$PRNT_{50}$ **0.8** when compared with wild type against Alpha (no significant difference in neutralization capacity)[328]	Two dose efficacy against the B.1.1.7 variant **86.3%** (95% CI, 71.3-93.5)[40] **93.6%** (95% CI, 81.7-97.8) against the Alpha variant[321] *Against non-B.1.1.7 variant* **96%** (95% CI, 74-99.5) (≥7 days after second dose)[322] *Against B.1.1.7 variant* **86%** (95% CI, 71-94) (≥7 days after second dose)[322]
Beta (B.1.351)	Neutralization was **diminished by a factor of 5**. Despite this, the BNT162b2 mRNA vaccine still provides some	NAbs were **6-fold** lower. Nevertheless, NAbs were still found to be protective[325].	Two doses of the vaccine had no efficacy against the B.1.351 (VE = **21.9%;** 95% CI, -49.9 to 59.8)[317].	Efficacy against moderate-severe-critical Covid-19 due to the variant was **52.0%** (>14 days) and **64.0%** (>28 days). Efficacy against	No published data	NT_{GM} **35.03 (95% CI, 27.46-44.68**); **8.75-fold** reduction in neutralization capacity when compared to	GMT **61.57 (95% CI, 36.34-104.3)** against Beta variant with significant reduction in neutralization titre[333]	**51.0%** (95% CI, -0.6-76.2) efficacy against B.1.351 variant[334]

	protection against B.1.351[329] **100%** (95% CI, 53.5-100)[330].		*Against mild-to-moderate symptomatic COVID-19 associated with B.1.351 variant >14 days after second injection*: **10.4%** (95% -76.8 to 54.8; South Africa) [24 June – 09 November 2020][317]	severe-critical COVID-19 was **73.1%** (>14 days) and **81.7%** (>28 days)[318]. Demonstrated **3.6-fold** reduction in neutralization sensitivity[331]. Neutralization titres were decreased by **6.7-fold**[332].		natural infection sera[319]. **82.5%** of NAb titres were above or equal to the Nab positivity cut-off (20 units) against wild-type[319].		
Gamma (P.1)	*Single dose:* *≥21 days*: **83%** against hospitalization and death[335]. *Two doses*: *≥14 days*: **98%** against hospitalization and death[335].	**3.2-fold** reduction in neutralization capacity when compared to wild-type[336].	*Single dose:* *≥21 days*: **94%** against hospitalization and death[335]. *Two doses:* **64%** (95% CI, -2-87) [n=18][337] Efficacy against Zeta (P.2) [2 doses]: **69%** (95% CI, 55-78)[337]	Demonstrated **3.4-fold** reduction in neutralization sensitivity[331].	No published data	**49.6%** against P.1 (>14 days after 1st dose)[315]. Neutralization decreased by **7.5-fold** when compared to wild-type[327].	No available data	No available data
Delta (1.671.2)	**Reduced NAb activity** relative to B.1.1.7 strain[338].	**2.1-fold** reduction in neutralization capacity when compared to wild-type[336].	*Single dose:* *≥21 days*: **90%** against hospitalization and death[335].	Demonstrated **1.6-fold** reduction in neutralization sensitivity[331].	Demonstrated **reduced neutralizing capacity**. However, there were no	NT_{GM} **24.48** (95% CI,19.2-31.2)[319]. **69.17%** of NAb titres were above or equal to the	**65.2** (95% CI, 33.1-83.0) estimated efficacy[116]	No available data

				Neutralization titres were decreased by **5.4-fold**[332].	differences in the NAbs titres against B.1.617.2 in vaccinated individuals vs. those naturally infected, suggesting the vaccine has a similar level of protection against infection as natural infections[326].	Nab positivity cut-off (20 units) against wild-type[319].	GMT **68.97** (95% CI, 24.72-192.4) against Delta variant with significant reduction in neutralization titre[333]	
PHASE III TRIALS RESULTS[lxxv]								
Number of participants (vaccine/ placebo)	43,448 (21,720/ 21,728)[122]	30,420 (15,210/15,210)[107]	17,178 (8597/8581)[314]	39,321 (19,630/19,691)[318]	26,917 (13,459/13458); or 26,914 (13,465/13,458)[203]	9,823 (4,953/4,870)[113]	25,798 (12,899/12899)[116]	14,039 (7,020/7,019)[40]
Total COVID-19 cases (vaccine/ control)	170(8/162)[122]	196 (11/185)[107]	332 (84/248)[314]	464 (116/348)[318]	121(26/95) or 116(21/95)[203]	253(85/168)[113]	130 (24/106)[116]	106(10/96)[40]

[lxxv] Phase III trials were conducted between 27 July and 14 November 2020 for BNT162b2/ COMIRNATY, 27 July and 23 October 2020 for Spikevax/ Moderna, 23 April and 6 December 2020 for Vaxzevria/ ChAdOx1 nCoV-19/ AZD1222/ Covishield, 21 September 2020 and 22 January 2021 for Janssen Covid-19 vaccine/ Johnson & Johnson, 16 July and 20 December 2020 for Sinopharm/ BBIB-CorV, 21 July and 16 December 2020 for the Sinovac/ CoronaVac vaccine, 16 November 2020 and 7 January 2021 for the COVAXIN vaccine, and 28 September 2020 and 28 November 2020 for the Novavax vaccine. All trials were conducted prior to the transmission of the more contagious variant strains, particularly the delta variant (B.1.617.2). Studies are currently ongoing to determine the effectiveness of the vaccines against the delta variant.

Efficacy estimates in Phase III trials	Starting from 7 days after 2nd dose: **95.0%** (95% CI, 90.3 to 97.6) in population without prior SARS-CoV-2 infection. Efficacy of **94.6%** (95% CI, 89.9 to 97.3) in population with or without prior infection. **100%** among adolescents (12-15 years old)[122].	After a median follow-up of less than 63 days: Efficacy of **94.1%** (95% CI, 89.3 to 96.8; P<0.001). **100%** among adolescents (12 to <18 years old)[107].	Two standard doses: efficacy was **63·1%** (95% CI 51.8 to 71.7; ≥14 days) while those with first low dose and standard 2nd dose the efficacy was **80.7%** (95% CI 62.1 to 90.2). Pooled analysis efficacy was **66.7%** (95% CI 57.4 to 74.0). For any nucleic acid amplification test-positive swab: efficacy was 54.1% (95% CI 44.7 to 61.9)[314].	VE against moderate-severe-critical Covid-19 was **66.9%** (95% CI 59.0 to 73.4) after 14 days post vaccine administration, and **66.1%** (95% CI 55.0 to 89.1) after 28 days. VE against severe-critical COVID-19 cases was **76.7%** (95% CI 54.6 to 89.1) after 14 days and **85.4%** (95% CI 54.2 to 96.9) after 28 days[318].	After 14 days, efficacy against symptomatic cases was **72.8%** (95% CI 58.1 to 82.4; in WIV04 vaccine) or **78.1%** (95% CI 64.8 to 86.3; in HBO2 vaccine)[203].	After 14 days, efficacy against symptomatic cases was **50.7%** (95% CI 35.9 to 0-62.0).[113]	**77.8%** (95% CI, 65.2-86.4) against symptomatic COVID-19 starting at ≥14 days after second dose[116]	**83.4%** (95% CI, 73.6-89.5) starting at ≥14 days after first dose[40] **89.7%** (95% CI, 80.2-94.6) starting at ≥7 days after second dose[40]
Efficacy against hospitalization and death	**100%** (after 7 days)[122]	**100%** (≥14 days)[107]	**100%** (after 21 days)[314]	**76.7%** (≥14 days) or **85.4%** (≥28 days)[318]	**100%** (>14 days)[203]	**100%** (>14 days)[113]	**93.4%** (>14 days) against severe COVID-19[116]	**100%** (after 7 days)[40].
Phase III clinical trial serious adverse events	Serious adverse events were observed in a similar proportion of vaccine (0.6%) and placebo (0.5%) recipients. These events also occur at a similar frequency within	The frequency of grade 3 adverse events was similar in both the vaccine (1.5%) and placebo groups (1.3). Serious adverse events were observed in a similar proportion	Serious adverse events were balanced across the study arms. 79 cases occurred in the vaccine group and 89 cases in the placebo group – 3 cases were considered related to the	Serious adverse events were reported in 0.4% of vaccine recipients and 0.4% of placebo recipients. Seven of the serious adverse events were considered to be related to	A cross-sectional survey collected data on adverse events following vaccination in the UAE - none of the symptoms were of serious nature or required hospitalization[112].	Overall incidence of serious adverse events was 0.5% (31 in placebo group and 33 in vaccine group). All adverse events were determined to be unrelated to the vaccine[113].	Rates of local and systemic AEs reported in the BBV152 group as mild (11·2%), moderate (0·8%), or severe (0·3%) were comparable	<u>Phase II:</u> Nine serious adverse events were reported, only one of which was assessed as related to the vaccine: acute colitis[340].

	the general population[103,339].	in both groups (0.6%). 3 Bell's Palsy cases occurred in the vaccine group and one Bell's Palsy case occurred in the placebo group[107].	experimental or control vaccine (out of 11 636 vaccine recipients): transverse myelitis, haemolytic anaemia and a case of fever higher than 40°C [109].	the vaccine: Guillain-Barré syndrome (1), pericarditis (1), brachial radiculitis (1), hypersensitivity (1), Bell's Palsy (2), & severe generalized weakness, fever & headache (1)[318].			to the placebo group [116] 15 deaths, none considered related to the vaccine or placebo[116]	
	PHASE III TRIAL OTHER							
Comments	Specific populations were excluded (HIV and immunocompromised patients, and pregnant women).	Calculation of efficacy were not based on the total number of confirmed Covid-19 cases.		**<u>2-DOSE EFFICACY</u>** *<u>Efficacy against symptomatic (moderate to severe/ critical) SARS-CoV-2 infection</u>* **94%** (95% CI, 58-100) in the US. **75%** (95% CI, 55-87) globally.[20] *<u>Efficacy against severe/ critical SARS-CoV-2 infection</u>*	Only 2 severe cases occurred in the control group and none in the vaccine group (very few cases to get a reliable estimate).	-	-	Novavax is currently awaiting FDA, EMA, and WHO EUL approval. Upcoming information regarding results of clinical trials or approval will be updated in upcoming reports

				100% (95% CI, 33-100)[20]					

	VACCINE PRODUCTION SITES							
	BNT162b2/ COMIRNATY (Pfizer-BioNTech, USA)[lxxvi]	**Spikevax/ Moderna COVID-19 Vaccine/ mRNA-1273 (Moderna, USA)**[lxxvii]	**Vaxzevria/ ChAdOx1 nCoV-19/ AZD1222/ Covishield (AstraZeneca/Oxford, UK, India)**[lxxviii]	**Janssen COVID-19 vaccine/Johnson & Johnson (Janssen, USA)**[lxxix]	**Sinopharm/BBIBP-CorV, China**[lxxx]	**Sinovac CoronaVac, China**[lxxxi]	**COVAXIN / BBV152 (Bharat Biotech, India)**	**Novavax/ NVX-CoV2373**
EUL holder	BioNTech Manufacturing GmbH (Germany)	ModernaTX, Inc. (USA)[1] Moderna Biotech (Spain)[2]	AstraZeneca AB (Sweden)	Janssen-Cilag International NV (Belgium)	Beijing Institute of Biological Products Co., Ltd. (BIBP) (China)	Sinovac Life Sciences Co., Ltd. (China)	Bharat Biotech International Limited (India)	Novavax (USA)

[lxxvi] WHO recommendation BioNTech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) – COMIRNATY. *WHO.* https://extranet.who.int/pqweb/vaccines/who-recommendation-covid-19-mrna-vaccine-nucleoside-modified-comirnaty

[lxxvii] 1. WHO recommendation ModernaTX, Inc/USFDA COVID-19 mRNA vaccine (nucleoside modified). *WHO*. https://extranet.who.int/pqweb/vaccines/who-recommendation-modernatx-incusfda-covid-19-mrna-vaccine-nucleoside-modified
2. WHO recommendation Moderna COVID-19 mRNA Vaccine (nucleoside modified). *WHO*. https://extranet.who.int/pqweb/vaccines/covid-19-mrna-vaccine-nucleoside-modified

[lxxviii] WHO recommendation AstraZeneca/ EU approved sites COVID-19 vaccine (ChAdOx1-S) [recombinant]. *WHO.* https://extranet.who.int/pqweb/vaccines/covid-19-vaccine-chadox1-s-recombinant-0

[lxxix] WHO recommendation Janssen-Cilag International NV (Belgium) COVID-19 Vaccine (Ad26.COV2-S [recombinant]). *WHO*. https://extranet.who.int/pqweb/vaccines/who-recommendation-janssen-cilag-international-nv-belgium-covid-19-vaccine-ad26cov2-s

[lxxx] WHO recommendation COVID-19 vaccine BIBP/Sinopharm. *WHO.* https://extranet.who.int/pqweb/vaccines/who-recommendation-covid-19-vaccine-bibp

[lxxxi] WHO recommendation of Sinovac COVID-19 vaccine (Vero Cell [Inactivated]) – CoronaVac. *WHO*. https://extranet.who.int/pqweb/vaccines/who-recommendation-sinovac-covid-19-vaccine-vero-cell-inactivated-coronavac

Production sites (Drug substance)	BioNTech Manufacturing GmbH (Mainz, Germany) BioNTech Manufacturing Marburg (Marburg, Germany) Rentschler Biopharma SE (Laupheim, Germany) Wyeth BioPharma Division of Wyeth Pharmaceuticals (USA)	Lonza Biologics, Inc., (USA)[1] Moderna TX, Inc. (USA)[1] Lonza AG (Switzerland)[2]	Henogen S.A (Belgium) Catalent Maryland, Inc. (USA) Oxford Biomedica (UK) Ltd. (United Kingdom) SK Bioscience (Republic of Korea) Halix B.V (Netherlands) WuXi Biologics (China)	Janssen Vaccines & Prevention B.V. (The Netherlands) Janssen Biologics B.V. (The Netherlands) Emergent Manufacturing Operations Baltimore LLC (USA)	Beijing Institute of Biological Products Co., Ltd. (China)	Sinovac Life Sciences Co., Ltd. (China)	-	Novavax (Bohumil, Czech Republic)
Production sites (Drug product)	Baxter Oncology GmbH (Halle/ Westfallen, Germany) BioNTech Manufacturing GmbH (Mainz, Germany) Pfizer Manufacturing Belgium NV (Belgium)	Baxter Pharmaceutical Solutions, LLC. (USA)[1] Catalent Indiana, LLC. (USA)[1] Rovi Pharma Industrial Services, S.A. (Spain)[2]	Catalent Anagni (Italy) CP Pharmaceuticals (United Kingdom) IDT Biologika (Germany) SK Bioscience (Republic of Korea)	Janssen Biologics B.V. (The Netherlands) Janssen Pharmaceutica NV (Belgium) Aspen SVP. (South Africa) Catalent Indiana LLC. (USA)	Beijing Institute of Biological Products Co., Ltd. (China)	Sinovac Life Sciences Co., Ltd. (China)	-	Novavax (Bohumil, Czech Republic)

	Novartis Pharma Stein AG (Switzerland) Mibe GmbH Arzneimittel (Brehna, Germany) Delpharm Saint-Remy (France) Sanofi-Aventis Deutschland GmbH (Germany)		Universal Farma, S.L. ("Chemo") (Spain) Amylin Ohio LLC (USA)	Grand River Aseptic Manufacturing Inc. (USA) Catalent Anagni S.R.L. (Italy)				
Diluent suppliers	Pfizer Perth, Australia Fresenius Kabi, USA	-	-	-	-	-	-	-

References

1. European Medicines Agency. Comirnaty and Spikevax: EMA recommendations on extra doses and boosters. European Medicines Agency. https://www.ema.europa.eu/en/news/comirnaty-spikevax-ema-recommendations-extra-doses-boosters. Published 2021. Updated 4 October. Accessed 5 October, 2021.
2. Hall VJ, Foulkes S, Saei A, et al. Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study). *SSRN - Preprint.* 2021. https://doi.org/10.2139/ssrn.3790399
3. Pilishvili T, Gierke R, Fleming-Dutra KE, et al. Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel. *N Engl J Med.* 2021. https://doi.org/10.1056/NEJMoa2106599
4. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *New England Journal of Medicine.* 2021. https://doi.org/10.1056/NEJMoa2114114
5. Martínez-Baz I, Trobajo-Sanmartín C, Miqueleiz A, et al. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.* 2021;26(39). https://doi.org/10.2807/1560-7917.ES.2021.26.39.2100894
6. Rahmani K, Shavaleh R, Forouhi M, et al. Effectiveness of COVID-19 Vaccines and Post-vaccination SARS-COV 2 Infection, Hospitalization, and Mortality: a Systematic Review and Meta-analysis of Observational Studies. *medRxiv.* 2021:2021.2011.2003.21265819. https://doi.org/10.1101/2021.11.03.21265819
7. Young-Xu Y, Korves C, Roberts J, et al. Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans. *JAMA Netw Open.* 2021;4(10):e2128391. https://doi.org/10.1001/jamanetworkopen.2021.28391
8. Starrfelt J, Buanes EA, Juvet LK, et al. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, January – September 2021. *medRxiv.* 2021:2021.2011.2012.21266222. https://doi.org/10.1101/2021.11.12.21266222
9. Public Health England. *Public Health England vaccine effectiveness report.* 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/989360/PHE_COVID-19_vaccine_effectiveness_report_March_2021_v2.pdf.
10. Thomson EC, Rosen LE, Shepherd JG, et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. *Cell.* 2021;184(5):1171-1187.e1120. https://doi.org/10.1016/j.cell.2021.01.037
11. Chung H, He S, Nasreen S, et al. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. *BMJ.* 2021;374:n1943. https://doi.org/10.1136/bmj.n1943
12. Lumley SF, Rodger G, Constantinides B, et al. An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare

workers by antibody and vaccination status. *Clinical infectious diseases.* 2021. https://doi.org/10.1093/cid/ciab608

13. Singh C, Naik BN, Pandey S, et al. Effectiveness of COVID-19 Vaccine in Preventing Infection and Disease Severity: A Case Control Study from an Eastern State of India. *Epidemiology and Infection.* 2021:1-20. https://doi.org/10.1017/S0950268821002247
14. Corchado-Garcia J, Puyraimond-Zemmour D, Hughes T, et al. Real-World Effectiveness of Ad26.COV2.S Adenoviral Vector Vaccine for COVID-19. *SSRN - Preprint.* 2021. https://doi.org/10.2139/ssrn.3835737
15. Polinski JM, Weckstein AR, Batech M, et al. Effectiveness of the Single-Dose Ad26.COV2.S COVID Vaccine. *medRxiv.* 2021:2021.2009.2010.21263385. https://doi.org/10.1101/2021.09.10.21263385
16. Self WH, Tenforde MW, Rhoads JP, IVY Network. Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions. *Morbidity & Mortality Weekly Report.* 2021. https://doi.org/10.15585/mmwr.mm7038e1
17. Braeye T, Cornelissen L, Catteau L, et al. Vaccine effectiveness against infection and onwards transmission of COVID-19: Analysis of Belgian contact tracing data, January-June 2021. *Vaccine.* 2021;39(39):5456-5460. https://doi.org/https://doi.org/10.1016/j.vaccine.2021.08.060
18. Ranzani OT, Leite RdS, Castilho LD, et al. Vaccine effectiveness of Ad26.COV2.S against symptomatic COVID-19 and clinical outcomes in Brazil: a test-negative study design. *medRxiv.* 2021:2021.2010.2015.21265006. https://doi.org/10.1101/2021.10.15.21265006
19. Corchado-Garcia J, Zemmour D, Hughes T, et al. Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19. *JAMA Netw Open.* 2021;4(11):e2132540. https://doi.org/10.1001/jamanetworkopen.2021.32540
20. Johnson & Johnson. Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S. Johnson & Johnson. https://www.jnj.com/johnson-johnson-announces-real-world-evidence-and-phase-3-data-confirming-strong-and-long-lasting-protection-of-single-shot-covid-19-vaccine-in-the-u-s. Published 2021. Updated 21 September. Accessed 21 September, 2021.
21. Sadoff J, Struyf F, Douoguih M. A plain language summary of how well the single-dose Janssen vaccine works and how safe it is. *Future Virol.* 2021;16(11):725-739. https://doi.org/10.2217/fvl-2021-0199
22. Jahromi M, Al Sheikh MH. Partial protection of Sinopharm vaccine against SARS COV2 during recent outbreak in Bahrain. *Microb Pathog.* 2021;158:105086. https://doi.org/10.1016/j.micpath.2021.105086
23. Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. *New England Journal of Medicine.* 2021. https://doi.org/10.1056/NEJMoa2107715
24. Cerqueira-Silva T, Oliveira VdA, Pescarini J, et al. Influence of age on the effectiveness and duration of protection in Vaxzevria and CoronaVac vaccines. *medRxiv.* 2021:2021.2008.2021.21261501. https://doi.org/10.1101/2021.08.21.21261501
25. Desai D, Khan AR, Soneja M, et al. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study. *Lancet Infect Dis.* 2021. https://doi.org/10.1016/s1473-3099(21)00674-5
26. A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults. In. ClinicalTrials.gov2021.

https://clinicaltrials.gov/ct2/show/NCT04533399?term=Novavax&cond=Covid19&draw=2.

27. A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom. In. ClinicalTrials.gov2021. https://clinicaltrials.gov/ct2/show/NCT04583995?term=Novavax&cond=Covid19&draw=2&rank=2.
28. Paris C, Perrin S, Hamonic S, et al. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data. *Clinical Microbiology and Infection.* 2021. https://doi.org/10.1016/j.cmi.2021.06.043
29. Katz MA, Bron Harlev E, Chazan B, et al. Covid-19 Vaccine Effectiveness in Healthcare Personnel in six Israeli Hospitals (CoVEHPI). *medRxiv.* 2021:2021.2008.2030.21262465. https://doi.org/10.1101/2021.08.30.21262465
30. Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. *medRxiv.* 2021:2021.2008.2006.21261707. https://doi.org/10.1101/2021.08.06.21261707
31. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *The Lancet.* 2021;398(10309):1407-1416. https://doi.org/10.1016/S0140-6736(21)02183-8
32. Irizarry RA, Robles-Fontan MM, Nieves EG, Cardona-Gerena I, Irizarry RA. Time-Varying Effectiveness of Three Covid-19 Vaccines in Puerto Rico. *medRxiv.* 2021:2021.2010.2017.21265101. https://doi.org/10.1101/2021.10.17.21265101
33. Fabiani M, Ramigni M, Gobbetto V, Mateo-Urdiales A, Pezzotti P, Piovesan C. Effectiveness of the comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021. *Eurosurveillance.* 2021;26(17):1-7. https://doi.org/10.2807/1560-7917.ES.2021.26.17.2100420
34. Knobel P, Serra C, Grau S, et al. Coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness in asymptomatic healthcare workers. *Infection Control & Hospital Epidemiology.* 2021:1-2. https://doi.org/10.1017/ice.2021.287
35. Gomes D, Beyerlein A, Katz K, et al. Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany. *PLoS One.* 2021;16(11):e0259370. https://doi.org/10.1371/journal.pone.0259370
36. Tande AJ, Pollock BD, Shah ND, Binnicker M, Berbari EF. mRNA Vaccine Effectiveness Against Asymptomatic SARS-CoV-2 Infection Over a Seven-Month Period. *Infect Control Hosp Epidemiol.* 2021:1-7. https://doi.org/10.1017/ice.2021.399
37. McQuade ETR, Platts-Mills JA. ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates. *The Lancet.* 2021;397(10291):2247-2248. https://doi.org/10.1016/S0140-6736(21)00951-X
38. Bhatnagar T, Chaudhuri S, Ponnaiah M, et al. Effectiveness of BBV152/Covaxin and AZD1222/Covishield Vaccines Against Severe COVID-19 and B.1.617.2/Delta Variant in India, 2021: A Multi-Centric Hospital-Based Case-Control Study. *SSRN.* 2021. https://doi.org/https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3955739
39. Paixão ES, Wong KL, Alves FJO, de Araújo Oliveira V, Cerqueira-Silva T, Júnior JB. Effectiveness of the CoronaVac Vaccine in Prevention of Symptomatic and Progression to Severe COVID-19 in Pregnant Women in Brazil. *SSRN.* 2021. https://ssrn.com/abstract=3962119.

40. Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. *New England Journal of Medicine.* 2021. https://doi.org/10.1056/NEJMoa2107659
41. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *New England Journal of Medicine.* 2021;385(7):585-594. https://doi.org/10.1056/NEJMoa2108891
42. Nasreen S, Chung H, He S, et al. Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. *medRxiv.* 2021:2021.2006.2028.21259420. https://doi.org/10.1101/2021.06.28.21259420
43. Seppälä E, Veneti L, Starrfelt J, et al. Vaccine effectiveness against infection with the delta (b.1.617.2) variant, norway, april to august 2021. *Eurosurveillance.* 2021;26(35). https://doi.org/10.2807/1560-7917.ES.2021.26.35.2100793
44. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *The Lancet.* 2021;397(10293):2461-2462. https://doi.org/10.1016/S0140-6736(21)01358-1
45. Pouwels KB, Pritchard E, Matthews P, et al. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. *medRxiv.* 2021:2021.2008.2018.21262237. https://doi.org/10.1101/2021.08.18.21262237
46. Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nature Medicine.* 2021. https://doi.org/10.1038/s41591-021-01446-y
47. Bruxvoort K, Sy LS, Qian L, et al. Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants. *medRxiv.* 2021:2021.2009.2029.21264199. https://doi.org/10.1101/2021.09.29.21264199
48. Chen Y, Shen H, Huang R, Tong X, Wu C. Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac. *The Lancet Infectious Diseases.* 2021;21(8):1071-1072. https://doi.org/10.1016/S1473-3099(21)00287-5
49. Gidari A, Sabbatini S, Bastianelli S, et al. Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected. *Journal of Infection.* 2021. https://doi.org/10.1016/j.jinf.2021.07.019
50. Ranzani O, Hitchings M, Neto M, et al. Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study. *medRxiv preprint.* 2021. https://doi.org/10.1101/2021.05.19.21257472
51. World Health Organization. The Sinovac-CoronaVac COVID-19 vaccine: What you need to know. World Health Organization. https://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know?gclid=Cj0KCQjw4eaJBhDMARIsANhrQADBYtFm2zMvzbfjthveE2gmCJTRl_jPc4HPlIFSwdZpzTix45gmEM0aAml9EALw_wcB. Published 2021. Updated 2 September 2021. Accessed 8 September, 2021.
52. State of Israel Ministry of Health. Vaccine efficacy among those first vaccinated. https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf Published 2021. Accessed 25 August, 2021.
53. Andrews N, Tessier E, Stowe J, et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK *Public Health England - Preprint.* 2021. https://khub.net/documents/135939561/338928724/Vaccine+effectiveness+and+durat

ion+of+protection+of+covid+vaccines+against+mild+and+severe+COVID-19+in+the+UK.pdf/10dcd99c-0441-0403-dfd8-11ba2c6f5801.

54. Nanduri S, Pilishvili T, Derado G, Schrag SJ. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1–August 1. *Morbidity & Mortality Weekly Report.* 2021;70(34):163-1166. https://doi.org/10.15585/mmwr.mm7034e3
55. Cohn BA, Cirillo PM, Murphy CC, Krigbaum NY, Wallace AW. Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021. *medRxiv.* 2021:2021.2010.2013.21264966. https://doi.org/10.1101/2021.10.13.21264966
56. Mayo Foundation for Medical Education and Research (MFMER). Do COVID-19 vaccines protect against the variants? Mayo Clinic. Published 2021. Updated 24 August 2021. Accessed 8 September, 2021.
57. Chin ET, Leidner D, Zhang Y, et al. Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison. *New England Journal of Medicine.* 2021. https://doi.org/10.1056/NEJMc2114089
58. Mlcochova P, Kemp SA, Shanker Dhar M, et al. SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough. *bioRxiv.* 2021:2021.2005.2008.443253. https://doi.org/10.1101/2021.05.08.443253
59. Li X-n, Huang Y, Wang W, et al. Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study. *Emerging Microbes & Infections.* 2021:1-32. https://doi.org/10.1080/22221751.2021.1969291
60. Uriu K, Kimura I, Shirakawa K, et al. Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum. *New England Journal of Medicine.* 2021. https://doi.org/10.1056/NEJMc2114706
61. Clifford S, Waight P, Hackman J, et al. Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission - a prospective cohort study in England. *medRxiv.* 2021:2021.2011.2024.21266401. https://doi.org/10.1101/2021.11.24.21266401
62. Stowe J, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against hospital admission with the delta (B.1.617.2) variant *Public Health Enland Publishing - Preprint.* 2021. https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/479607329?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F479607266.
63. Foley KE. J&J shot effective against Delta variant in large South Africa study. Politico. https://www.politico.eu/article/johnson-johnson-coronavirus-vaccine-delta-variant/. Published 2021. Updated 6 August 2021. Accessed 7 September, 2021.
64. de Gier B, Andeweg S, Joosten R, et al. Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021. *Eurosurveillance.* 2021;26(31). https://doi.org/10.2807/1560-7917.ES.2021.26.31.2100640
65. Tenforde MW, Self WH, Naioti EA, et al. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults

— United States, March–July 2021. *Morbidity & Mortality Weekly Report.* 2021;70(34):1156-1162. https://doi.org/10.15585/mmwr.mm7034e2

66. Grannis SJ, Rowley EA, Ong TC, et al. Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021. *Morbidity & Mortality Weekly Report.* 2021;70(37):1291–1293. https://www.cdc.gov/mmwr/volumes/70/wr/mm7037e2.htm.
67. Tartof SY, Slezak JM, Fischer H, et al. Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study. *SSRN - Preprint.* 2021. https://doi.org/10.2139/ssrn.3909743
68. Sheikh A, Robertson C, Taylor B. BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant. *New England Journal of Medicine.* 2021. https://doi.org/10.1056/NEJMc2113864
69. Johnson & Johnson. Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response. Johnson & Johnson. https://www.jnj.com/positive-new-data-for-johnson-johnson-single-shot-covid-19-vaccine-on-activity-against-delta-variant-and-long-lasting-durability-of-response. Published 2021. Updated 1 July 2021. Accessed 8 September, 2021.
70. Hu Z, Tao B, Li Z, et al. Effectiveness of inactive COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China. *medRxiv.* 2021:2021.2009.2002.21263010. https://doi.org/10.1101/2021.09.02.21263010
71. Israel A, Merzon E, Schäffer AA, et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort. *medRxiv.* 2021:2021.2008.2003.21261496. https://doi.org/10.1101/2021.08.03.21261496
72. Salvagno GL, Henry B, Pighi L, De Nitto S, Lippi G. Total Anti-SARS-CoV-2 Antibodies Measured 6 Months After Pfizer-BioNTech COVID-19 Vaccination in Healthcare Workers. *SSRN- Preprint.* 2021. https://doi.org/10.2139/ssrn.3915349
73. Collier A-rY, Yu J, McMahan K, et al. Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines. *New England Journal of Medicine.* 2021;385(21):2010-2012. https://doi.org/10.1056/NEJMc2115596
74. Barin B, Kasap U, Selçuk F, Volkan E, Uluckan O. Longitudinal Comparison of SARS-CoV-2 Anti-Spike RBD IgG antibody Responses After CoronaVac, BNT162b2, ChAdOx1 nCoV-19 Vaccines and Evaluation of a Single Booster Dose of BNT162b2 or CoronaVac After a Primary CoronaVac Regimen. *SSRN - Preprint.* 2021. https://ssrn.com/abstract=3929973.
75. Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. *New England Journal of Medicine.* 2021. https://doi.org/10.1056/NEJMoa2114583
76. Doria-Rose N, Suthar MS, Makowski M, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. *New England Journal of Medicine.* 2021;384(23):2259-2261. https://doi.org/10.1056/NEJMc2103916
77. Flaxman A, Marchevsky N, Jenkin D, et al. Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222). *SSRN - Preprint.* 2021. https://doi.org/10.2139/ssrn.3873839
78. Sadoff J, Le Gars M, Cardenas V, et al. Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting.

medRxiv. 2021:2021.2008.2025.21262569. https://doi.org/10.1101/2021.08.25.21262569
79. Barouch DH, Stephenson KE, Sadoff J, et al. Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination. *New England Journal of Medicine.* 2021. https://doi.org/http://doi.org/10.1056/NEJMc2108829
80. Badano MN, Sabbione F, Keitelman I, et al. Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2. *medRxiv.* 2021:2021.2010.2002.21264432. https://doi.org/10.1101/2021.10.02.21264432
81. Ju B, Zhou B, Song S, et al. Potent antibody immunity to SARS-CoV-2 variants elicited by a third dose of inactivated vaccine. *bioRxiv.* 2021:2021.2011.2010.468037. https://doi.org/10.1101/2021.11.10.468037
82. Li M, Yang J, Wang L, et al. A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *medRxiv.* 2021:2021.2008.2003.21261544. https://doi.org/10.1101/2021.08.03.21261544
83. Wang K, Cao YR, Zhou Y, et al. A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2. *medRxiv.* 2021:2021.2009.2002.21261735. https://doi.org/10.1101/2021.09.02.21261735
84. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. *medRxiv.* 2021:2021.2008.2025.21262584. https://doi.org/10.1101/2021.08.25.21262584
85. Iskander J, Frost JK, Russell S, et al. Effectiveness of Vaccination Against Reported SARS-CoV-2 Infection in United States Coast Guard Personnel Between May and August 2021: A Time-Series Analysis. *medRxiv.* 2021:2021.2011.2019.21266537. https://doi.org/10.1101/2021.11.19.21266537
86. Feikin D, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y. Duration of Effectiveness of Vaccines Against SARS-CoV-2 Infection and COVID-19 Disease: Results of a Systematic Review and Meta-Regression. *SSRN.* 2021. https://ssrn.com/abstract=3961378.
87. Poukka E, Baum U, Palmu AA, et al. Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021. *medRxiv.* 2021:2021.2011.2003.21265791. https://doi.org/10.1101/2021.11.03.21265791
88. Cohn BA, Cirillo PM, Murphy CC, Krigbaum NY, Wallace AW. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. *Science.* 2021:eabm0620. https://doi.org/10.1126/science.abm0620
89. Lan F-Y, Sidossis A, Iliaki E, et al. Continued Effectiveness of COVID-19 Vaccination among Urban Healthcare Workers during Delta Variant Predominance. *medRxiv.* 2021:2021.2011.2015.21265753. https://doi.org/10.1101/2021.11.15.21265753
90. Baden LR, ElSahly HM, Essink B, et al. Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge. *medRxiv.* 2021:2021.2009.2017.21263624. https://doi.org/10.1101/2021.09.17.21263624
91. Prunas O, Warren JL, Crawford FW, et al. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. *medRxiv.* 2021:2021.2007.2013.21260393. https://doi.org/10.1101/2021.07.13.21260393
92. Riemersma KK, Grogan BE, Kita-Yarbro A, et al. Shedding of Infectious SARS-CoV-2 Despite Vaccination when the Delta Variant is Prevalent - Wisconsin, July 2021.

medRxiv. 2021:2021.2007.2031.21261387. https://doi.org/10.1101/2021.07.31.21261387

93. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Effect of vaccination on household transmission of sars-cov-2 in england. *New England Journal of Medicine.* 2021;385(8):759-760. https://doi.org/10.1056/NEJMc2107717
94. Shah ASV, Gribben C, Bishop J, et al. Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households. *medRxiv.* 2021:2021.2003.2011.21253275. https://doi.org/10.1101/2021.03.11.21253275
95. de Gier B, Andeweg S, Backer JA, et al. Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021. *Euro Surveill.* 2021;26(44). https://doi.org/10.2807/1560-7917.Es.2021.26.44.2100977
96. Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. *Lancet.* 2021;397(10282):1351-1362. https://doi.org/10.1016/s0140-6736(21)00628-0
97. Kemp SA, Cheng MTK, Hamilton W, et al. Transmission of B.1.617.2 Delta Variant between vaccinated healthcare workers in Delhi, India. *medRxiv.* 2021:2021.2011.2019.21266406. https://doi.org/10.1101/2021.11.19.21266406
98. Bosch W, Cowart JB, Bhakta S, et al. COVID-19 Vaccine-Breakthrough Infections Requiring Hospitalization in Mayo Clinic Florida through August 2021. *Clin Infect Dis.* 2021. https://doi.org/10.1093/cid/ciab932
99. Mizrahi B, Lotan R, Kalkstein N, et al. Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. *Nat Commun.* 2021;12(1):6379. https://doi.org/10.1038/s41467-021-26672-3
100. Dash GC, Subhadra S, Turuk J, et al. Breakthrough SARS-CoV-2 infections among BBV-152 (COVAXIN®) and AZD1222 (COVISHIELDTM) recipients: Report from the eastern state of India. *Journal of Medical Virology.* 2021. https://doi.org/10.1002/jmv.27382
101. Chau NVV, Ngoc NM, Nguyet LA, et al. An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. *EClinicalMedicine.* 2021;41:101143. https://doi.org/10.1016/j.eclinm.2021.101143
102. Maurya D, Kaur A, Faraz F, Tandon S, Rana A, Grover S. Assessment of breakthrough infections among post-vaccinated healthcare workers in a Tertiary Dental Hospital in New Delhi, India. *medRxiv.* 2021:2021.2011.2015.21266333. https://doi.org/10.1101/2021.11.15.21266333
103. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. *MMWR Morbidity and mortality weekly report.* 2020;69(50):1922-1924. https://doi.org/10.15585/mmwr.mm6950e2
104. Im JH, Kim E, Lee E, et al. Adverse Events with the Pfizer-BioNTech COVID-19 Vaccine among Korean Healthcare Workers. *Yonsei Med J.* 2021;62(12):1162-1168. https://doi.org/10.3349/ymj.2021.62.12.1162
105. Caminati M, Guarnieri G, Batani V, et al. Covid-19 vaccination in patients with severe asthma on biologic treatment: Safety, tolerability, and impact on disease control. *Vaccines.* 2021;9(8). https://doi.org/10.3390/vaccines9080853

106. Haroun F, Alharbi M, Hong A. Case series on the safety of mRNA COVID19 vaccines in cancer patients undergoing treatment. *Journal of Clinical Oncology.* 2021;39(15 SUPPL). https://doi.org/10.1200/JCO.2021.39.15_suppl.e14562
107. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine.* 2020;384(5):403-416. https://doi.org/10.1056/NEJMoa2035389
108. Wei N, Fishman M, Wattenberg D, Gordon M, Lebwohl M. "COVID arm": A reaction to the Moderna vaccine. *JAAD case reports.* 2021;10:92-95. https://doi.org/10.1016/j.jdcr.2021.02.014
109. Voysey M, Costa Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *The Lancet.* 2021;397(10269):99-111. https://doi.org/10.1016/S0140-6736(20)32661-1
110. Ghiasi N, Valizadeh R, Arabsorkhi M, et al. Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion. 2021. https://doi.org/http://immunopathol.com/PDF/ipp-7-e31.pdf
111. Shay DK, Gee J, Su JR, et al. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March–April 2021. *Morbidity and Mortality Weekly Report.* 2021;70(18):680–684. https://doi.org/http://dx.doi.org/10.15585/mmwr.mm7018e2external
112. Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side Effects and Perceptions Following Sinopharm COVID-19 Vaccination. *Int J Infect Dis.* 2021. https://doi.org/10.1016/j.ijid.2021.08.013
113. Palacios R, Batista AP, Santos Nascimento Albuquerque C, et al. Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study. *SSRN - Preprint.* 2021. https://doi.org/http://dx.doi.org/10.2139/ssrn.3822780
114. Durmaz K, Temiz SA, Zuhal K, Dursun R, Abdelmaksoud A. Allergic and Cutaneous reactions following Inactivated SARS-CoV-2 vaccine (CoronaVac®) in Healthcare workers. *Clin Exp Dermatol.* 2021. https://doi.org/10.1111/ced.14896
115. Benjamanukul S, Traiyan S, Yorsaeng R, et al. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers. *J Med Virol.* 2021. https://doi.org/10.1002/jmv.27458
116. Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial. *medRxiv.* 2021:2021.2006.2030.21259439. https://doi.org/10.1101/2021.06.30.21259439
117. Kim HW, Jenista ER, Wendell DC, et al. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. *JAMA Cardiology.* 2021. https://doi.org/10.1001/jamacardio.2021.2828
118. Bozkurt B, Kamat I, Hotez PJ. Myocarditis With COVID-19 mRNA Vaccines. *Circulation.* 2021;144(6):471-484. https://doi.org/doi:10.1161/CIRCULATIONAHA.121.056135
119. Kafil T, Lamacie MM, Chenier S, et al. mRNA COVID-19 Vaccination and Development of CMR-confirmed Myopericarditis. *medRxiv.* 2021:2021.2009.2013.21262182. https://doi.org/10.1101/2021.09.13.21262182
120. Cirillo N. Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns. *Journal of Oral Pathology & Medicine.* 2021;50(4):424-427. https://doi.org/10.1111/jop.13165

121. Shimabukuro T. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.* 2021;21(3):1332-1337. https://doi.org/10.1111/ajt.16516
122. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of Medicine.* 2020;383(27):2603-2615. https://doi.org/10.1056/NEJMoa2034577
123. Cohen OG, Clark AK, Milbar H, Tarlow M. Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine. *Hum Vaccin Immunother.* 2021:1-2. https://doi.org/10.1080/21645515.2021.1963173
124. Temiz SA, Abdelmaksoud A, Dursun R, Durmaz K, Sadoughifar R, Hasan A. Pityriasis rosea following SARS-CoV-2 vaccination: A case series. *Journal of Cosmetic Dermatology.* 2021. https://doi.org/10.1111/jocd.14372
125. Vassallo C, Boveri E, Brazzelli V, et al. Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine. *Dermatol Ther.* 2021:e15076. https://doi.org/10.1111/dth.15076
126. Santovito LS, Pinna G. A case of reactivation of varicella-zoster virus after BNT162b2 vaccine second dose? *Inflamm Res.* 2021:1-3. https://doi.org/10.1007/s00011-021-01491-w
127. Fathy RA, McMahon DE, Lee C, et al. Varicella Zoster and Herpes Simplex Virus Reactivation Post-COVID-19 Vaccination: A Review of 40 Cases in an International Dermatology Registry. *J Eur Acad Dermatol Venereol.* 2021. https://doi.org/10.1111/jdv.17646
128. Papasavvas I, de Courten C, Herbort CP, Jr. Varicella-zoster virus reactivation causing herpes zoster ophthalmicus (HZO) after SARS-CoV-2 vaccination - report of three cases. *J Ophthalmic Inflamm Infect.* 2021;11(1):28. https://doi.org/10.1186/s12348-021-00260-4
129. Soub HA, Ibrahim W, Maslamani MA, A. Ali G, Ummer W, Abu-Dayeh A. Kikuchi-Fujimoto disease following SARS CoV2 vaccination: Case report. *IDCases.* 2021;25. https://doi.org/10.1016/j.idcr.2021.e01253
130. Chamarti K, Dar K, Reddy A, Gundlapalli A, Mourning D, Bajaj K. Thrombotic Thrombocytopenic Purpura Presentation in an Elderly Gentleman Following COVID Vaccine Circumstances. *Cureus.* 2021;13(7):e16619. https://doi.org/10.7759/cureus.16619
131. Collins EC, Carr MJ, Kim JS, et al. Immune thrombocytopenia in 2 healthy young women after the Pfizer-BioNTech BNT16B2b2 messenger RNA coronavirus disease 2019 vaccination. *J Am Coll Emerg Physicians Open.* 2021;2(5):e12531. https://doi.org/10.1002/emp2.12531
132. Horino T. IgA nephropathy flare-up following SARS-CoV-2 vaccination. *QJM : monthly journal of the Association of Physicians.* 2021. https://doi.org/10.1093/qjmed/hcab223
133. Hughes DL, Brunn JA, Jacobs J, Todd PK, Askari FK, Fontana RJ. Guillain-Barré syndrome after COVID-19 mRNA vaccination in a liver transplant recipient with favorable treatment response. *Liver Transpl.* 2021. https://doi.org/10.1002/lt.26279
134. Osowicki J, Morgan H, Harris A, Crawford NW, Buttery JP, Kiers L. Guillain-Barré Syndrome in an Australian state using both mRNA and adenovirus-vector SARS-CoV-2 vaccines. *Ann Neurol.* 2021. https://doi.org/10.1002/ana.26218

135. Perna D, Jones J, Schadt CR. Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine. *JAAD Case Rep.* 2021. https://doi.org/10.1016/j.jdcr.2021.08.035
136. Iwata H, Kamiya K, Kado S, et al. Case of immunoglobulin A vasculitis following coronavirus disease 2019 vaccination. *J Dermatol.* 2021. https://doi.org/10.1111/1346-8138.16167
137. Mücke VT, Knop V, Mücke MM, Ochsendorf F, Zeuzem S. First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report. *BMC Infect Dis.* 2021;21(1):958. https://doi.org/10.1186/s12879-021-06655-x
138. Elias C, Cardoso P, Gonçalves D, Vaz I, Cardoso L. Rhabdomyolysis Following Administration of Comirnaty(®). *Eur J Case Rep Intern Med.* 2021;8(8):002796. https://doi.org/10.12890/2021_002796
139. Franquemont S, Galvez J. Subacute Thyroiditis After mRNA Vaccine for Covid-19. *Journal of the Endocrine Society.* 2021;5(Suppl 1):A956-A957. https://doi.org/10.1210/jendso/bvab048.1954
140. Sato K, Mano T, Niimi Y, Toda T, Iwata A, Iwatsubo T. Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database. *Int J Infect Dis.* 2021;111:310-312. https://doi.org/10.1016/j.ijid.2021.08.071
141. Buján Bonino C, Moreiras Arias N, López-Pardo Rico M, et al. Atypical erythema multiforme related to BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine. *Int J Dermatol.* 2021. https://doi.org/10.1111/ijd.15894
142. Yoshifuji A, Ishioka K, Masuzawa Y, et al. COVID-19 vaccine induced interstitial lung disease. *J Infect Chemother.* 2021. https://doi.org/10.1016/j.jiac.2021.09.010
143. Valenzuela DA, Groth S, Taubenslag KJ, Gangaputra S. Acute macular neuroretinopathy following Pfizer-BioNTech COVID-19 vaccination. *Am J Ophthalmol Case Rep.* 2021;24:101200. https://doi.org/10.1016/j.ajoc.2021.101200
144. Coffman JR, Randolph AC, Somerson JS. Parsonage-Turner Syndrome After SARS-CoV-2 BNT162b2 Vaccine: A Case Report. *JBJS Case Connect.* 2021;11(3). https://doi.org/10.2106/jbjs.Cc.21.00370
145. Rubinstein TJ. Thyroid Eye Disease Following COVID-19 Vaccine in a Patient With a History Graves' Disease: A Case Report. *Ophthalmic Plast Reconstr Surg.* 2021. https://doi.org/10.1097/iop.0000000000002059
146. Yamamoto K, Mashiba T, Takano K, et al. A case of exacerbation of subclinical hyperthyroidism after first administration of bnt162b2 mrna covid-19 vaccine. *Vaccines.* 2021;9(10). https://doi.org/10.3390/vaccines9101108
147. Nassar M, Chung H, Dhayaparan Y, et al. COVID-19 vaccine induced rhabdomyolysis: Case report with literature review. *Diabetes & metabolic syndrome.* 2021;15(4):102170-102170. https://doi.org/10.1016/j.dsx.2021.06.007
148. Hong S, Fata M, Rahim M, Hanly B, Omidvari K. A RARE CASE OF INTERNAL JUGULAR VEIN THROMBOSIS AFTER MRNA COVID-19 VACCINE. *Chest.* 2021;160(4):A457-A458. https://doi.org/10.1016/j.chest.2021.07.449
149. Alkhalifah MI, Alsobki HE, Alwael HM, Al Fawaz AM, Al-Mezaine HS. Herpes Simplex Virus Keratitis Reactivation after SARS-CoV-2 BNT162b2 mRNA Vaccination: A Report of Two Cases. *Ocular Immunology and Inflammation.* 2021. https://doi.org/10.1080/09273948.2021.1986548
150. Abou-Foul AK, Ross E, Abou-Foul M, George AP. Cervical lymphadenopathy following coronavirus disease 2019 vaccine: clinical characteristics and implications

for head and neck cancer services. *J Laryngol Otol.* 2021;135(11):1025-1030. https://doi.org/10.1017/s0022215121002462
151. Klomjit N, Alexander MP, Fervenza FC, et al. COVID-19 vaccination and glomerulonephritis. *Kidney Int Rep.* 2021. https://doi.org/10.1016/j.ekir.2021.09.008
152. Rodríguez-Martín M, Corriols-Noval P, López-Simón E, Morales-Angulo C. Ramsay Hunt syndrome following mRNA SARS-COV-2 vaccine. *Enferm Infecc Microbiol Clin (Engl Ed).* 2021. https://doi.org/10.1016/j.eimce.2021.06.003
153. Baffa ME, Maglie R, Giovannozzi N, et al. Sweet syndrome following sars-cov2 vaccination. *Vaccines.* 2021;9(11). https://doi.org/10.3390/vaccines9111212
154. Kaulen LD, Doubrovinskaia S, Mooshage C, et al. Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series. *European Journal of Neurology.* 2021. https://doi.org/10.1111/ene.15147
155. Duke H, Posch L, Green L. Axillary adenopathy following COVID-19 vaccination: A single institution case series. *Clin Imaging.* 2021;80:111-116. https://doi.org/10.1016/j.clinimag.2021.05.023
156. Nistri R, Barbuti E, Rinaldi V, et al. Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases. *Frontiers in Neurology.* 2021;12. https://doi.org/10.3389/fneur.2021.765954
157. Ahmad SA, Salih BK, Hama Hussein KF, Mikael TM, Kakamad FH, Salih AM. Aseptic meningoencephalitis after COVID-19 vaccination: A case report. *Ann Med Surg (Lond).* 2021;71:103028. https://doi.org/10.1016/j.amsu.2021.103028
158. Takeyama R, Fukuda K, Kouzaki Y, et al. Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: a case report. *Acta Neurochir (Wien).* 2021:1-5. https://doi.org/10.1007/s00701-021-05038-0
159. Temiz SA, Abdelmaksoud A, Wollina U, et al. Cutaneous and Allergic reactions due to COVID-19 vaccinations: A review. *Journal of Cosmetic Dermatology.* 2021. https://doi.org/10.1111/jocd.14613
160. Atak MF, Farabi B, Kalelioglu MB, Rao BK. Pigmented purpuric dermatosis after BNT162B2 mRNA COVID-19 vaccine administration. *J Cosmet Dermatol.* 2021. https://doi.org/10.1111/jocd.14607
161. Kaplan B, Farzan S, Coscia G, et al. Allergic reactions to COVID-19 vaccines and addressing vaccine hesitancy: Northwell Health experience. *Ann Allergy Asthma Immunol.* 2021. https://doi.org/10.1016/j.anai.2021.10.019
162. Rechavi Y, Shashar M, Lellouche J, Yana M, Yakubovich D, Sharon N. Occurrence of BNT162b2 vaccine adverse reactions is associated with enhanced SARS-CoV-2 IgG antibody response. *Vaccines.* 2021;9(9). https://doi.org/10.3390/vaccines9090977
163. Iftikhar H, Noor SMU, Masood M, Bashir K. Bell's Palsy After 24 Hours of mRNA-1273 SARS-CoV-2 Vaccine. *Cureus.* 2021;13(6):e15935-e15935. https://doi.org/10.7759/cureus.15935
164. Thimmanagari K, Veeraballi S, Roach D, Al Omour B, Slim J. Ipsilateral Zoster Ophthalmicus Post COVID-19 Vaccine in Healthy Young Adults. *Cureus.* 2021;13(7):e16725. https://doi.org/10.7759/cureus.16725
165. Drerup KA, Gläser R. SARS-CoV-2—update on skin manifestations, predictive markers and cutaneous reactions after vaccination. *Hautarzt.* 2021. https://doi.org/10.1007/s00105-021-04881-7
166. Khan E, Shrestha AK, Colantonio MA, Liberio RN, Sriwastava S. Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature. *Journal of Neurology.* 2021. https://doi.org/10.1007/s00415-021-10785-2

167. Christensen SK, Ballegaard M, Boesen MS. Guillian Barré syndromeafter mRNA-1273 vaccination against COVID-19. *Ugeskr Laeger.* 2021;183(35). Published 2021/09/04.
168. Matarneh AS, Al-Battah AH, Farooqui K, Ghamoodi M, Alhatou M. COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect. *Clin Case Rep.* 2021;9(9):e04756. https://doi.org/10.1002/ccr3.4756
169. Agaronov A, Makdesi C, Hall CS. Acute generalized exanthematous pustulosis induced by Moderna COVID-19 messenger RNA vaccine. *JAAD Case Rep.* 2021;16:96-97. https://doi.org/10.1016/j.jdcr.2021.08.013
170. Ajmera KM. Fatal case of rhabdomyolysis post-covid-19 vaccine. *Infection and Drug Resistance.* 2021;14:3929-3935. https://doi.org/10.2147/IDR.S331362
171. Mack M, Nichols L, Guerrero DM. Rhabdomyolysis Secondary to COVID-19 Vaccination. *Cureus.* 2021;13(5):e15004. https://doi.org/10.7759/cureus.15004
172. Ganga K, Solyar AY, Ganga R. Massive Cervical Lymphadenopathy Post-COVID-19 Vaccination. *Ear Nose Throat J.* 2021:1455613211048984. https://doi.org/10.1177/01455613211048984
173. Tagini F, Carrel L, Fallet B, Gachoud D, Ribi C, Monti M. Behçet's-like adverse event or inaugural Behçet's disease after SARS-CoV-2 mRNA-1273 vaccination? *Rheumatology (Oxford, England).* 2021. https://doi.org/10.1093/rheumatology/keab751
174. Català A, Muñoz-Santos C, Galván-Casas C, et al. Cutaneous reactions after SARS-COV-2 vaccination: A cross-sectional Spanish nationwide study of 405 cases. *The British journal of dermatology.* 2021. https://doi.org/10.1111/bjd.20639
175. Guzmán-Pérez L, Puerta-Peña M, Falkenhain-López D, et al. Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2. *Journal of the European Academy of Dermatology and Venereology.* 2021. https://doi.org/10.1111/jdv.17547
176. Perera R, Fletcher J. Thromboembolism and the Oxford-AstraZeneca vaccine. *BMJ.* 2021;373:n1159. https://doi.org/10.1136/bmj.n1159
177. Schulz JB, Berlit P, Diener HC, et al. COVID-19 vaccine-associated cerebral venous thrombosis in Germany. *Annals of neurology.* 2021. https://doi.org/10.1002/ana.26172
178. Al Rawahi B, BaTaher H, Jaffer Z, Al-Balushi A, Al-Mazrouqi A, Al-Balushi N. Vaccine-induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCOV19) vaccine-A case report. *Res Pract Thromb Haemost.* 2021;5(6):e12578. https://doi.org/10.1002/rth2.12578
179. Asmat H, Fayeye F, Alshakaty H, Patel J. A rare case of COVID-19 vaccine-induced thrombotic thrombocytopaenia (VITT) involving the veno-splanchnic and pulmonary arterial circulation, from a UK district general hospital. *BMJ Case Rep.* 2021;14(9). https://doi.org/10.1136/bcr-2021-244223
180. Alalwan AA, Abou Trabeh A, Premchandran D, Razeem M. COVID-19 Vaccine-Induced Thrombotic Thrombocytopenia: A Case Series. *Cureus.* 2021;13(9):e17862. https://doi.org/10.7759/cureus.17862
181. Wolthers SA, Stenberg J, Nielsen HB, Stensballe J, Pedersen HP. Intracerebral haemorrhage twelve days after vaccination with ChAdOx1 nCoV-19. *Ugeskr Laeger.* 2021;183(35). Published 2021/09/04.
182. Fang WC, Chiu LW, Hu SC. Psoriasis exacerbation after first dose of AstraZeneca coronavirus disease 2019 vaccine. *J Dermatol.* 2021. https://doi.org/10.1111/1346-8138.16137

183. Corrêa DG, Cañete LAQ, dos Santos GAC, de Oliveira RV, Brandão CO, da Cruz LCH. Neurological symptoms and neuroimaging alterations related with COVID-19 vaccine: Cause or coincidence? *Clinical Imaging.* 2021;80:348-352. https://doi.org/10.1016/j.clinimag.2021.08.021
184. Oh HK, Kim EK, Hwang I, et al. COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021. *Osong Public Health Res Perspect.* 2021;12(4):264-268. https://doi.org/10.24171/j.phrp.2021.0157
185. Mohta A, Arora A, Srinivasa R, Mehta RD. Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria being treated with cyclosporine—A report of 3 cases. *Journal of Cosmetic Dermatology.* 2021. https://doi.org/10.1111/jocd.14437
186. Wantavornprasert K, Noppakun N, Klaewsongkram J, Rerknimitr P. Generalized Bullous Fixed Drug Eruption after ChAdOx1 nCoV-19 Vaccination. *Clin Exp Dermatol.* 2021. https://doi.org/10.1111/ced.14926
187. Oo WM, Giri P, de Souza A. AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link? *J Neuroimmunol.* 2021;360:577719. https://doi.org/10.1016/j.jneuroim.2021.577719
188. Pedrazini MC, da Silva MH. "Pityriasis Rosea-like cutaneous eruption as a possible dermatological manifestation after Oxford-AstraZeneca vaccine: case report and brief literature review.". *Dermatol Ther.* 2021:e15129. https://doi.org/10.1111/dth.15129
189. Leerunyakul K, Pakornphadungsit K, Suchonwanit P. Case Report: Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination. *Front Med (Lausanne).* 2021;8:752443. https://doi.org/10.3389/fmed.2021.752443
190. Wu RW, Lin TK. Oxford-AstraZeneca COVID-19 vaccine-induced acute localized exanthematous pustulosis. *J Dermatol.* 2021. https://doi.org/10.1111/1346-8138.16138
191. Elbæk MV, Vinding GR, Jemec GBE. Darier's Disease Flare following COVID-19 Vaccine. *Case Rep Dermatol.* 2021;13(2):432-436. https://doi.org/10.1159/000517256
192. Tan A, Stepien KM, Narayana STK. Carnitine palmitoyltransferase II deficiency and post-COVID vaccination rhabdomyolysis. *Qjm.* 2021. https://doi.org/10.1093/qjmed/hcab077
193. Sriphrapradang C, Shantavasinkul PC. Graves' disease following SARS-CoV-2 vaccination. *Endocrine.* 2021. https://doi.org/10.1007/s12020-021-02902-y
194. Nasuelli NA, De Marchi F, Cecchin M, et al. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine. *Neurol Sci.* 2021;42(11):4747-4749. https://doi.org/10.1007/s10072-021-05467-w
195. Mehta H, Handa S, Malhotra P, et al. Erythema nodosum, zoster duplex and pityriasis rosea as possible cutaneous adverse effects of Oxford-AstraZeneca COVID-19 vaccine: report of three cases from India. *J Eur Acad Dermatol Venereol.* 2021. https://doi.org/10.1111/jdv.17678
196. Chan JEZ, Irimpen A. Severe but self-limiting polyarthralgia with functional impairment following chadox1 ncov-19 vaccination in an elderly recipient. *Vaccines.* 2021;9(11). https://doi.org/10.3390/vaccines9111220
197. Panou E, Nikolaou V, Marinos L, et al. Recurrence of cutaneous T-cell lymphoma post viral vector COVID-19 vaccination. *J Eur Acad Dermatol Venereol.* 2021. https://doi.org/10.1111/jdv.17736

198. Jeong J, Choi HS. Sudden sensorineural hearing loss after COVID-19 vaccination. *International Journal of Infectious Diseases.* 2021;113:341-343. https://doi.org/10.1016/j.ijid.2021.10.025
199. Loo LK, Salim O, Liang D, et al. Acute-onset polyradiculoneuropathy after SARS-CoV2 vaccine in the West and North Midlands, United Kingdom. *Muscle Nerve.* 2021. https://doi.org/10.1002/mus.27461
200. U.S. Food & Drug Administration. Coronavirus (COVID-19) Update: July 13, 2021. U.S Food & Drug Administration. Published 2021. Updated 13 July 2021. Accessed 18 August, 2021.
201. Kemper M, Berssenbrügge C, Lenz G, Mesters RM. Vaccine-induced pseudothrombocytopenia after Ad26.COV2.S vaccination. *Annals of Hematology.* 2021. https://doi.org/10.1007/s00277-021-04611-y
202. Akuna M, Qureshi M, Miller N. VITT reaction associated with Johnson & Johnson vaccine. *Chest.* 2021;160(4):A811. https://doi.org/10.1016/j.chest.2021.07.764
203. Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. *JAMA.* 2021;326(1):35-45. https://doi.org/10.1001/jama.2021.8565
204. Huang L, Yao Z, Zhang J. Two cases of pityriasis rosea after the injection of coronavirus disease 2019 vaccine. *J Eur Acad Dermatol Venereol.* 2021. https://doi.org/10.1111/jdv.17648
205. Pan L, Zhang Y, Cui Y, Wu X. Bilateral uveitis after inoculation with COVID-19 vaccine: A case report. *Int J Infect Dis.* 2021. https://doi.org/10.1016/j.ijid.2021.09.075
206. Tutar NK, EyigÜRbÜZ T, Yildirim Z, Kale N. A variant of guillain-barre syndrome after sars-cov-2 vaccination: Amsan. *Ideggyogyaszati Szemle.* 2021;74(7-8):286-288. https://doi.org/10.18071/ISZ.74.0286
207. Saygılı ES, Karakilic E. Subacute thyroiditis after inactive SARS-CoV-2 vaccine. *BMJ Case Rep.* 2021;14(10). https://doi.org/10.1136/bcr-2021-244711
208. Zhang LW, Wang WJ, Li CH, Chen T. Erythema multiforme after SARS-CoV-2 vaccine. *J Eur Acad Dermatol Venereol.* 2021. https://doi.org/10.1111/jdv.17689
209. Noikongdee P, Police P, Phojanasenee T, et al. Prevalence of anti-platelet factor 4/polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais. *Res Pract Thromb Haemost.* 2021;5(7):e12600. https://doi.org/10.1002/rth2.12600
210. Chaijaras S, Seree-Aphinan C, Rutnin S, Ngamjanyaporn P, Rattanakaemakorn P. Serum sickness-like reaction following an administration of the first dose of inactivated COVID19 vaccine: a case report. *JAAD Case Rep.* 2021. https://doi.org/10.1016/j.jdcr.2021.11.004
211. Shimazawa R, Ikeda M. Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech). *Journal of Pharmaceutical Policy and Practice.* 2021;14(1):46. https://doi.org/10.1186/s40545-021-00326-7
212. Saito K, Shimizu T, Suzuki-Inoue K, Ishida T, Wada Y. Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine. *Neurol Sci.* 2021:1-3. https://doi.org/10.1007/s10072-021-05543-1
213. Bril F, Fettig DM. Reply to: "Comment on "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?"". *Journal of Hepatology.* 2021. https://doi.org/10.1016/j.jhep.2021.06.008
214. Palla P, Vergadis C, Sakellariou S, Androutsakos T. Letter to the editor: Autoimmune hepatitis after COVID-19 vaccination. A rare adverse effect? *Hepatology.* 2021. https://doi.org/10.1002/hep.32156

215. Maniscalco GT, Manzo V, Di Battista ME, et al. Severe Multiple Sclerosis Relapse After COVID-19 Vaccination: A Case Report. *Front Neurol.* 2021;12:721502. https://doi.org/10.3389/fneur.2021.721502
216. Takenaka T, Matsuzaki M, Fujiwara S, Hayashida M, Suyama H, Kawamoto M. Myeloperoxidase Anti-neutrophil Cytoplasmic Antibody Positive Optic Perineuritis after mRNA Coronavirus Disease-19 Vaccine: A Case Report. *Qjm.* 2021. https://doi.org/10.1093/qjmed/hcab227
217. Endo B, Bahamon S, Martínez-Pulgarín DF. Central retinal vein occlusion after mRNA SARS-CoV-2 vaccination: A case report. *Indian J Ophthalmol.* 2021;69(10):2865-2866. https://doi.org/10.4103/ijo.IJO_1477_21
218. Vinzamuri S, Pradeep TG, Kotian R. Bilateral paracentral acute middle maculopathy and acute macular neuroretinopathy following COVID-19 vaccination. *Indian J Ophthalmol.* 2021;69(10):2862-2864. https://doi.org/10.4103/ijo.IJO_1333_21
219. Elboraey MO, Essa E. Stevens-Johnson syndrome post second dose of Pfizer COVID-19 vaccine: a case report. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2021;132(4):e139-e142. https://doi.org/10.1016/j.oooo.2021.06.019
220. Bakir M, Almeshal H, Alturki R, Obaid S, Almazroo A. Toxic Epidermal Necrolysis Post COVID-19 Vaccination - First Reported Case. *Cureus.* 2021;13(8):e17215. https://doi.org/10.7759/cureus.17215
221. Onn PY, Chang CL. Lichenoid cutaneous skin eruption and associated systemic inflammatory response following Pfizer-BioNTech mRNA COVID-19 vaccine administration. *Respirol Case Rep.* 2021;9(11):e0860. https://doi.org/10.1002/rcr2.860
222. Yesilkaya UH, Sen M, Tasdemir BG. A novel adverse effect of the BNT162b2 mRNA vaccine: First episode of acute mania with psychotic features. *Brain Behav Immun Health.* 2021;18:100363. https://doi.org/10.1016/j.bbih.2021.100363
223. Flannery P, Yang I, Keyvani M, Sakoulas G. Acute Psychosis Due to Anti-N-Methyl D-Aspartate Receptor Encephalitis Following COVID-19 Vaccination: A Case Report. *Frontiers in Neurology.* 2021;12. https://doi.org/10.3389/fneur.2021.764197
224. Rossi A, Magri F, Michelini S, et al. Recurrence of alopecia areata after covid-19 vaccination: A report of three cases in Italy. *Journal of Cosmetic Dermatology.* 2021. https://doi.org/10.1111/jocd.14581
225. Walter A, Kraemer M. A neurologist's rhombencephalitis after comirnaty vaccination. A change of perspective. *Neurological Research and Practice.* 2021;3(1). https://doi.org/10.1186/s42466-021-00156-7
226. Kahn B, Apostolidis SA, Bhatt V, et al. Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination. *Crit Care Explor.* 2021;3(11):e0578. https://doi.org/10.1097/cce.0000000000000578
227. Cecchi N, Giannotta JA, Barcellini W, Fattizzo B. A case of severe aplastic anaemia after SARS-CoV-2 vaccination. *British Journal of Haematology.* 2021. https://doi.org/10.1111/bjh.17947
228. Dell'Antonia M, Anedda S, Usai F, Atzori L, Ferreli C. Bullous pemphigoid triggered by COVID-19 vaccine. Rapid resolution with corticosteroid therapy. *Dermatol Ther.* 2021:e15208. https://doi.org/10.1111/dth.15208
229. Hanna J, Ingram A, Shao T. Minimal Change Disease After First Dose of Pfizer-BioNTech COVID-19 Vaccine: A Case Report and Review of Minimal Change Disease Related to COVID-19 Vaccine. *Canadian Journal of Kidney Health and Disease.* 2021;8. https://doi.org/10.1177/20543581211058271

230. Nishiguchi Y, Matsuyama H, Maeda K, Shindo A, Tomimoto H. Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination. *BMC Neurology.* 2021;21(1). https://doi.org/10.1186/s12883-021-02489-x
231. Pawlowski C, Rincón-Hekking J, Awasthi S, et al. Cerebral Venous Sinus Thrombosis is not Significantly Linked to COVID-19 Vaccines or Non-COVID Vaccines in a Large Multi-State Health System. *Journal of Stroke and Cerebrovascular Diseases.* 2021;30(10). https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.105923
232. Sung JG, Sobieszczyk PS, Bhatt DL. Acute Myocardial Infarction Within 24 Hours After COVID-19 Vaccination. *Am J Cardiol.* 2021;156:129-131. https://doi.org/10.1016/j.amjcard.2021.06.047
233. Murvelashvili N, Tessnow A. A Case of Hypophysitis Following Immunization With the mRNA-1273 SARS-CoV-2 Vaccine. *Journal of Investigative Medicine High Impact Case Reports.* 2021;9. https://doi.org/10.1177/23247096211043386
234. Herrera M, West K, Holstein H. ERYTHEMA NODOSUM-LIKE RASH AFTER SARS-COV-2 VACCINATION: A CASE REPORT. *Chest.* 2021;160(4):A1380. https://doi.org/10.1016/j.chest.2021.07.1261
235. Saxby K, Kingsborough B, Young D, Capone D. MODERNA VACCINE PULMONARY EMBOLISM: ASSOCIATION VS COINCIDENCE. *CHEST.* 2021;160(4):A54. https://doi.org/10.1016/j.chest.2021.07.086
236. Thappy S, Thalappil SR, Abbarh S, Al-Mashdali A, Akhtar M, Alkadi MM. Minimal change disease following the Moderna COVID-19 vaccine: first case report. *BMC Nephrol.* 2021;22(1):376. https://doi.org/10.1186/s12882-021-02583-9
237. Finsterer J. Before attributing encephalomyelitis to SARS-CoV-2 vaccinations thoroughly exclude differentials. *Annals of Clinical and Translational Neurology.* 2021. https://doi.org/10.1002/acn3.51469
238. Sekar A. Lupus nephritis flare post Moderna mRNA-1273 coronavirus vaccine. *Qjm.* 2021. https://doi.org/10.1093/qjmed/hcab284
239. Abramson M, Mon-Wei Yu S, Campbell KN, Chung M, Salem F. IgA Nephropathy After SARS-CoV-2 Vaccination. *Kidney Medicine.* 2021. https://doi.org/10.1016/j.xkme.2021.05.002
240. Londoño MC, Gratacós-Ginès J, Sáez-Peñataro J. Another case of autoimmune hepatitis after SARS-CoV-2 vaccination – still casualty? *Journal of Hepatology.* 2021;75(5):1248-1249. https://doi.org/10.1016/j.jhep.2021.06.004
241. Bril F. Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: One or even several swallows do not make a summer. *Journal of Hepatology.* 2021;75(5):1256-1257. https://doi.org/10.1016/j.jhep.2021.08.001
242. Edwards AE, Vathenen R, Henson SM, Finer S, Gunganah K. Acute hyperglycaemic crisis after vaccination against COVID-19: A case series. *Diabet Med.* 2021:e14631. https://doi.org/10.1111/dme.14631
243. Essam R, Ehab R, Al-Razzaz R, Khater MW, Moustafa EA. Alopecia areata after ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca): a potential triggering factor? *J Cosmet Dermatol.* 2021. https://doi.org/10.1111/jocd.14459
244. Crane P, Wong C, Mehta N, Barlis P. Takotsubo (stress) cardiomyopathy after ChAdOx1 nCoV-19 vaccination. *BMJ Case Rep.* 2021;14(10). https://doi.org/10.1136/bcr-2021-246580
245. Rinaldi V, Bellucci G, Sforza M, et al. Suspected acute disseminated encephalomyelitis (ADEM) after ChAdOx1 nCoV-19 vaccine: A case report. *Journal of the neurological sciences official journal of the World Federation of Neurology.* 2021;429:119796.

246. Wolf ME, Luz B, Niehaus L, Bhogal P, Bäzner H, Henkes H. Thrombocytopenia and Intracranial Venous Sinus Thrombosis after "COVID-19 Vaccine AstraZeneca" Exposure. *Journal of Clinical Medicine.* 2021;10(8):1599. https://www.mdpi.com/2077-0383/10/8/1599.
247. Bayas A, Menacher M, Christ M, Behrens L, Rank A, Naumann M. Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination. *The Lancet.* 2021;397(10285):e11. https://doi.org/10.1016/S0140-6736(21)00872-2
248. Jain E, Pandav K, Regmi P, Michel G, Altshuler I. Facial Diplegia: A Rare, Atypical Variant of Guillain-Barré Syndrome and Ad26.COV2.S Vaccine. *Cureus.* 2021;13(7):e16612. https://doi.org/10.7759/cureus.16612
249. Patel SN, Yonekawa Y. Acute macular neuroretinopathy following SARS-CoV-2 vaccination. *Retinal cases & brief reports.* 2021. https://doi.org/10.1097/ICB.0000000000001195
250. MacNeil JR, Su JR, Broder KR, et al. Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021. *MMWR Morbidity and mortality weekly report.* 2021;70(17):651-656. https://doi.org/10.15585/mmwr.mm7017e4
251. Troeltzsch M, Berndt R, Troeltzsch M. Comment on "Oral lichen planus following the administration of vector based COVID-19 vaccine (Ad26.COV2.S)". Authors' reply. *Oral Diseases.*n/a(n/a). https://doi.org/https://doi.org/10.1111/odi.14060
252. Tunjungputri RN, Tetrasiwi EN, Veronica M, Pandelaki J, Ibrahim F, Nelwan EJ. Vaccine-associated disease enhancement: a case report of post-vaccination COVID-19. *International Journal of Antimicrobial Agents.* 2021;58. https://doi.org/10.1016/j.ijantimicag.2021.106421.86
253. Lane S, Shakir S. Reports of myocarditis and pericarditis following mRNA COVID-19 vaccines: A review of spontaneously reported data from the UK, Europe, and the US. *medRxiv.* 2021:2021.2009.2009.21263342. https://doi.org/10.1101/2021.09.09.21263342
254. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. *New England Journal of Medicine.* 2021. https://doi.org/10.1056/NEJMoa2110737
255. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. *New England Journal of Medicine.* 2021. https://doi.org/10.1056/NEJMoa2109730
256. Simone A, Herald J, Chen A, et al. Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. *JAMA Internal Medicine.* 2021. https://doi.org/10.1001/jamainternmed.2021.5511
257. Levin D, Shimon G, Fadlon-Derai M, et al. Myocarditis following COVID-19 vaccination - A case series. *Vaccine.* 2021. https://doi.org/10.1016/j.vaccine.2021.09.004
258. Frenck RW, Klein NP, Kitchin N, et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. *New England Journal of Medicine.* 2021;385(3):239-250. https://doi.org/10.1056/NEJMoa2107456
259. Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. *New England Journal of Medicine.* 2021. https://doi.org/10.1056/NEJMoa2116298

260. Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children <12 Years of Age. In: https://ClinicalTrials.gov/show/NCT04816643;
261. Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. *N Engl J Med.* 2021. https://doi.org/10.1056/NEJMoa2109522
262. A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age. In: https://ClinicalTrials.gov/show/NCT04796896;
263. Ewen Callaway. COVID vaccines and kids: five questions as trials begin. https://www.nature.com/articles/d41586-021-01061-4. Published 2021. Accessed August 11, 2021, 2021.
264. Han B, Song Y, Li C, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. *The Lancet Infectious Diseases.* 2021. https://doi.org/10.1016/S1473-3099(21)00319-4
265. Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine [press release]. May 3, 2021 2021. https://ir.novavax.com/2021-05-03-Novavax-Initiates-Pediatric-Expansion-for-Phase-3-Clinical-Trial-of-COVID-19-Vaccine.
266. Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age [press release]. 25 October 2021 2021. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-top-line-data-phase-23-study-covid-19.
267. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. *Lancet Infect Dis.* 2021. https://doi.org/10.1016/s1473-3099(21)00462-x
268. COVAXIN in a Pediatric Cohort. In: https://ClinicalTrials.gov/show/NCT04918797;
269. A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) at Risk for SARS-CoV-2. In. ClinicalTrials.gov2021. https://clinicaltrials.gov/ct2/show/NCT04611802?id=NCT04917523+OR+NCT05003466+OR+NCT05003479+OR+NCT04998240+OR+NCT04611802&draw=2&rank=5&load=cart.
270. Glatman-Freedman A, Hershkovitz Y, Kaufman Z, Dichtiar R, Keinan-Boker L, Bromberg M. Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021. *Emerging Infectious Diseases.* 2021;27(11):2919-2922. https://doi.org/10.3201/eid2711.211886.
271. Tartof; SY, Slezak; JM, Fischer; H, et al. Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study. *SSRN - Preprint.* 2021. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3909743.
272. Olson S, Newhams MM, Halasa NB, et al. Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years *Morbidity & Mortality Weekly Report.* 2021;70. https://doi.org/10.15585/mmwr.mm7042e1
273. Chai Q, Nygaard U, Schmidt RC, Zaremba T, Møller AM, Thorvig CM. Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. *Acta Paediatr.* 2021. https://doi.org/10.1111/apa.16141

274. Nakazawa E, Uchimura T, Hirai Y, et al. New-onset pediatric nephrotic syndrome following Pfizer-BioNTech SARS-CoV-2 vaccination: a case report and literature review. *CEN Case Reports.* 2021. https://doi.org/10.1007/s13730-021-00656-0
275. Das BB, Moskowitz WB, Taylor MB, Palmer A. Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? *Children.* 2021;8(7). https://doi.org/10.3390/children8070607
276. University of Oxford. Comparing COVID-19 Vaccine Schedule Combinations. https://comcovstudy.org.uk/about-com-cov2. Published 2021. Accessed September 2, 2021.
277. Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. *Lancet.* 2021. https://doi.org/10.1016/S0140-6736(21)01694-9
278. Schmidt T, Klemis V, Schub D, et al. Immunogenicity and reactogenicity of a heterologous COVID-19 prime-boost vaccination compared with homologous vaccine regimens. *medRxiv.* 2021:2021.2006.2013.21258859. https://doi.org/10.1101/2021.06.13.21258859
279. Borobia AM, Carcas AJ, Pérez-Olmeda M, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. *The Lancet.* 2021;398(10295):121-130. https://doi.org/10.1016/S0140-6736(21)01420-3
280. Pozzetto B, Legros V, Djebali S, et al. Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination. *Nature.* 2021. https://doi.org/10.1038/s41586-021-04120-y
281. Yorsaeng R, Vichaiwattana P, Klinfueng S, et al. Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria). *medRxiv.* 2021:2021.2009.2001.21262955. https://doi.org/10.1101/2021.09.01.21262955
282. Li J, Hou L, Guo X, et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. *medRxiv.* 2021:2021.2009.2003.21263062. https://doi.org/10.1101/2021.09.03.21263062
283. Kant R, Dwivedi G, Zaman K, et al. Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin. *Journal of Travel Medicine.* 2021. https://doi.org/10.1093/jtm/taab166
284. Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain. In: https://ClinicalTrials.gov/show/NCT04993560;
285. Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern [press release]. Cambridge, Massachusetts, May 5 2021. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-initial-booster-data-against-sars-cov.
286. Flaxman A, Marchevsky NG, Jenkin D, et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). *Lancet.* 2021. https://doi.org/10.1016/s0140-6736(21)01699-8
287. Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination [press release]. Novavax, August 5, 2021 2021. https://ir.novavax.com/2021-08-05-Novavax-Announces-COVID-19-Vaccine-Booster-

Data-Demonstrating-Four-Fold-Increase-in-Neutralizing-Antibody-Levels-Versus-Peak-Responses-After-Primary-Vaccination.
288. PFIZER AND BIONTECH ANNOUNCE PHASE 3 TRIAL DATA SHOWING HIGH EFFICACY OF A BOOSTER DOSE OF THEIR COVID-19 VACCINE [press release]. 21 October 2021 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-phase-3-trial-data-showing.
289. Efficacy & Safety of BNT162b2 booster - C4591031 2 month interim analysis [press release]. Pfizer and BioNTech, CDC, 19 November 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-11-19/02-COVID-Perez-508.pdf.
290. PFIZER AND BIONTECH ANNOUNCE SUBMISSION OF INITIAL DATA TO U.S. FDA TO SUPPORT BOOSTER DOSE OF COVID-19 VACCINE [press release]. NEW YORK & MAINZ, Germany2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-submission-initial-data-us-fda.
291. Eliakim-Raz N, Leibovici-Weisman Y, Stemmer A, et al. Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years. *Jama.* 2021. https://doi.org/10.1001/jama.2021.19885
292. Wu K, Choi A, Koch M, et al. Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster. *medRxiv.* 2021:2021.2005.2005.21256716. https://doi.org/10.1101/2021.05.05.21256716
293. Bar-On YM, Goldberg Y, Mandel M, et al. Protection Across Age Groups of BNT162b2 Vaccine Booster against Covid-19. *medRxiv.* 2021:2021.2010.2007.21264626. https://doi.org/10.1101/2021.10.07.21264626
294. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. *New England Journal of Medicine.* 2021. https://doi.org/10.1056/NEJMoa2114255
295. Patalon T, Gazit S, Pitzer VE, Prunas O, Warren JL, Weinberger DM. Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three doses of the BNT162b2 Vaccine. *medRxiv.* 2021:2021.2008.2029.21262792. https://doi.org/10.1101/2021.08.29.21262792
296. Andrews N, Stowe J, Kirsebom F, Gower C, Ramsay M, Lopez Bernal J. Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study. *medRxiv.* 2021:2021.2011.2015.21266341. https://doi.org/10.1101/2021.11.15.21266341
297. Iketani S, Liu L, Nair MS, et al. A third COVID-19 vaccine shot markedly boosts neutralizing antibody potency and breadth. *medRxiv.* 2021:2021.2008.2011.21261670. https://doi.org/10.1101/2021.08.11.21261670
298. Atmar RL, Lyke KE, Deming ME, et al. Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report. *medRxiv.* 2021:2021.2010.2010.21264827. https://doi.org/10.1101/2021.10.10.21264827
299. Yorsaeng R, Suntronwong N, Phowatthanasathian H, et al. Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults. *medRxiv.* 2021:2021.2009.2016.21263692. https://doi.org/10.1101/2021.09.16.21263692
300. Keskin AU, Bolukcu S, Ciragil P, Topkaya AE. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. *J Med Virol.* 2021. https://doi.org/10.1002/jmv.27350

301. Walsh EE, Frenck RW, Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. *New England Journal of Medicine.* 2020;383(25):2439-2450. https://doi.org/10.1056/NEJMoa2027906
302. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2—preliminary report. *New England Journal of Medicine.* 2020.
303. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. *New England Journal of Medicine.* 2020;383(25):2427-2438. https://doi.org/10.1056/NEJMoa2028436
304. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *The Lancet.* 2020;396(10267):1979-1993. https://doi.org/10.1016/S0140-6736(20)32466-1
305. Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1–2a trial of Ad26. COV2. S Covid-19 vaccine. *New England Journal of Medicine.* 2021;384(19):1824-1835.
306. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *The Lancet Infectious Diseases.* 2021;21(1):39-51. https://doi.org/10.1016/S1473-3099(20)30831-8
307. Karamese M, Tutuncu EE. The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older. *Journal of Medical Virology.* 2021. https://doi.org/10.1002/jmv.27289
308. Angkasekwinai N, Sewatanon J, Niyomnaitham S, et al. Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers. *medRxiv.* 2021:2021.2010.2003.21264451. https://doi.org/10.1101/2021.10.03.21264451
309. Singh AK, Phatak SR, Singh NK, et al. Antibody Response after First-dose of ChAdOx1-nCOV (Covishield™®) and BBV-152 (Covaxin™®) amongst Health Care Workers in India: Preliminary Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study. *medRxiv.* 2021:2021.2004.2007.21255078. https://doi.org/10.1101/2021.04.07.21255078
310. Tada T, Zhou H, Dcosta BM, et al. Neutralization of Mu and C.1.2 SARS-CoV-2 Variants by Vaccine-elicited Antibodies in Individuals With and Without Previous History of Infection. *bioRxiv.* 2021:2021.2010.2019.463727. https://doi.org/10.1101/2021.10.19.463727
311. Pilishvili T, Fleming-Dutra KE, Farrar JL, et al. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021. *MMWR Morbidity and mortality weekly report.* 2021;70(20):753–758. https://doi.org/http://dx.doi.org/10.15585/mmwr.mm7020e2external
312. Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. *The Lancet.* 2021;397(10285):1646-1657. https://doi.org/10.1016/S0140-6736(21)00677-2
313. Prendecki M, Willicombe M. Single-dose SARS-CoV-2 vaccination efficacy in the elderly. *The Lancet Infectious Diseases.* 2021;21(11):1474-1475. https://doi.org/10.1016/S1473-3099(21)00354-6

314. Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *The Lancet.* 2021;397(10277):881-891. https://doi.org/10.1016/S0140-6736(21)00432-3
315. Hitchings MDT, Ranzani OT, Scaramuzzini Torres MS, et al. Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study. *medRxiv.* 2021:2021.2004.2007.21255081. https://doi.org/10.1101/2021.04.07.21255081
316. El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *New England Journal of Medicine.* 2021. https://doi.org/10.1056/NEJMoa2113017
317. Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. *New England Journal of Medicine.* 2021;384(20):1885-1898. https://doi.org/10.1056/NEJMoa2102214
318. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med.* 2021;384(23):2187-2201. https://doi.org/10.1056/NEJMoa2101544
319. Vacharathit V, Aiewsakun P, Manopwisedjaroen S, et al. SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus neutralization in sera from CoronaVac vaccinees and naturally infected COVID-19 patients. *medRxiv.* 2021:2021.2007.2010.21260232. https://doi.org/10.1101/2021.07.10.21260232
320. Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. *Lancet.* 2021. https://doi.org/10.1016/s0140-6736(21)02000-6
321. Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. *medRxiv.* 2021:2021.2010.2005.21264567. https://doi.org/10.1101/2021.10.05.21264567
322. Sacks HS. The Novavax vaccine had 90% efficacy against COVID-19 ≥7 d after the second dose. *Ann Intern Med.* 2021. https://doi.org/10.7326/acpj202111160-124
323. Thompson MG, Burgess JL, Naleway AL, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021. *MMWR Morbidity and mortality weekly report.* 2021;70(13):495-500. https://doi.org/10.15585/mmwr.mm7013e3external
324. Jalkanen P, Kolehmainen P, Häkkinen HK, et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. *Nat Commun.* 2021;12(1):3991. https://doi.org/10.1038/s41467-021-24285-4
325. Moderna. *Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa.* 2021. https://investors.modernatx.com/node/10841/pdf.
326. Jeewandara C, Aberathna IS, Pushpakumara PD, et al. Antibody and T cell responses to Sinopharm/BBIBP-CorV in naïve and previously infected individuals in Sri Lanka. *medRxiv.* 2021:2021.2007.2015.21260621. https://doi.org/10.1101/2021.07.15.21260621

327. Fernández J, Bruneau N, Fasce R, et al. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies. *Journal of Medical Virology.* 2021. https://doi.org/10.1002/jmv.27310
328. Sapkal GN, Yadav PD, Ella R, et al. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2. *Journal of Travel Medicine.* 2021;28(4). https://doi.org/10.1093/jtm/taab051
329. Jalkanen P, Kolehmainen P, Häkkinen HK, et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. *Nature Communications.* 2021;12(1). https://doi.org/10.1038/s41467-021-24285-4
330. Thomas SJ, Moreira ED, Kitchin N, et al. Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. *medRxiv.* 2021:2021.2007.2028.21261159. https://doi.org/10.1101/2021.07.28.21261159
331. Jongeneelen M, Kaszas K, Veldman D, et al. Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern. *bioRxiv.* 2021:2021.2007.2001.450707. https://doi.org/10.1101/2021.07.01.450707
332. Tada T, Zhou H, Samanovic MI, et al. Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants. *bioRxiv.* 2021:2021.2007.2019.452771. https://doi.org/10.1101/2021.07.19.452771
333. Yadav PD, Sapkal GN, Ella R, et al. Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. *Journal of travel medicine.* 2021. https://doi.org/10.1093/jtm/taab104
334. Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. *New England Journal of Medicine.* 2021;384(20):1899-1909. https://doi.org/10.1056/NEJMoa2103055
335. Buntz B. AstraZeneca, Pfizer Moderna vaccines fare well against Beta, Gamma and Delta variants in study. Drug Discovery & Development. https://www.drugdiscoverytrends.com/astrazeneca-pfizer-moderna-vaccines-fare-well-against-beta-gamma-and-delta-variants-in-study/. Published 2021. Updated 23 July 2021. Accessed 9 September 2021.
336. Choi A, Koch M, Wu K, et al. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants. *bioRxiv.* 2021:2021.2006.2028.449914. https://doi.org/10.1101/2021.06.28.449914
337. Clemens SAC, Folegatti PM, Emary KRW, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. *Nat Commun.* 2021;12(1):5861. https://doi.org/10.1038/s41467-021-25982-w
338. Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. *The Lancet.* 2021;397(10292):2331-2333. https://doi.org/10.1016/S0140-6736(21)01290-3
339. Chagla Z. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose. *Annals of Internal Medicine.* 2021;174(2):JC15. https://doi.org/10.7326/ACPJ202102160-015
340. Formica N, Mallory R, Albert G, et al. Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults. *medRxiv.* 2021:2021.2002.2026.21252482. https://doi.org/10.1101/2021.02.26.21252482